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Melanocortin peptides are endogenously produced peptides originating from the post-
translational processing of the pro-opiomelanocortin hormone (POMC), exerting their 
effect by binding to class A G-protein-coupled 7 transmembrane domain receptors, 
positively coupled to adenylate cyclase. To date five melanocortin receptors have been 
identified and termed MC1 to MC5. MC1 and MC3 have previously been proposed to exert 
anti-inflammatory effects by modulating the host inflammatory response. The expression 
and the functional activity of both receptors was identified and confirmed in the C-20/A4 
chondrocyte cell-line, isolated primary bovine and in situ bovine articular chondrocytes.  
Pro-inflammatory cytokines including IL-1β, IL-6, IL-8, TNF-α, produced by activated 
articular chondrocytes significantly up-regulate matrix metalloproteinases (MMPs) gene 
expression, and inhibit the chondrocyte’s compensatory synthesis pathways required to 
restore the integrity of the degraded extracellular matrix (ECM). Human C-20/A4 and 
primary bovine articular chondrocytes were found to produce CC and CXC chemokines, 
which induced the release of matrix degrading enzymes and activated cell apoptotic 
pathways. TNF-α significantly up-regulated the expression of pro-inflammatory cytokines 
and chemokines IL-1β, IL-6, IL-8, MCP-1 and MMP1 and 13 from C-20/A4 cell line and 
freshly isolated primary bovine articular chondrocytes.  An effect attenuated in the 
presence of α-MSH and D[TRP]8-γ-MSH. The MC3/4 antagonist SHU9119 blocked the 
effects of D[TRP]8-γ-MSH but not α-MSH.  
TNF-α (60.0 pg/ml) stimulation caused ~30% cell death and was partially, but 
significantly inhibited by treatment of the cells with the melanocortin peptides. The anti-
inflammatory and chondroprotective effect of melanocortin peptides were then tested on 
in situ bovine articular chondrocytes, injured by a single blunt impact delivered by a drop 
tower. The mechanical injury caused significant cell death and up-regulation of the pro-
inflammatory cytokines IL-6 and IL-8, which were significantly reduced on pre-treatment 
of cartilage explants with melanocortin peptides.  
Modulation of pro-inflammatory pathways and inflammation-modulated cartilage 
destruction with subsequent chondrocyte apoptosis appears to be logical development in 
the potential medical therapy of OA. The small molecular weight of melanocortin 
peptides should facilitate the absorption from the GI tract and the movement to the 
cartilage matrix, which together with creative drug delivery methods might potentially 
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Mammalian cartilage is a complex and developmentally critical tissue that has 
been historically defined as a vertebrate tissue component of the skeletal system, 
fundamentally different in structure and function from bone tissue. It functions as 
an internal cellular support tissue and is composed of fibrous proteins and 
mucopolysaccharides (Cole and Hall, 2004). Three different types of cartilage 
exist in mammals; each differing in the arrangement and proportion of 
extracellular fibrous (collagen) or non-fibrous (proteoglycans) macromolecules 
within the extracellular matrix (ECM), in the distribution and morphology of the 
only resident cell type – the chondrocyte, and their anatomical location and 
functions within the body (Hall, 1998).  
Hyaline cartilage, also wildly known as articular cartilage, is the most studied 
cartilaginous tissue. It is particularly important due to its function in development, 
as it lays down the scaffold for the future development of most of the key bones 
within the body, and due to its preservation at the joint interfaces, where it 
creates a smooth surface for frictionless joint movement. It is also the primary 
tissue affected by arthritic pathologies (Hollander et al., 2010). 
In hyaline cartilage, the proportion of collagen to proteoglycans, is such that 
under polarized light microscope the tissue appears glassy, with translucent blue-
white appearance in early age, turning pale and opaque with aging (Van der 
Korst et al., 1968, Hall, 1998). Articular cartilage constitutes the temporary 
embryonic skeleton, before its replacement with bone. It can also be found in the 
epiphyseal plates between the diaphysis and epiphysis of growing long bones, 
where it is responsible for the longitudinal growth of the bone (Martel-Pelletier 
and Pelletier, 2010). In adults, this type of cartilage is present in the articulating 
surfaces of articular joints, in the wall of the large respiratory passages, such as 
the nose, larynx, trachea, bronchus, and at the ventral ends of the ribs that move 
with the sternum. The tissue is avascular, alymphatic and aneural and populated 
only by chondrocytes, which are responsible for the synthesis, exportation and 
degradation of ECM components – proteoglycan, fibrous collagen (type I, type II, 
and small amounts of types VI, IX and XI) and other proteins. The surface areas 





but its principle adaptation is to withstand compressive forces (Martel-Pelletier 
and Pelletier, 2010). 
Fibrocartilage, or white fibrocartilage, is another type of cartilage found mainly in 
the invertebrate disks of the spine, the attachment of some ligaments to the 
bones, in the pubic symphysis, but also in knee, jaw and healing bones 
(Benjamin and Evans, 1990, Benjamin and Ralphs, 1998). Its main function is to 
withstand compression forces. Fibrocartilage is a very dense connective tissue, 
composed mainly from collagen type I (Eyre and Muir, 1975), relatively little 
proteoglycan (Gillard et al., 1979, Koob and Vogel, 1987) and some elastic 
material (Buckwalter et al., 1976). It develops by metaplasia from pre-cartilage, 
hyaline cartilage and particularly from fibrous tissue, and these features precede 
the appearance of cartilage cells (Benjamin and Evans, 1990).  
The third type of cartilage is the elastic cartilage, or yellow fibrocartilage. Elastic 
cartilage is composed of elastic fibres as well as collagens and proteoglycans 
and is mainly found in the auricle of the ears, in the Eustachian tubes and 
epiglottis. It is described as rubber-like, highly and reversibly deformable. Elastic 
cartilage chondrocytes highly resemble those in hyaline cartilage, but these 
synthesize elastin in addition to the other matrix components (Hall, 1998). 
1.1.1 Articular Cartilage – structure and function.  
The mechanical resistance and flexibility of cartilage occurs because of the four 
components of the extracellular matrix and their properties – proteoglycans, 
collagen, interstitial fluid and chondrocytes. Proteoglycans are proteins 
composed of highly negatively charged glycosaminoglycans (GAGs), covalently 
attached through O-glycosidic bond at their reducing ends to the core protein, 
commonly chondroitin sulphate (CS) or keratan sulphate (KS) (Jackson et al., 
1991). Aggrecan, one of the largest proteoglycans and the major one in articular 
cartilage, is a large chondroitin sulphate proteoglycan composed of a large 
number of GAG monomers and represents the bulk of the proteoglycans in 
cartilage (Watanabe et al., 1998). It interacts with the hyaluronan and other link 
proteins to form macromolecular complexes, trapped by the collagen network 





et al., 1991). Decorin, biglycan and fibromodulin, are smaller proteoglycans, rich 
in leucine, representing around 20-25% of all proteoglycans in cartilage, and are 
associated with the proteoglycans and the ‘ground substance’ – the main 
components of which are large carbohydrates and other proteins (Hardingham 
and Fosang, 1992). A central component of the proteoglycan aggregates is 
hyaluronan, which is a non-sulphated glycosaminoglycan and is present in 
relatively small amounts in cartilage. It is, however, an important component of 
the matrix, as CD44, expressed on the chondrocytes cell surface, bind to 
hyaluronan, thus embedding the chondrocyte within the extracellular matrix 
(Figure 1.1). 
Collagen fibres are the principle component of connective tissues and are 
composed of bundles of fibrils, which are made of stacked molecules of helical 
polypeptide chains. Fourteen different types of collagens exist, which vary both in 
size and in configuration (Eyre, 2004). Articular cartilage is mainly composed of a 
unique type of collagen, type II, which is structurally characterised by the 
aggregation of large fibrillar homotrimer complexes, with three identical α-chains 
peptides (formed by the repeating tri-peptide sequence Gly-x-y) each adopting 
left-handed helical conformation (Hall, 1998) with the three chains twisted 
together in a right-handed helix. Collagen type II in cartilage forms a 3D fibrillar 
network of rope-like molecular aggregates, which together with the proteoglycans 
is essential for maintaining the tissue volume, shape and tensile strength (Eyre et 
al., 1992) . Collagen II represents >95% of all the collagens present in the 
cartilage. Other collagens found in cartilage include type I, type IX, type X, which 
play an essential role in the matrix organization. Collagen type IX is a non-fibril, 
highly glycosilated collagen that covalently links to type II collagen fibrils, thereby 
helping in the interweaving and cross-linking of the collagen fibrils and trapping 
the hydrated proteoglycans. Collagen type IX is additionally regarded as a 
proteoglycan due to a CS chain attached and is thought to provide lateral 








Figure 1.1 Articular cartilage zones and zonal orientation of collagen type II fibrils. 
A simplified diagram of a perpendicular section of articular cartilage and underlying 
bone, showing the heterogeneity of the cartilage matrix. Arcades of collagen bundles 
originating in the calcified zone and binding the non-calcified cartilage are extending 
towards the articular surface and then curving back down. In sequence from the articular 
surface to the subchondral bone, the collagen bundles are tangential, radial and 
perpendicular. The collagen fibres are continuous with those in the calcified 
layer of cartilage but not with underlying subchondral bone. The morphology of 
the collagen-fibril network influences the local stresses and strains in the 
articular cartilage. 
 
The organisation and distribution of ECM macromolecules and chondrocytes 
differs significantly within the tissue and can be separated into four distinct 
regions. The first region located at the articular surface of the cartilage is the 





parallel to tangential stress and is associated with low concentration of aggrecan 
and high concentrations of decorin. The middle zone contains thick radially, 
randomly oriented, looser bundles of collagen, whilst the deep zone (also called 
radial zone) contains perpendicularly oriented collagen fibrils and the calcified 
cartilage zone (located between the deep zone and the subchondral bone) 
serves as a mechanical buffer (Muir et al., 1970, Wilson et al., 2004). It has been 
observed that the cell density progressively decreases from the superficial zone 
to the deep zone, whereas relative to collagen, cell volume and the proteoglycan 
content increase.  
Within cartilage, there are not only topographical variations in the quantity of 
proteoglycan, but also the type, thus contributing to the physical properties of the 
matrix. The GAG side chains of proteoglycans are sulphated and responsible for 
a fixed negative charge density, which binds mainly sodium, but also other 
mobile cations (Lesperance et al., 1992). This process, together with the quality 
and quantity of the collagen network is deterministic for the osmotic pressure of 
the extracellular fluid around chondrocytes. Extracellular osmolarity in healthy 
articular cartilage ranges between 350 and 480 mOsm.kg-1 H2O, hereafter 
termed ‘mOsm’ (Maroudas, 1976) and is highly dynamic, in response to changes 
in matrix hydration (Urban, 1994). During osteoarthritis, the collagen matrix 
degrades and the concentration of GAG diminishes in a disease progression-
dependent way, leading to decreased osmolarity to between 280-350 mOsm 
(Maroudas, 1976, Bush and Hall, 2001a, Bush and Hall, 2005).  
The proteoglycan molecules (3–10 % of tissue on wet weight basis) are highly 
negatively charged with sulphate, SO42– and carboxyl (COO–) functional groups, 
which, together with the positively charged cations drawn from the synovial fluid, 
cause the osmotic pressure in the matrix to increase and consequently leads to 
water inhibition and tissue inflation. However, within the cartilage, the expansion 
of the proteoglycans is limited by the tension of the collagen matrix (15 – 30 % of 
tissue on wet weight basis), which restricts proteoglycans hydration to only 20 % 
of their actual capacity, and thus creates swelling pressure within the cartilage, 
contributing to its compressibility (Hall, 1998). When cartilage is loaded, during 
normal daily activities, water is extruded and the PGs are further compressed, 





essential nutrients, until the swelling pressure of the aggrecan is balanced again 
by the tensile force of the collagen matrix. The interstitial fluid (65 – 80 % of the 
tissue) is what forms the aqueous environment in which the chondrocytes reside. 
It supplies the cells with substrates, nutrients and matrix biosynthesis precursors, 
and also allows for metabolic by-products to be eliminated from the tissue.  
1.1.2  Chondrocytes. 
Connective tissues are highly active living tissues with capacity to support and 
resist mechanical forces, crucial for the musculoskeletal system. The cells of 
connective tissues continually produce and maintain appropriate macromolecules 
that give the tissue its required mechanical properties. This occurs by 
synchronised equilibrium of anabolism and catabolism of those macromolecules 
(Gardner, 1992).  
Chondrocytes are present at a very low density of ~ 1-5 % of the adult cartilage 
tissue, with approximately 1.0 x 103 cells per mm3 (human femoral head), and 
depending on the location, little or no cell division (Hall, 1998). Although the role 
of the chondrocytes has historically been marginalized because they do not play 
a direct mechanical role, they are the only existing units capable of producing, 
repairing or degrading the matrix. Additionally, chondrocytes ‘sense’ physical 
changes in their environment and this determines matrix metabolism and 
ultimately the mechanical characteristics of the tissue, the osmotic composition of 
the interstitial fluid, cell-matrix interactions and the rate of diffusion of substances 
between the synovial fluid and the interstitial fluid. 
Chondrocytes in cartilage are heterogeneous, and this is related to the 
topography within different zones of the tissue (Stockwell and Meachim, 1973, 
Hall, 1998). In addition chondrocytes can exist as single units or in groups of up 
to six cells. Differences in the morphology of zonal chondrocytes can be easily 
observed. Chondrocytes from the superficial zone occur singly or in pairs, are 
small (8–15 µm in diameter), sparsely distributed and ellipsoid in morphology. In 
the middle zone, chondrocytes are oval-shaped approximately 15–25 µm in 
diameter and are arranged radially, singularly or in pairs (Stockwell, 1971, Hall et 





they are found in small groups or short columns of about 3–5 cells (Hall, 1998, 
Hall et al., 1996). 
Early studies have identified that the matrix immediately surrounding the 
chondrocyte in hyaline cartilage is different and more specialised than the 
intercellular/interterritorial matrix, which led to the identification of a primary 
functional and metabolic unit termed ‘chondron’ (Poole et al., 1992). The 
chondron consists of one or several chondrocytes, the pericellular, or “lacunar” 
matrix, which is rich in proteoglycans and possibly hyaluronic acid, relatively no 
collagens, and the pericellular rib, which includes types VI, II and IX collagen 
(Figure 1.2). It has been hypothesized that the microenvironment, surrounding 
the chondrocytes within their chondrons, serves to protect the chondrocytes by 
dampening the physicochemical, osmotic and mechanical changes that happen 
during dynamic loading (Poole et al., 1992). Continuous with the pericellular 
matrix is the territorial matrix, which is composed of basket-like network of cross-
linked collagen fibrils, forming a capsule around the chondron, which the 
chondrocyte contacts through numerous cytoplasmic processes, rich in 
microfilaments. The pericellular collagens diverge and converge at the superficial 
pole of the chondron capsule, forming a pericellular channel between the interior 
of the chondron and the intercellular matrix. It has been suggested that, during 
compressive pressure to tissue, these “pericellular channels” underline a 
mechanism for the chondrocytes to sense changes in the osmotic pressure and 






















Figure 1.2 High power phase contrast confocal micrograph of articular hyaline 
cartilage excised from adult (18-24 months old) bovine ‘knee’ joint.  
Articular cartilage has a complex internal structure. Composed of four poorly demarcated 
zones, the most superficial, uppermost zone forms the gliding surface and is in contact 
with the synovial cavity of the joint. Small elliptical chondrocytes are oriented parallel to 
the surface; chondrocytes in deeper zones are larger, more rounded, and arranged in 
vertical columns. The term chondron encompasses the chondrocyte and its pericellular 







1.2.1 Rheumatoid Arthritis (RA). 
Rheumatoid arthritis is a complex systemic, inflammatory pathology, primarily 
affecting the joints, with cardiovascular problems being causal to 40% of the 
morbidity associated with this pathology. RA is one of the most common of the 
arthritides, affecting middle-aged males and females, with a marked female bias 
(approx. 2.5 times; (Lee and Weinblatt, 2001) as well as children (in the case of 
juvenile variant). Rheumatoid arthritis has acute or insidious onset, and typically, 
but not exclusively, affects the joints in a symmetrical manner the radiocarpal and 
metacarpophalangeal, proximal interphalangeal joints of the hands and feet and 
occasionally large joints (Lee and Weinblatt, 2001). Cardinal features of RA are 
early morning stiffness and pain, which can last for more than 1 h, joint swelling 
and deformity, synovial thickening, reduced range of motion of the affected joint 
and systemic features including flu-like symptoms, fatigue, fever, depression and 
weight loss (Lee and Weinblatt, 2001). 
The exact pathology of RA is still not understood, but it is generally accepted to 
be a disease of autoimmune origin, resulting in a continual immunological 
reaction, mostly directed against joint tissues, but may also have manifestations 
as a more systemic syndrome involving a variety of organs (formation of 
rheumatoid nodules in skin, salivary inflammation, pulmonary fibrosis, pericardial 
inflammation, myocarditis, mononeuritis, anemia, thrombocytosis, vasculitis (Lee 
and Weinblatt, 2001). Characteristic findings in RA joints include synovial 
inflammation with an accumulation of inflammatory cells, increased synovial 
levels of pro-inflammatory cytokines, and the formation of a characteristic area of 
granulation tissue known as a pannus, which is formed from both synovial cells 
and the cellular infiltrate, and appears to contribute to the destruction of the 
underlying cartilage (Lee and Weinblatt, 2001). 
Quantitative analyses have shown that a wide variety of pro-inflammatory 
cytokines are present in inflamed synovial tissue and are produced in moderate 
to high concentrations in RA. Tumor necrosis factor (TNF)-α and Interleukin (IL)-





tissue (Chu et al., 1991, Wood et al., 1992, Lee and Weinblatt, 2001), where they 
act as potent stimulators of proliferation, matrix metalloproteinase expression, up-
regulation and release of pro-inflammatory cytokines and prostaglandin 
production (Lee and Weinblatt, 2001). Previous studies have identified IL-1β as 
the main mediator for the initiation of the proteolysis in rheumatoid arthritis and in 
other inflammatory joint diseases (Dayer et al., 1979, Mizel et al., 1981, Krane, 
1982, Baracos et al., 1983, Wood et al., 1992). The enhanced secretion of 
collagenases and prostaglandin E2 (PGE2), by synovial cells, is considered a 
factor for the degenerative progression that is clinically observed. TNF-α, a 
potent stimulator of collagenase and PGE2 production in synovial cells (Choi et 
al., 2009, Chu et al., 1991, Kunisch et al., 2009), is also implicated in the disease 
progression with production in far larger quantities than IL-1β under some 
circumstances in vivo.  
Whilst RA is generally classified as an autoimmune disease, the mechanisms 
involved and the significance of auto-antibodies routinely detected in RA patients, 
remain uncertain. The main auto-antibodies, detected in roughly 70–80 % of RA 
patients (Avouac et al., 2006), are rheumatoid factor (RF) and anti-cyclic 
citrulinated peptide (anti-CCP), antibodies directed against the fragment 
crystallizable (Fc) region of IgG antibodies and proteins containing citrulline (a 
modified form of the amino acid arginine), respectively (van Venrooij et al., 2008, 
van Venrooij and Zendman, 2008, Getting et al., 2009). It is suggested that these 
antibodies may be involved in RA via the formation of immune complexes, which 
together with their target antigens result in complement activation, the release of 
other pro-inflammatory mediators from the synovium, and leukocyte recruitment 
and infiltration into the joint space (Lee and Weinblatt, 2001, Brennan and 
McInnes, 2008, van Venrooij and Pruijn, 2008). 
1.2.2 Metabolic Arthritis/Gouty Arthritis. 
Gouty arthritis is a chronic joint disease caused by the deposition of monosodium 
urate monohydrate (MSU) crystals in the joints (McCarty et al., 1966, McGill and 
Dieppe, 1991, Chilappa et al., 2010). It is an inflammatory arthritis that 
predominantly affects middle-aged/older individuals, with incidence significantly 





arthritis can occur in any synovial joint, but mainly manifests as a monoarthritic 
attack in the smaller joints, particularly the metatarsophalangeal joint, with clinical 
manifestation of symptoms including erythema, edema of the affected joints and 
severe pain (McGill and Dieppe, 1991). Gouty arthritis occurs predominantly as a 
consequence of hyperuricaemia (increased levels of plasma urate; a product of 
purine metabolism), although other factors including joint trauma and local 
temperature may be additionally involved (Heuckenkamp et al., 1982, Fokter and 
Repse-Fokter, 2010). When plasma solubility of urate is exceeded, MSU crystals 
deposit in a range of soft tissues and joints, resulting in gouty arthritis. 
The mechanisms of urate-induced inflammation are not completely understood. 
Gouty arthritis seems to be initiated primarily by an innate immune response, 
particularly due to the intense infiltration of blood-borne neutrophils and 
monocytes into the joint space (Terkeltaub et al., 1991a,b; Villiger et al., 1992), 
resulting from the elevated secretion of pro-inflammatory mediators, such as IL-
1β, IL-6, IL-8, TNF-α and thus the increased expression of endothelial cell 
adhesion molecules (di Giovine et al., 1991, Villiger et al., 1992). Recent work 
has shown that toll-like receptors TLR2 and TLR4, present on phagocytes and 
other cells contained in the joint environment, recognize the MSU crystals, which 
upon binding to the receptors, induce generation of these pro-inflammatory 
intermediaries, thereby providing a possible mechanism for disease instigation 
and progression (Cronstein and Terkeltaub, 2006).   
1.2.3 Osteoarthritis (OA).  
Osteoarthritis is a slowly progressive, degenerative, multifactorial disease 
characterized by gradual degradation and loss of articular cartilage, and resulting 
in loss of joint mobility and pain (Goldring, 2000a, Aigner and Stove, 2003, 
Goldring and Goldring, 2007). OA has been classified as a late-onset, complex 
disease, which affects over 100 million individuals all over the world (Iliopoulos et 
al., 2008). It is the most common of the arthritides, and is largely a disease of the 
elderly and middle aged. In theory, OA can affect any synovial joint in the body, 
but OA lesions are typically localized to the weight-bearing regions of the larger 
joints (the hip, knee and spine), and later in those of the hand (Buckwalter and 





The exact pathogenesis of osteoarthritis is not fully understood with obesity, age, 
abnormal joint loading and sport injuries all being risk factors (De Bri et al., 1998), 
but OA is more than just the result of “wear and tear” (Aigner et al., 2004b). 
Abnormal joint loading causes changes in physiology of the chondrocyte, which 
mediate the biosynthesis of ECM macromoledules. It is now generally accepted 
that the articular chondrocytes play an important role in the initiation and 
progression of OA (Goldring, 2000b).  
It is not yet known what is the exact role of the chondrocyte in the initiation and 
progression of osteoarthritis, due to the complexity of the disease process and its 
high localization of focal lesions. Dieppe, 1994 hypothesized that the initiation 
and the progression of osteoarthritis within individual joints, and even the disease 
distribution between the joints, may be ascertained by the specific balance 
between local and systemic factors (Dieppe and Kirwan, 1994). In the cases 
where, for example, excessive mechanical loads cause micro-damage to 
cartilage, chondrocytes might not be involved directly. The injury might initiate a 
sequence of cartilage ECM damage, before the obvious changes to chondrocyte 
physiology are detected. It has been observed that there are focal defects (peak 
loading location) in osteoarthritis of the hip and knee, suggesting that in some 
cases mechanical factors are not only an important risk factor for the 
development of changes to chondrocyte physiology, but also a key disease 
initiation factor. Additionally, normal ‘wear and tear’ has been considered a 
significant risk factor for the development of the disease; however, the fact that 
the increase in middle zone tissue hydration is the first detectable change, and 
without any change to the collagen content, this must be resulting from 
weakening of the collagen network (Stockwell, 1991, Gardner, 1992). These 
changes vary significantly from the processes taking place during aging, whereby 
cartilage loses hydration and becomes ‘dry’. If the effect of the physio-chemical 
environment of the chondrocytes on their physiology is considered, it is possible 
to hypothesize that a group of susceptible chondrocytes, with changes to their 
physiology, start a sequence of events leading to the production of mechanically 
compromised matrix and predisposing cartilage to damage and degradation (Hall 






However, other factors are also implicated in this intricate disease process. OA is 
generally regarded as primarily non-inflammatory arthropathy. Nonetheless, 
elevation of pro-inflammatory cytokines in the cartilage of many OA patients has 
been detected (Westacott and Sharif, 1996, Fernandes et al., 2002) and local 
inflammation has been observed in animal models of the disease (Goldring, 
2000a, Rai et al., 2008). Elevated levels of pro-inflammatory cytokines induce the 
expression and secretion of cartilage-degrading proteases by chondrocytes, 
leading to the degradation of cartilage ECM (Shlopov et al., 2000, Fernandes et 
al., 2002).  
Additionally, chondrocyte apoptosis and senescence are processes that can also 
lead to impaired ECM synthesis (Kim et al., 2000, Aigner et al., 2004a, Roach et 
al., 2004, Kim and Blanco, 2007). Generally, a variety of chemical stimuli appear 
to promote chondrocyte apoptosis by elevating pro-inflammatory cytokines, nitric 





1.2.3.1 Etiology and Epidemiology of OA. 
Osteoarthritis, the most prevalent musculoskeletal system disorder throughout 
the world, is believed to be a consequence of mechanical and biological events 
that destabilize the normal link of matrix synthesis and degradation within 
articular cartilage. OA is exceptionally common, particularly among people over 
40 years of age (Guccione, 1997). It represents a major cause of morbidity, 
disability and social isolation, especially where the hip and knee are involved, as 
this can lead directly to reduced mobility (Ettinger and Afable, 1994). 
Radiographic changes of joints occur in the majority of people by the age of 65 
and are present in more that 80 % of people over 75 years old (Arden and Nevitt, 
2006). OA is a disease affecting joint cartilage and the subchondral bone. Its 
earliest pathologic manifestation is the degradation of cartilage, which when 
extensive, is visible on radiographs as a narrowing of joint space. Consequent 
changes in the bone include eburnation of underlying bone, osteophyte formation 
and sometimes formation of cysts on the subchondral bone (Martel-Pelletier et 
al., 1999). Additionally, there are radiographically visible lateral ostheophytes, 
before any changes in the joint space can be detected. The disorder leads to 
significant increase in morbidity, especially in the elderly (Guccione, 1997), whilst 
osteoarthritis of the knee and hip have the highest social cost and most 
associated disability (Bergstrom et al., 1986).  
Knee OA is very common and frequently symptomatic illness, often associated 
with disability, whereas hip OA is slightly less prevalent with symptoms, which 
are often more severe and more frequent. Knee osteoarthritis prevalence 
increases with age (Lawrence et al., 1966, Hernborg and Nilsson, 1973, 
Bergstrom et al., 1986, Felson et al., 1987) from negligible in those aged 25 – 
34% to 20 – 40 % prevalence in people aged >70 years. The prevalence is 
higher in males than in females up to approximately 45 years old, after which the 
reverse is true, probably due to the inhibitory effect of estrogen on matrix 
metalloproteinases (MMPs) production and activation (Claassen et al., 2010).  
Population-based radiographic prevalence England surveys were performed for 
hip OA and found that radiographic OA increases with age in subjects aged 55-
74 years, with 16% of men and 6% of women affected. However, other studies of 





older men and women and lower rates (ranging from 4-7 %) in general as 
compared to the studies in England (Lawrence and Zinn, 1970, Zinn, 1970, 
Danielsson et al., 1984). It has been found that race plays an important role in 
the incurrence of OA, with Afro-Caribbean, Chinese and Asian showing much 
lower rates of hip OA than Caucasian (for a review see: (Allen, 2010, Allen et al., 
2010).  
There are a number of possible causes for the increase of disease prevalence 
with age including metabolic changes occurring with ageing, which are not 
parallel to biochemical changes, but may render cartilage more susceptible to 
fatigue fractures (Claassen et al., 2011).  However, there are other risk factors 
that have been found to correlate with the incidence of OA.  Population based 
studies have found an association between obesity and radiographic OA of the 
hands, feet and knee (Denisov et al., 2010), but clinical studies evaluating this 
relation have not been consistent. Animal studies on rodents have demonstrated 
that major joint injury causes OA, whereby OA is actually induced by controlled 
tears of meniscus and cruciate ligament (Troyer, 1982). Such damage is often 
associated with damage to articular cartilage, the primary lesion of OA and 
changes in biomechanics, with the latter causing increased shear stress on local 
areas of articular cartilage. Job occupation can also influence the rate of OA 
incidence, with repetitive use of particular joints appearing to be a major risk 
factor for osteoarthritis especially of the hands (McCarthy et al., 1994, Rossignol 
et al., 2005, Fontana et al., 2007, Ding et al., 2010). This has also been identified 
within the knee (Dahaghin et al., 2009, Reid et al., 2010, McWilliams et al., 2011) 
and hip (Rossignol et al., 2005, Franklin et al., 2010), although the specific 
physical activity that causes it is not well understood. Other studies have 
identified other possible risk factors for osteoarthritis, such as diabetes, 
hypertension, cardiovascular disease, peripheral vascular disease, congestive 
heart failure, which have also been suggested to play a role in the initiation of 
osteoarthritis of knees, hips, hands and spines of patients  (Felson et al., 2000, 
Solomon, 2001, Marks and Allegrante, 2002b, Marks and Allegrante, 2002a, 
Singh et al., 2002, Bray, 2004, Parada-Turska and Majdan, 2005). There is still, 






1.2.3.2 Molecular mechanisms involved in cartilage degradation. 
Often the different forms of arthritis are divided into inflammatory and non-
inflammatory, where inflammatory indicates cellular inflammation resulting from 
the infiltration of various activated leukocytes into the joint and mediating 
cartilage destruction. Even though osteoarthritis has been usually referred to as a 
non-inflammatory pathology, due to the lack of infiltrating inflammatory cells in 
early stages of the disease, there is mounting body of evidence indicating that 
cartilage degradation is largely the result of chondrocyte-borne inflammation at a 
molecular level (Goldring, 2000b, Pelletier et al., 2001b, Attur et al., 2002). 
Abnormal mechanical forces appear to ‘awaken’ adult chondrocytes from a state 
of low metabolic activity and stimulate the production of a host of pro-
inflammatory mediators. These include pro-inflammatory cytokines and 
chemokines, such as IL-1β, IL-6, IL-8, IL-17, IL-18, monocyte chemoatractant 
protein 1 (MCP1) and reactive oxygen species (ROS; such as superoxide, 
hydrogen peroxide [H2O2] and peroxynitrite).  These together with lipid-derived 
inflammatory stimuli (including prostaglandins and leukotrienes) serve to increase 
the catabolic activity of chondrocytes (Shlopov et al., 2000, Hardy et al., 2002, 
Fernandes et al., 2002, Gosset et al., 2010). The result is an increase in the 
release of matrix metalloproteinases (MMPs) and aggrecanases, which can 
directly degrade the cartilage matrix. It has been proposed that, at least in part, 
the damage of the cartilage matrix might be an attempt of the chondrocytes to 
remove and replace the damaged matrix (Shlopov et al., 2000, Hardy et al., 
2002, Fernandes et al., 2002, Gosset et al., 2010). 
1.2.3.2.1 Cytokines. 
In addition to age-related and biomechanical changes in the function of 
chondrocytes, inflammation, and the following deregulation of cytokine synthesis 
are major contributors to the misbalanced rate of anabolism and catabolism 
(Fernandes et al., 2002, Goldring and Berenbaum, 2004). Recently, in vivo and 
in vitro studies have demonstrated the involvement and the effects of pro-
inflammatory cytokines, and particularly IL-1β and TNF-α, in the destruction of 
articular cartilage during osteoarthritis (Fraser et al., 2003, Goldring and 





IL-1β, also known as catabolin, is a small, 17 kDa, cytokine protein encoded by 
the IL1B gene in humans (Auron et al., 1985, March et al., 1985). IL-1β, a 
member of the interleukin 1 cytokine family, is proteolytically activated by 
caspase 1 and has important functions in the inflammatory response. It is 
involved in various cellular activities, such as cell proliferation, differentiation and 
apoptosis (Oppenheim et al., 1989, Friedlander et al., 1996, Beasley and 
Cooper, 1999)  
TNF-α, or cachexin, is a cytokine implicated in systemic inflammation, with 
particular relevance to acute phase reaction stimulation. It is a 17kDa protein, 
encoded by TNFA gene, with a primary role in the regulation of immune cells as 
a potent inducer of inflammation and apoptosis. Two receptors that recognize 
TNF-α have been identified and termed TNFR1 (TNF receptor type 1; p55/60) 
and TNFR2 (TNF receptor 2; p75/80), with TNFR1 being expressed by most 
tissues and TNFR2 being mainly expressed on the cells of the immune system 
(Locksley et al., 2001, Hehlgans and Pfeffer, 2005). Interestingly, the density of 
TNFR1 has been shown to be significantly greater in chondrocytes isolated from 
OA lesions compared to those isolated from areas not affected by the disease 
(Westacott et al., 1994), thereby proposing an important role for this cytokine in 
the progression of OA.  
Upon binding to TNFR1, TNF-α, causes a conformation change in the receptors, 
which leads to the activation of the death domain (DD), enabling the adaptor 
protein (TNF-α receptor type 1 – associated death domain; TRADD) to bind to 
DD, and thus initiating a series of phosphorylation events. One group of proteins 
that mediate these phosphorylation events is the mitogen-activated protein 
kinase group, or MAPK-group (Garrington and Johnson, 1999), which is a serine-
threonine kinase family that consists of the c-Jun N-terminal kinases (ERKs) and 
the p38 MAPK-activated protein kinases, downstream of pro-inflammatory 
cytokines, osmotic stress, or apoptotic signals (Lin et al., 1995, Aizawa et al., 
2001). The stimuli first activate MAPK kinase kinases or MAPKKKs, which in turn 
phosphorylate and activate the MAPKK, kinase that then activates MAPK. 
MAPKK and MAPK then translocate into the nucleus of the respective cell, where 





(AP-1; a member of the c-Jun family) which is especially involved in MMP13 
transcription activation (Lim and Kim, 2011).  
TNF-α and IL-1β are strong activators of the NF-κB signalling pathway in 
chondrocytes. First, TRADD recruits TNF-α receptor associated factor-2 (TRAF2) 
and RIP (receptor interacting serine-threonine protein kinase). TRAF2 in turn 
recruits the multi-component protein kinase IKK, enabling RIP-induced activation 
of it. The inhibitory IκBα is phosphorylated by IKK, which causes its subsequent 
degradation and ultimately the release and translocation of NF-κB into the 
nucleus, thereby activating a vast array of pro-inflammatory and catabolic genes 
(Liu-Bryan and Terkeltaub, 2010). However, it remains controversial whether 
inflammatory cytokines are primary or secondary regulators of articular cartilage 
degradation in osteoarthritis. Regardless, it has been shown that physiological 
loading of cartilage may protect against cartilage degradation by inhibiting the 
degradation of IKKβ activity in the canonical NF-κB transcriptional activation 
(Dossumbekova et al., 2007).  
TNF-α and IL-1β together with a large number of other cytokines and growth 
factors trans-activate MMP promoters by convergence of AP-1 and ETS (E 
twenty six) through activation of p38, JNK and PKC signalling (Figure 1.3) 
(Iwamoto et al., 1990, Ahmed et al., 2003, Tower et al., 2003, Muddasani et al., 
2007, Im et al., 2007, Sampieri et al., 2008, Lim and Kim, 2011). The induction of 
MMP13 promoter activity by IL-1β in chondrocytes has been shown to require 
one or more of the ETS sites and interaction between factors such as RUNX2 
and AP-1 (cFos/cJun), which subsequently interact directly with the MMP13 
promoter (Mengshol et al., 2001; Selvamurugan et al., 2004). Interestingly, PGE2, 
an activator of both AP-1 and Fos-dependent promoters via PKA and PKC 
signalling pathways has been shown to dose-dependently inhibit the expression 
of MMP13, thereby suggesting a crosstalk between signalling pathways with 
adjacent transcriptional control elements and opposing effects on MMP13 
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Figure 1.3 IL-1β  and TNF-α  molecular mechanism of action.  
IL1R binds IL-1β but requires the IL1R accessory protein (IL-1RAcP) to transduce a signal. IL-1β 
binding causes activation of two kinases, IRAK-1 and IRAK-4, associated with the IL1R complex. 
IRAK-1 (IL1R Associated Kinase) activates and recruits TRAF6 to the IL1R complex. TRAF6 
activates two pathways, one leading to NF-κB activation and another leading to c-jun activation. 
The TRAF associated protein ECSIT leads to c-Jun activation through the MAPK/JNK signalling 
system. TRAF6 also signals through the TAB1/TAK1 kinases to activate NIK, which 
phosphorylates IKK therefore triggers the degradation of IκB, and activation of NF-κB (Baud and 
Karin, 1999). TRAF2 (has been implicated in the activation of two distinct pathways that leads to 
the activation of Activation Protein-1 (AP-1) via the JNК, MEKK, p38 and together with RIP, NF-
κB activation via the NIK (NF-κB Inducing Kinase). TNF-α activates MAPKs: ERK1 and ERK2 





Other cytokines gaining increasing attention include IL-6, a potent pleiotropic 
cytokine, expressed by human chondrocytes in vitro and in vivo (Bender et al., 
1990, Wang et al., 2010a,b), which has been suggested to play an important role 
in pathogenesis of osteoarthritis. It is thought to elicit both pro-inflammatory and 
anti-inflammatory effects in cartilage (Bender et al., 1990, Goldring, 2000a) 
through binding to IL-6 receptor (IL-6R), a two-subunit type I cytokine receptor. 
The IL-6 receptor alpha subunit (IL6Rα) contains the ligand-binding domain and 
IL-6 signal transducer component (gp130, also called CD130), which is shared by 
other cytokines from the IL-6 family (IL-11, IL-27, cilliary neurotropic factor 
[CNTF], cardiotropin [CT-1], CT-like cytokine [CLC], leukaemia inhibitory factor 
[LIF], oncostatin M; (Kishimoto et al., 1995). Binding of IL-6 to its receptor 
initiates a signal transduction cascade that activates JAK1/STAT3 (Signal 
Transducer and Activator of Transcription) and extracellular signal-regulated 
kinases (ERK)-1/2 pathways (Heinrich et al., 1998, Heinrich et al., 2003, Fischer 
and Hilfiker-Kleiner, 2007). The activated JAK1 phosphorylates STAT3, which 
dimerises and translocates into the nucleus, where it activates the transcription of 
STAT3 response elements (Hirano et al., 2000). IL-6 can be directly induced by 
TNF-α and IL-1β, although IL-6 on its own has been shown to directly augment 
the expression of MMP1 and MMP13 (Shlopov et al., 2000) 
CXCL8, or IL-8 is a leucocyte chemotactic activating cytokine (chemokine), a 
member of the CXC chemokine family, encoded by the IL8 gene, with a primary 
function in angiogenesis, chemoattraction and activation of neutrophils (Modi et 
al., 1990, Harada et al., 1994a, Belperio et al., 2000). Various cell types produce 
IL-8 upon stimulation, as it is one of the major mediators of the inflammatory 
response (Akahoshi et al., 1994, Harada et al., 1994 a,b).  
Chondrocytes have not only been found to express IL8, but the TNF-α-induced 
activation of NF-κB in chondrocytes also contributes to increased IL-8 protein 
production (Facchini et al., 2005). In fact, chondrocytes are a rich source of IL-8 
and its synthesis is up-regulated in arthritic pathologies and by increased 
inflammatory cytokines levels (Borzi et al., 1999, Pulsatelli et al., 1999). The role 
of chemokines as second step mediators of local inflammation has gained 
increasing evidence (Baggiolini, 1998, Luster, 1998), whereby chondrocytes 





1990, Lotz et al., 1992, Recklies and Golds, 1992). Mian and colleagues have 
demonstrated that IL-8 is involved in NF-κB activation and the over-expression of 
MMP2 and MMP9 and that targeting of this cytokine with anti-IL-8 antibody leads 
to down-regulation of these proteases (Mian et al., 2003). That suggests that IL-8 
can promote increase in matrix metalloproteinases expression, angiogenesis and 
neutrophil-mediated inflammation in the affected joint (Lotz et al., 1992, Strieter et 
al., 1992, Hu et al., 1993, Norrby, 1996), leading to further cartilage destruction, 
and makes it an interesting target for drug intervention. 
1.2.3.2.2 Nitric oxide and Cyclooxygenase. 
Among other inflammatory mediators found to be involved in the pathological 
process of OA is nitric oxide (NO).  It has been shown that osteoarthritic cartilage 
secretes large quantities of NO and ROS in addition to high levels of 
nitrite/nitrates, detected in serum and synovial fluid of arthritis patients (Karan et 
al., 2003). This process might be caused by the increased expression of 
inducible nitric oxide synthase, or iNOS (Martel-Pelletier and Pelletier, 2010).  
Two iso-forms of cyclooxygenase (COX), COX-1 and COX-2, catalyse the rate-
limiting step in the biochemical conversion of arachidonic acid to prostaglandins 
and thromboxane A2 (TXA2) (Smith et al., 1996). COX-1 is a constitutively 
expressed protein that is thought to produce basal concentrations of 
prostaglandins and TxA2 necessary for normal physiologic functions in many 
tissues. Moreover, COX-dependent production of prostaglandin E2 (PGE2) occurs 
in many tissues through closely regulated and synchronized activities of 
cytoplasmic phospholipase A2 (cPLA2), COX, and PGE synthase (PGES, for 
review, see refs: (Murakami et al., 2000). COX enzymes catalyze the formation of 
prostaglandin H2 (PGH2) from arachidonic acid, followed by the isomerisation of 
PGH2 to PGE2 by PGES. COX-2, PGES, and their major pro-inflammatory 
product, PGE2, have been shown to be induced by pro-inflammatory cytokines 
(Murakami et al., 2000, Vane and Botting, 1998a).  
Aberrant expression of COX-2 protein in articular cartilage concurs with 
significant increase in the levels of PGE2, an indication of osteoarthritis (Amin et 





Pelletier et al., 2001a, Goldring and Berenbaum, 2004). The major 
prostaglandins synthesized by chondrocytes are PGE2 and PGD2. Although 
some studies have suggested that PGE2 has anabolic effects at low 
concentrations (DiBattista et al., 1996) and that it can suppress MMP13 and 
MMP1-mediated catabolism (Tchetina et al., 2007), higher concentrations of this 
prostaglandin, such as those reached during inflammation lead to severe 
cartilage erosion and chondrocyte apoptosis (Amin et al., 1997, Attur et al., 
2008). Zhu and collagues show that exogenously added PGD2 diminishes T/C-
28a2 chondrocyte cell line viability (Zhu et al., 2010).  
In addition to regulating metalloproteinases, pro-inflammatory cytokines such as 
IL-1β and TNF-α have been shown to suppress the expression of COL2A1 by 
chondrocytes in vitro (Reginato et al., 1993, Goldring et al., 1994 a,b). In 
contrast, increased anabolic activity of chondrocytes has been observed in 
osteoarthritic cartilage, possibly due to the cytokine-induced PGE2 formation, 
which up-regulates COL2A1 transcription (Goldring et al., 1994b, Miyamoto et al., 
2003).  
1.2.3.2.3 Anti-inflammatory cytokines and proteins.  
In addition to the above mentioned pro-inflammatory cytokines, human 
chondrocytes have been shown to produce both IL-10 as well as the IL-10 
receptor (IL10R) with significantly higher levels in osteoarthritic chondrocytes 
compared to normal chondrocytes (Iannone et al., 2001). IL-10 is a pleiotropic 
cytokine with important immuno-regulatory functions, whose actions influence 
activities of many of the cell types in the immune system. IL-10 has potent anti-
inflammatory properties, repressing the expression of inflammatory cytokines 
such as TNF-α, IL-6 and IL-1β by activated cells. IL-10 receptor (IL10R) is a 
complex of tetramers consisting of two ligand-binding subunits (IL10R1) and two 
accessory signalling subunits (IL10R2). Upon binding of IL-10 to the extracellular 
domain of IL10R1, JAK1 and Tyrosine Kinase-2 (TYK2), which are constitutively 
associated with both IL10R1 and IL10R2, respectively, are activated by 
phosphorylation (Riley et al., 1999). These kinases then phosphorylate specific 
tyrosine residues on the intracellular domain of IL10R1, which when 





phosphorylated by JAK1 and translocates to the nucleus, where it binds with high 
affinity to SBE (STAT-Binding Elements) in the promoters of various IL-10 
responsive genes (Riley et al., 1999). IL-10 has also been reported to interfere 
with the activation of p38/MAPK pathway, thus inhibiting the activation of NF-κB. 
Direct stimulation of OA chondrocytes with IL-10 has been shown to inhibit the 
TNF-α-dependent activation of osteoarthritic chondrocytes and therefore to 
down-regulate the expression of MMP1 and MMP13 (Shlopov et al., 2000). 
Interestingly, IL-10 (Lee and Chau, 2002) induces heme oxygenase-1 (HO-1), 
which is expressed and functionally active in chondrocytes from OA cartilage 
(Fernandez et al., 2003). HO-1 is implicated in the protection against tissue injury 
and is modulated by cytokines such as IL-1β and TNF- α, the latter of which 
down-regulate HO-1(Fernandez et al., 2003). 
HO-1 expression can be strongly induced at transcription level in most tissues by 
various stress factors including heavy metal, heat shock, ultra violet radiation, 
endotoxin, hypoxia, hyperoxia, ischemia, hydrogen peroxide, pro-inflammatory 
cytokines (i.e. IL-1β, TNF-α), NO, cellular glutathione storage depletion and high 
levels of its substrate heme (Wagener et al., 2003). Contained within the 
promoter region of HO-1 are the oxidative stress-responsive transcription factor 
NF-E2-related factor 2 (Nrf2), NF-κB, AP-1, AP-2 and CREB. Alternatively, HO-1 
can be negatively regulated by agents such as scavengers of ROS due to their 
ability to reduce oxidative stress within the body (Lautier et al., 1992). Primarily, 
HO-1 induction prevents cellular damage and tissue injury by removing excess 
free heme within the body. In addition, heme acts as a prosthetic group for the 
activity of inflammatory enzymes including iNOS and COX-2 (Willis, 1999) and is 
involved in the generation of ROS and RNS that causes cellular stress (Jeney et 
al., 2002).  
1.2.3.2.4  Matrix metalloproteinases in OA. 
Proteinases are involved in essential steps of cartilage and bone homeostasis. 
Normal cartilage ECM is in a state of dynamic equilibrium, with a balance 
between anabolism and catabolism, brought about by the balance between the 
proteinases that degrade the cartilage and their inhibitors. It is believed that a 





degradation of cartilage ECM observed in osteoarthritis (Kevorkian et al., 2004). 
MMPs are induced by TNF-α, IL-1β, which in combination with IL-6, IL-8, 
oncostatin M, and other pro-inflammatory mediators, synergistically enhance 
MMPs production in vitro, ex vivo and in vivo (Shlopov et al., 2000, Hui et al., 
2003, Hall et al., 2003, Cawston et al., 2003). 
MMPs are responsible for the enzymatic cleavage of peptide bonds (Turk, 2006, 
Lah et al., 2006) for the completion of many biological processes, such as 
digestion, blood coagulation, immune functions, development, apoptosis and 
processing of precursors needed for collagen synthesis (Dickinson, 2002). 
Proteases selectively hydrolyse a peptide bond in the polypeptide chains of the 
target protein and are subdivided into two main groups depending on the location 
of the preferred peptide bond – endopeptidases and exopeptidases. 
Exopeptidases are subdivided into aminopeptidases or carboxypeptidases – 
peptidases that cleave substrate molecules at the amino-terminal or the carboxy-
terminal position, respectively (Barrett, 1980, Cawston and Wilson, 2006). 
Endopeptidases cleave in the middle of the target polypeptide chain and can be 
subdivided into groups depending on the chemical group involved in the process 
of catalysis – aspartic-, threonine- and cysteine-proteinases (intracellular, 
functioning at acid pH), or serine- and metallo- proteinases (extracellular, act at 
neutral pH; Figure 1.4)(Cawston and Wilson, 2006).  
Degradation of the components of ECM is accomplished by a family of more than 
26 zinc-containing endopeptidases termed matrix metalloproteinases (MMPs), 
which are either secreted into the extracellular space, or attached to the plasma 
membrane of the respective cell (Visse and Nagase, 2003). They share 
homologous amino acid sequences, contain conserved domains related to their 
specific substrate preference, and allow recognition of other proteins (Visse and 
Nagase, 2003). As a family, MMPs can degrade nearly all of the cartilage ECM 







Figure 1.4 Summary of proteases. 
In general, MMPs are composed of three distinct domains (Rannou et al., 2006): 
a pre-domain, needed for enzyme maturation and secretion from the cell; pro-
domain, required for the maintenance of the enzyme in inactive state; and the 
catalytic domain, which contains a zinc atom and performs the hydrolysis of the 
peptide bond. MMPs are categorized into at least five main groups, according to 
their substrates, cellular localization and primary structure: collagenases, 
gelatinases, stromelysins and membrane bound (MT)-MMPs (Table 1.1; Figure 
1.4). MMPs are tightly controlled at several levels – transcriptional control, pro-
enzyme activation, and inhibition of active enzymes by endogenous inhibitors 
(Chakraborti et al., 2003). At transcriptional level, MMPs gene expression is 
regulated by pro-inflammatory cytokines and growth factors. After binding to their 
specific receptors, these stimuli activate an intracellular cascade of events, 
leading to the activation of AP-1 transcription factors and that leads to the up-











MMP1 (collagenase-1)*, MMP8 (collagenase-2), 




















MMP14 (MT1-MMP), MMP15 (MT2-MMP), 
MMP16 (MT3-MMP), MMP17 (MT4-MMP), 
MMP24 (MT5-MMP), MMP25 (MT6-MMP). 
 
MMPs, matrix metalloproteinases; MT, membrane type. 
*Proteases studied in the present study. 
Another mechanism of regulation is the secretion of pro-enzymes MMPs. The 
proteinases are secreted in inactive form, and require the removal of the pro-
domain by MT1-, MT2-, MT5-MMP, plasmin, uPA (urokinase) for activation 
(Chakraborti et al., 2003). Upon removal of the pro-domain, MMPs become 
transiently unstable and undergo conformational change, involving a dissociation 
of a cysteine residue from the zinc atom in the catalytic domain, thereby 
exposing the active site and allowing for trans-auto activation of the MMP 
(Chakraborti et al., 2003). 
Most cells in the body express MMPs, even though some proteases are 
associated with a particular cell type. For example the principle substrate for 
MMP2, or gelatinase A and MMP9, or gelatinase B is the type IV collagen. 
MMP3, also called stromelysin activates MMP1, or collagenase-1, and is able to 
cleave a broad range of matrix proteins (Vincenti et al., 1996). Both MMP1 and 





MMP13, or collagenase-3, which is expressed primarily by cartilage and bone 
during development and by the chondrocytes in OA (Borden and Heller, 1997, 
Mengshol et al., 2000, Martel-Pelletier et al., 2001, Kevorkian et al., 2004).  
The only mammalian interstitial proteases that can specifically cut triple-helical 
interstitial collagens (type and type II) at natural pH are collagenases (Gadher et 
al., 1990, Kevorkian et al., 2004), which cleave at a single locus three quarters 
from the N-terminus, leading to the unwinding of the α-chains. The major 
collagenases able to perform this enzymatic reaction (MMP1, MMP8 and 
MMP13) were found elevated in OA cartilage compared to normal tissue (Reboul 
et al., 1996; Martel-Pelletier et al., 2000). The specific role of MMP8, however, in 
OA progression remains to be investigated.  
IL-1β and TNF-α are thought to be the most important cytokines relevant to 
osteoarthritis, with increased levels in OA chondrocytes (Tetlow et al., 2001). 
They are thought to down-regulate anabolic genes such as aggrecan and type II 
collagen, as well as to directly up-regulate the expression of MMP1, MMP3 and 
MMP13 (Shlopov et al., 1997, Bau et al., 2002). MMP13 specifically hydrolyses 
type II collagen more rapidly and efficiently than MMP1 and MMP8 (Mitchell et 
al., 1996). Chondrocytes obtained from cartilage adjacent to OA lesions 
expressed high levels of both MMP1 and MMP13 (Shlopov et al., 1997).   
Kevorkian and colleagues conducted the expression profiling of MMPs in 
cartilage samples obtained from the hips and knees of normal and OA patients 
(Kevorkian et al., 2004). Examination of collagenases showed that MMP8 
expression was undetected thus suggesting that it is unlikely to play a role in 
cartilage destruction. MMP9 and MMP2, however, are significantly over-
expressed in OA cartilage. The inducible MMP9 is thought to have a secondary 
role, since it contributes to cleaving collagen fibres only after the chains of the 
triple helix have been already cleaved by the interstitial collagenases (Stetler-
Stevenson et al., 1997). In contrast MMP2 and MMP14 (MT1-MMP) are both 
constitutively expressed and minimally regulated.  
MMP13 expression is highly increased in OA, consistent with the belief that it is 
the predominant protease in osteoarthritis (Kevorkian et al., 2004). Interestingly, 





was found to be highly increased in osteoarthritic knee cartilage, suggesting that 
the regulation of this collagenase may differ between joints. A dramatic decrease 
in MMP3 in diseased knee cartilage has also been found, and therefore a 
maintenance function of this protease, which is dysregulated in OA, is suggested 
(Kevorkian et al., 2004; Bau et al., 2002).  
1.2.3.2.5 Chondrocyte apoptosis and OA. 
Apoptosis, or programmed cell death, is a normal process during which an 
orchestrated sequence of events leads to cell death, primarily executed by 
enzymes called caspases (Kerr et al., 1972). Apoptosis is critical not only during 
development and tissue homeostasis, but also in the pathogenesis of a variety of 
diseases. Recent studies have revealed that apoptosis is associated with the 
onset and development of OA (Blanco et al., 1998, Kim et al., 2000, Sharif et al., 
2004, Musumeci et al., 2011), whereby the proportion of apoptotic cells in OA is 
greater compared to that in healthy cartilage (Aigner et al., 2001). The 
expression of several caspases, such as caspase-3 and caspase-8, has been 
found to be increased in human osteoarthritic cartilage and in animal models of 
the disease (Sharif et al., 2004, Robertson et al., 2006)  
Caspases are a unique family of cysteine-aspartic proteases (Alnemri et al., 
1996), which are triggered in early stages of apoptosis and are responsible for 
the activation of most of the events leading to cell death, by cleaving more than a 
dozen protein kinases, including focal adhesion kinases (FAK), Protein Kinases B 
& C (PKB & PKC), Raf1 and Lamins. The latter make up the inner lining of the 
nucleus, and their destruction leads to disintegration of the nuclear lamina, and 
shrinkage of the nucleus (Kerr et al., 1972) 
Apoptosis can be triggered by intrinsic stimuli such as DNA damage, or by 
extrinsic stimuli such as cytokines. One of the major cytokines, produced by 
variety of cells in response to infection or multitude of inflammatory stimulants is 
TNF-α. Activation of its receptor, TNFR1, a member of a family of death 
receptors is involved in the initiation of apoptosis. It is suggested that the TNFR1 
is a preassembled trimer, located on the plasma membrane, the cytoplasmic 
domain of each subunit of which contains a segment of about 70 amino acids 





associate to induce cell death, by either activating AP-1 and NF-κB (Figure 1.5), 
or inducing apoptosis. Binding of TNF-α to its receptor causes a conformational 
change in the death domain, which initiates the recruitment of a number of 
proteins as indicated in Figure 1.5, two pro-caspases join the protein complex 
and undergo proteolytic cleavage that yields active caspase-8. Caspase-8 is 
called an initiator caspase, because it instigates the apoptotic process by 
activating effector caspases, such as caspase-3, directly involved in carrying out 
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Figure 1.5 Molecular mechanism of caspase-driven programmed cell death.  
Initially, TRADD (TNFR-Associated Death Domain) protein, binds to TNFR1. Then, 
TRADD recruits FADD (Fas-Associated Death Domain), RAIDD (RIP-Associated ICH-
1/CED-3-homologous protein with a Death Domain), MADD (MAPK Activating Death 
Domain) and RIP (Receptor-Interacting Protein). Binding of TRADD and FADD to 
TNFR1 leads to the recruitment, oligomerization, and activation of Caspase-8 
Activated Caspase8 subsequently initiates a proteolytic cascade that includes effector 





1.2.4 Current therapies for the treatment of OA. 
A vast array of novel therapies have been developed over the last decade or so 
for the treatment of arthritic pathologies, especially RA, which now sit alongside 
the more traditional approaches that include methotrexate, non-steroidal anti-
inflammatory drugs (NSAIDs), and glucocorticoids (for review, see: Getting et al., 
2009). The most widely used therapies for OA are physiotherapy; non-selective 
COX-1/2 inhibitors such as ibuprofen, naproxen, usually prescribed with protein 
pump inhibitors such as omeprazole, to alleviate GI side-effects; COX-2 selective 
inhibitors, or ‘coxibs’ are another choice of therapy, usually given with low dose 
aspirin, to prevent CV side-effects, and a proton pump inhibitor. A third choice of 
therapy is glucocorticoids, prednisone being the drug of choice, administered via 
intra-articular (i. a.) injection. 
1.2.4.1 Non-steroidal anti-inflammatory drugs (NSAIDs).  
NSAIDs form an important class of drugs, the therapeutic applications of which 
have spanned several centuries. The ability of NSAIDs to treat fever and 
inflammation dates back about 3500 years ago to the time when Hippocrates 
prescribed an extract from willow bark. In the 17th century, the active ingredient of 
the bark salicin was discovered, in 1860, the German Kolbe company started 
producing salicylic acid for the first time and in 1899, Bayer started mass 
production of Acetylsalicylic acid, or as we know it aspirin (Vane, 2000). The 
mechanism of action of drugs like aspirin and Indomethacin was revealed by 
Professor Sir John Vane ~ 40 years ago (Vane, 1971). 
The primary effect of NSAIDs is pain relief, but they also exhibit anti-pyretic and 
anti-inflammatory effects (Vane, 1971) but do not modify the underlying causes 
of chronic diseases, and these drugs are thus prescribed for symptomatic relief 
only. The success of the NSAIDs in treating inflammatory disorders such as RA 
and OA was due to its inhibitory effects on the enzyme cyclooxygenase (COX) 
(Vane and Botting, 1998b) NSAIDs inhibit prostaglandin synthesis, which can 
lead to gastro intestinal (GI) toxicity, limiting its use in chronic inflammatory 
conditions such as OA (Tamblyn et al., 1997). Seminal work by Prof. Sir John 





forms of COX enzyme – COX-1 and COX-2 (Flower and Vane, 1972). The 
traditional NSAIDs, prescribed for the treatment of joint pain and inflammation, 
are known to bring about their anti-inflammatory effects by non-selective 
inhibition of COX activity. However, during inflammation, expression of COX-1 
levels do not change, whilst COX-2 levels are significantly up-regulated (Rao and 
Knaus, 2008), leading to increased production of pro-inflammatory 
prostaglandins. COX-1 on other hand does not appear to be associated with 
inflammation, but is highly expressed in the GI tract (Kargman et al., 1996), 
where it is involved in the production of cytoprotective PGE2 and PGI2, thereby 
reducing gastric acid secretion (by the parietal cells in the stomach), up-
regulating mucosal blood flow and initiating production of viscous protective 
mucus. This explains the adverse effect of the traditional NSAIDS (Lazzaroni and 
Bianchi Porro, 2004). COX-1 isoform is also widely expressed in platelets, where 
they are responsible for the formation of pro-aggregatory thromboxane A2 (TxA2). 
These adverse effects led to the development of selective COX-2 inhibitors to 
bring about a more targeted and specific anti-inflammatory effect (Lazzaroni and 
Bianchi Porro, 2004). However, post-marketing pharmacovigilance of selective 
COX-2 inhibitors including celecoxib and rofecoxib (VIOXX), highlighted an ~5 
fold increase in myocardial infarction (Mukherjee et al., 2001), explained by the 
effect of the selective COX-2 inhibitors on PGI2 production. PGI2 is a vasodilator 
and a potent inhibitor of platelet aggregation (McAdam et al., 1999), which was 
significantly attenuated by the selective COX-2 inhibitors. Although selective 
COX-2 inhibition has no effect on TxA2 production, they tip the natural balance 
between the TxA2 and PGI2 production, thus leading to an increased risk of 
thrombotic cardiovascular event as demonstrated more recently (Cannon et al., 
2006). Studies showed that selective inhibition, knock down or mutagenesis of 
COX-2, or deletion of the receptor for PGI2, accelerated thrombogenesis and 
elevated blood pressure in mice, an effect found to be attenuated by COX-1 
knock-down (Cheng et al., 2006). Discoveries like this led to the withdrawal of the 
very selective COX-2 inhibitor rofecoxib from the market in September 2004, just 






Glucocorticoids are endogenously produced hormones implicated in carbohydrate 
and protein metabolism and exert a potent regulatory effect on inflammation, innate 
and acquired immune response (Auphan et al., 1995). Additionally, they are potent 
anti-inflammatory drugs inhibiting the synthesis of pro-inflammatory cytokines, 
interleukins and iNOS, and the production of PGE2 by inhibiting the transcription of 
COX-2.  
Glucocorticoid receptor is a member of the family of nuclear receptors, which upon 
binding to their cognate ligands, migrate to the nucleus and act as positive or 
negative gene transcription regulators (Schacke et al., 2004)(Figure 1.6). In the case 
of positive regulation they trans-activate glucocorticoid response elements (GREs) 
that are located on the promoter region of the responsive genes (Beato et al., 1995, 
Mangelsdorf et al., 1995, Kastner et al., 1995).  Glucocorticoid receptors are able to 
negatively regulate transcriptional activation of certain genes in two descriptive 
mechanisms, one of which is referred to as trans-repression. Trans-repression 
involves repression of transcription factor AP-1, thus inhibiting its dissociation from 
the promoter (Konig et al., 1992). Another mechanism of action of glucocorticoid 
receptors is the repression of the NF-κB transcription factor family by physically 
associating with p65 subunit (Mukaida et al., 1994, Ray and Prefontaine, 1994, 
Caldenhoven et al., 1995) In addition, in most cell types excluding endothelial cells, 
the glucocorticoid receptors trans-activates the IκBα gene transcription, thus leading 
to prevention of NF-κB translocation in the nucleus (Auphan et al., 1995, Scheinman 
et al., 1995, Brostjan et al., 1996).  
Glucocorticoids are effective anti-inflammatory therapies; however side effects, 
including suppression of the immune response, healing impairment and gastric 
ulceration, can limit their use (Schacke et al., 2002). When used as anti-inflammatory 
agents, glucocorticoids also influence water and electrolyte balance, leading to 
Cushing’s syndrome, easy bruising, and redistribution of the fat in the abdominal 
region. Additionally, glucocorticoid drugs influence bone density by Ca2+ regulation 
and phosphate metabolism (Guaydier-Souquieres et al., 1996). While these adverse 
effects are not a problem in short-term oral therapy, or more localized application of 
the drugs (such as i.a. injections or topical ointments), they severely limit the long-
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Figure 1.6 Glucocorticoids mechanism of action.  
Glucocorticoid receptors are maintained in an inactive oligomeric complex by regulatory proteins 
such as HSP90 (Heat Shock Protein 90 kD), which after dimerizing bind to HSP70, FKBP52 and 
p23 phosphoprotein, all of which form the GR inhibitory complex. Upon binding to its 
glucocorticoid ligand in the cytoplasm, the inhibitory complex dissociates, induces conformational 
change that exposes the nuclear localization signal of the GR, which then translocates to the 
nucleus (Pelaia et al., 2003). There, the GR negatively regulate (trans-repress) gene transcription 
via physical interactions with transcription factors, activated by various pro-inflammatory stimuli 
(cytokines, etc.) such as the components of AP-1 – c-Jun and c-Fos, and the p65 domain of NF-
κB (Schoneveld et al., 2004, Davies et al., 2005). Other mechanisms by which glucocorticoids 
NF-κB-mediated activation of pro-inflammatory genes are by reducing the levels of 
phosphorylation of the carboxy-terminal domain of RNA Polymerase II, which is essential for the 
recruitment of this enzyme to the promoter region and by increasing the transcription and 
synthesis of IκB, thus causing NF-κB retention into the cytoplasm. The glucocorticoid family are 
also suggested to negatively regulate the MAPK family (JNK, ERK1, ERK2 and p38), therefore 






TNF-α is a primary pro-inflammatory cytokine detected in the synovium and 
plasma of RA patients and OA cartilage, and is known to be able to activate an 
array of pro-inflammatory cytokines, including IL-1β, IL-6, IL-8 and MCP-1. Anti-
inflammatory therapy with monoclonal antibodies (mAbs) directed against TNF-α 
has emerged in the 1990’s as a major advancement in the treatment of various 
immune-mediated diseases such as RA, ankylosing spondylitis, psoriatic arthritis 
and Crohn's disease. A huge boost to anti-inflammatory therapy developments 
has been the launch of the protein-based injectable etanercept (Enbrel®), and 
anti-TNF antibodies infliximab (Remicade®), adalimumab (Humira®) (Palladino 
et al., 2003, Wong et al., 2008), also referred to as ‘biologicals’. These anti-TNF 
monoclonal antibodies exert their beneficial effects by scavenging the pro-
inflammatory cytokine TNF-α.  
Infliximab is a chimeric monoclonal anti-TNF-α antibody, which binds to soluble 
and membrane-bound TNF-α, but not to TNF-β, and is able to effectively regulate 
and mediate inflammatory processes involved in a number of different 
inflammatory diseases such as RA, Crohns disease, and ulcerative colitis 
(Bingham, 2008, Haveran et al., 2011). Other anti-cytokine drugs available on the 
market are etanercept – a TNF receptor covalently linked to the Fc chain of IgG 
molecule, and anakinra – an IL-1 antagonist. Infliximab, adalimumab and 
etanercept inhibit the effect of TNF-α by binding to it, although etanercept can 
additionally bind to lymphotoxin-α. This can be of interest in the treatment of 
juvenile arthritis, due to lymphotoxin-α production by inflamed tissues 
(Heiligenhaus et al., 2011, Sevcic et al., 2011). 
Even though a beneficial effect has been assigned to these drugs in the clinical 
management of chronic arthritis and other inflammatory diseases, biologicals 
lead to a marked increase in opportunistic infections including tuberculosis (TB) 
with a 3-4-fold higher risk in patients taking infliximab compared to etanercept 
(Dixon et al., 2010). In part, this could be due to latent TB and so routine 
screening of individuals prior to commencing therapy is necessary. A recent 
review by Wallis identified that TNF antibodies pose a greater risk than soluble 





when used for prolonged period of time to treat inflammatory disease such as 
inflammatory bowel disease and Crohn disease causes psoriasis, urinary tract 
infections, nausea, rashes, decreased white and red cell count and platelet 
count, vasculitis, and development of lymphoma (Lee et al., 2007, Ko et al., 
2009, Fiorino et al., 2009). A number of cytokine antagonists are in development 
for treatment of RA, including those that target IL-6 (tocilizumab; approved for 
use in Japan), IL-15, and RANKL, as well as kinase inhibitors, including those 
that inhibit JAK-3 and SyK (Bingham, 2008). Although some patients respond 
well to these agents, development of novel therapies is essential should patients 
become refractory to current therapies.  
1.2.4.4 Endogenous novel therapeutics 
Annexin 1 is a member of the annexin superfamily of calcium and phospholipid 
binding proteins (Gerke and Moss, 2002, Perretti and Gavins, 2003). Due to its 
up-regulation by glucocorticoids, Annexin 1 has been suggested to function as a 
cellular mediator of the anti-inflammatory effects of glucocorticoids (Roviezzo et 
al., 2002). Cytokines such as IL-1β, TNF-α and IL-6 have been shown to 
augment Annexin 1 expression (Perretti and Gavins, 2003). A variety of functions 
have been attributed to this peptide, including inhibition of cell proliferation 
(Croxtall and Flower, 1992), anti-migratory and anti-inflammatory effects (Flower 
and Rothwell, 1994, Philip et al., 1997, Gerke and Moss, 2002, Perretti et al., 
2002), cell differentiation regulation, and membrane trafficking (Diakonova et al., 
1997, Traverso et al., 1999). The anti-inflammatory properties of Annexin 1 have 
been already demonstrated in animal models of RA and myocardial infarction 
(Perretti et al., 1993, Yang et al., 1999, La et al., 2001) 
The potential involvement of Annexin 1 in human conditions has been best 
described in RA, where the endogenous peptide inhibits experimental arthritis in 
animal models, and upon treatment with anti-annexin-1 antibody, the disease 
progression exacerbates severely and prevents glucocorticoid drug-mediated 
anti-inflammatory effects (e.g. dexamethasone) and up-regulates PGE2 and TNF-
α production by the synovium (Yang et al., 1997). These data suggested that 





manipulation of endogenous annexin-1 expression, may prove a beneficial 
treatment approach in arthritis and other inflammatory diseases. 
In concordance with the increasing interest in investigating the properties of 
endogenous anti-inflammatory mediators, the family of galectins is progressively 
examined for their immuno-regulatory and anti-inflammatory properties. Galectins 
(type of lectins, which bind to β-galactosidase), of which 14 mammalian subtypes 
have been identified, are wildly distributed in animals and possess a variety of 
functions, including inhibition of chronic inflammation (Dumic et al., 2006, Norling 
et al., 2009). 
Interest has been directed towards Galectin-1, -3 and -9, as these have been 
identified as important players in modulation of both acute and chronic 
inflammatory diseases (Norling et al., 2009). Galectin-1 exhibited anti-
inflammatory and immunosuppressive properties in a range of models of 
inflammatory disorders including colitis (Santucci et al., 2003), arthritis 
(Rabinovich et al., 1999) and diabetes (Perone et al., 2006). Galectin-3 is found 
in various epithelial cells and cartilage, as well as inflammatory cells such as 
macrophages, suggesting a role in inflammation (Henderson and Sethi, 2009). 
Increased expression of Galectin-3 and -9 have been detected in synovium of 
rheumatoid arthritis patients and to a lesser extent in osteoarthritic synovium 
(Ohshima et al., 2003, Seki et al., 2007), whereas Galectin-1 expression is down-
regulated in synovium from patients with juvenile idiopathic arthritis (Harjacek et 
al., 2001). Galectin-3 has been implicated in a variety of processes such as heart 
failure, fibrogenesis, tissue repair, inflammation, cancer and stroke (van 
Kimmenade et al., 2006, Yan et al., 2009a, Yan et al., 2009b, Liu et al., 2009, de 
Boer et al., 2009). 
Another class of endogenously produced peptides, with anti-inflammatory and 
immunosuppressive efficiencies are the melanocortin peptides (including α-MSH) 
found to be efficacious in experimental models of allergic inflammation (Grabbe 
et al., 1996, Luger et al., 2000), chronic inflammation (Ceriani et al., 1994), 
systemic inflammation (Delgado Hernandez et al., 1999), inflammatory bowel 
disease, brain inflammation (Rajora et al., 1997a,b) and autoimmune 
uveoretinitis (Taylor and Namba, 2001). A mechanistic approach has been 





G-protein coupled receptors, whose activation leads to increase in cyclic 
adenosine monophosphate (cAMP), thereby preventing NF-κB activation via 
preservation of IκBα protein and resulting in the reduction of production and 
synthesis of pro-inflammatory cytokines (Catania et al., 2004).  
1.3 Melanocortin system. 
The “melanophore stimulants” were discovered about 90 years ago during 
surgical ablation experiments by Hogben and Winten (Hogben and Winton, 
1922), in which the pituitary gland has been shown to be implicated in the 
change of skin colour of amphibian. This led to the recognition of pars intermedia 
as the origin of biological principle. In the 1950s an isolated frog skin assay was 
developed, which led to the extraction, molecular characterisation and sequence 
determination of melanocyte-stimulating hormones (MSHs; melanotropins) 
(Shizume et al., 1954). 
Melanocortins are ancient peptides which can be traced back over 700 million 
years and are derived from the pro-opiomelanocortin (POMC) gene (Heinig et al., 
1995). The melanocortin system has been shown to play numerous roles 
including melanogenesis, energy homeostasis regulation and modulation of 
inflammatory pathways, obesity, cardiovascular and sexual health (Wikberg et 
al., 2000). The discovery of anti-inflammatory and immuno-modulatory functions 
has led to a renewed interest in alpha-melanocyte stimulating hormone (α-MSH), 
which along with its related peptides and their cognate receptors are responsible 
for the transmission of these effects and might present potential treatment 
options for inflammatory diseases (Getting, 2002, Catania et al., 2004).  
The isolation and sequence determination of adrenocorticotrophic hormone 
(ACTH), β-lipotropin and γ-lipotropin demonstrated that the sequence for α-MSH 
was formed following proteolytic cleavage of ACTH (Nakanishi et al., 1979). 
These findings led to the hypothesis that the longer peptides might be serving as 
a precursor for the shorter proteins (Nakanishi et al., 1979). In 1979 and after 
deducing the whole amino acid sequence of the POMC peptide from its cDNA, 
Nakanishi and colleagues reported that it contains an unknown MSH-like peptide 
sequence, and identified a region bearing homology with α-MSH and β-MSH 





Due to the region separation by a dibasic amino acid cleavage sites, they 
predicted that the intervening peptide will be a secretory product and termed it γ-
MSH, due to the high homology to α-MSH and β-MSH. In the last 30 years 
POMC-derived molecules from many different species were analysed and their 
genes sequenced. It has been confirmed that POMC gene is expressed in many 
different tissues and the bioactive peptides, resulting from its post-translational 
processing, function as not only neuro-peptide regulators in the brain, but also in 
the periphery (D'Agostino and Diano, 2010). 
1.3.1 Pro-opiomelanocortin (POMC) protein. 
The POMC gene is 241 amino acids in humans (Takahashi et al., 1981), and 209 
in mouse (Uhler and Herbert, 1983) and rat (Drouin and Goodman, 1980). POMC 
is actively transcribed in several tissues, including the hypothalamus, pituitary 
and periphery including the immune system, lungs, spleen, melanocytes and the 
gastrointestinal tract (Wikberg et al., 2000). POMC is functionally inert, but 
undergoes extensive and tissue-specific post-translational modification in order 
to generate the range of smaller and biologically active peptides mentioned 
earlier (Rafin-Sanson et al., 2003; Figure 1.7).POMC is comprised of three 
domains: the N-terminus region, which contains γ-MSH (melanocyte stimulating 
hormone); the central highly conserved ACTH1-39 sequence with α-MSH at its N-
terminus; and the C- terminal β-lipotropin, which can be cleaved to generate β-
endorphin (Castro and Morrison, 1997). Many hormones and neurotransmitters 
are synthesized as large pro-hormones, which require cleavage in order to 
release biologically active fragments. Within the ACTH1-13 sequence and the 
endorphin system, the cleavage sites are usually located between two pairs of 
basic amino acid residues (-KK-, -RK-, -RR-, -KR-). There are seven members of 
the pro-hormone convertases (PC) family including PC1/3, PC2, furin/PACE, 
PACE4, PC4, PC5/6, and PC7/SPC7/LPC/PC8 (von Eggelkraut-Gottanka and 
Beck-Sickinger, 2004) and the range of processing enzymes expressed in 
particular tissue, defines the repertoire of POMC-derived products. Thus, PC1 
cleaves POMC into ACTH1-39 and β-lipotropin, together with low concentrations of 
β-endorphin, whilst PC2 cleaves POMC into β-endorphin and β-MSH (Figure 






Figure 1.7 Bioactive peptides formed following the post-translational processing 
of POMC.  
POMC in mammals is composed of 3 exons, of which exons 2 and 3 are translated into 
protein. Prohormone convertases 1 and 2 (PC1/2) break the parent POMC peptide into 
successively smaller peptides by cleavage at paired dibasic amino acid residues 
consisting of lysine (K) and/or arginine (R). Cleavage of pro-ACTH by PC1 gives rise to 
N-POC and joining peptide (JP). The final products are generated in a tissue specific 
manner by PC2, for example α-MSH and ACTH. They also involve additional enzymatic 
post-translational modifications, such as in the formation of mature α-MSH - removal of 
basic amino acid residues by the C-terminal by carboxypeptidases (CPE), amidation by 
α-amidating mono-oxygenase (PAM) and finally acetylation of α-MSH by n-
acetyltransferase (N-AT). The final products include the melanocortins (MSHs and 
ACTH), β-endorphin and corticotrophin-like intermediate peptide (CLIP). There are 
intermediate peptides whose biological function remains unclear, such as β-lipotrophin 
and γ-lipotrophins.  All melanocortin peptides contain the common amino acid motif 
sequence, with ACTH and α-MSH also having in common the tripeptide KPV, which has 





1.3.2 Melanocortin receptors: Binding and distribution. 
Melanocortin peptides exert their biological effects by binding to the smallest 
family of membrane bound guanine nucleotide-binding protein-coupled receptors 
(GPCRs). These are composed of seven transmembrane spanning α-helices 
connected by three intracellular and three extracellular loops and short 
extracellular N-terminus and short intracellular C-terminus (Catania et al., 2004). 
All melanocortin receptors possess two highly conserved cysteine residues in 
their C-terminus that form covalent disulphide bonds and therefore stabilize the 
receptor structure. 
The melanocortin receptor (MC) family consists of five members that have been 
cloned and termed MC1 to MC5. Each receptor is positively coupled to adenylate 
cyclase; with activation leading to cAMP accumulation following ligation by the 
common, core tetrapeptide sequence His-Phe-Arg-Trp (HFRW; Wikberg et al., 
2000; Getting, 2006). Even though α-MSH has equal affinity to MC3 and MC4, it 
has been shown to be somewhat specific to MC1 (Schioth et al., 1996, 2005; 
Siegrist and Eberle, 1995). Conversely, β-MSH, γ3-MSH and ACTH have been 
shown to have the highest affinity for MC4 (Schioth et al., 1996, Harrold et al., 
2003), MC3 (Gantz et al., 1993a) and MC2 (Getting, 2006) respectively.  
MCs are expressed in a multitude of tissues (Catania et al., 2004) with varying 
levels of sequence homology between different receptors. For example, there is 
38 % similarity between MC2 and MC4 and 60 % between MC4 and MC5. In 
addition to elevations in cAMP, α-MSH can down-regulate NF-κB activation by 
preventing phosphorylation and degradation of IκB and thus cytokine synthesis 
(Figure 1.8) (Kelly et al., 2006). Increases in intracellular calcium and secondary 
activation of inositol tri-phosphate have also been proposed as potential 
mechanisms of action (Wikberg et al., 2000). In addition, PKC and/or PKA 
recognition sites have been identified on the melanocortin receptors, suggesting 
that MCs may act as activators of these signaling pathways (Chhajlani and 
Wikberg, 1992). A number of natural and synthetic melanocortin peptides have 





1.3.2.1 Melanocortin 1 Receptor (MC1). 
MC1, a 317-amino-acid protein cloned in 1992 (Chhajlani and Wikberg, 1992, 
Mountjoy et al., 1994), is an intronless gene, located on chromosome 16q24.3. It 
has a multitude of functions including pigmentation, antipyresis and anti-
inflammatory, due to its expression peripherally on melanocytes (Chhajlani and 
Wikberg, 1992; Mountjoy et al., 1992), monocytes (Bhardwaj et al., 1997), 
neutrophils (Catania et al., 1996), endothelial cells (Hartmeyer et al., 1997), 
fibroblasts (Hill et al., 2006), mast cells (Adachi et al., 1999), lymphocytes 
(Neumann Andersen et al., 2001) and macrophages (Star et al., 1995) and within 
the central nervous system (Xia et al., 1995). A recent publication has unveiled 
that human chondrocytes express MC1 (Grassel et al., 2009). The receptor is 
activated by a number of endogenous peptides, with α-MSH being the most 
active followed by ACTH1-39, with β-MSH and γ-MSH causing weak activation 
(Getting, 2006). Truncated peptides ACTH4-10 and ACTH1-10 do not activate MC1, 
suggesting that both the amino and carboxyl-terminal ends of α-MSH (ACTH1-13) 
are important for full biological activation (Tatro, 1996).  The relative affinity of 
melanocortin peptides for MC1 is shown in Table 1.2 bellow. Grässel and 
colleagues detected not only MC1 expression in articular chondrocytes in vitro, 
and in articular cartilage in situ, but they also found transcripts for MC2, MC5 and 
PCs, and confirmed these receptors were successfully translated into functionally 
active proteins, which upon activation modulate various pro-inflammatory 
cytokines, collagens and MMPs (Grässel et al., 2009)   
1.3.2.2 Melanocortin 2 Receptor/ACTH receptor (MC2). 
MC2 is an intronless gene, located on chromosome 18p11.2 and is translated into 
a 297-amino-acid long receptor (homo sapiens). It is unique among the other 
melanocortin receptors, as it is activated only by ACTH1-39, with no biological 
efficacy attributed to other melanocortin peptides (Getting, 2006). It has been 
detected in the adrenal cortex with expression within the zona fasciculata and the 
zone glomerulosa, the sites responsible for the synthesis and release of 
glucocorticoids and mineralcorticoids respectively (Mountjoy et al., 1992, Gantz 
and Fong, 2003) therefore it is essential for steroidogenesis. This receptor was 





adipocytes (mus musculus) (Boston and Cone, 1996) with a role in lipolysis when 
activated by ACTH (Boston, 1999). Mutations in this receptor are associated with 
the rare autosomal recessive disorder Familial Glucocorticoid Deficiency type 1, 
also known as hereditary unresponsiveness to ACTH (Clark et al., 1993). 
1.3.2.3 Melanocortin 3 receptor (MC3). 
MC3 is an intronless gene located on chromosome 20q13.2-q13.3 and its 
translation results in a protein, composed of 361 amino acids (homo sapiens) 
and 323 (mus musculus). MC3 is expressed in the periphery and CNS (Gantz et 
al., 1993a), with ACTH1-39, α, β and γ-MSH all equally potent in activating the 
receptor (Table 1.2).  
In contrast to MC1 the truncated peptides ACTH4-10 and ACTH1-10 are fully active 
at MC3 (Gantz et al., 1993c), suggesting that the core region HFRW is enough for 
activation. Expression was originally detected in the brain, placenta and the gut 
(Gantz et al., 1993a) but unlike the MC1 and MC2, no expression was detected in 
melanocytes or adrenal cortex (Gantz et al., 1993a). γ-MSH fails to induce an 
increase in circulating corticosterone, thereby it has been postulated that 
activation at MC3 does not stimulate the hypothalamic-pituitary-adrenal (HPA) 
axis (Getting et al., 1999). Significant MC3 expression has been reported within 
the hypothalamus and the limbic system, as well as the septum, hippocampus, 
thalamus and the midbrain (Roselli-Rehfuss et al., 1993). This pattern of 
expression has prompted the search of a central function played by MC3 which 
appeared to be energy metabolism (Butler and Cone, 2003). Receptor 
expression has also been detected in the heart (Guarini et al., 2002, Getting et 
al., 2004), where it has been demonstrated to mediate myocardial protection 
(Getting et al., 2004) and in peritoneal (Getting et al., 1999, 2001) and knee joint 
MØ (Getting et al., 2002) whereby modulating immune response to inflammation 
(Getting, 2002). The latter is suggested following the observation that activation 
of MC3 leads to an initial reduction in pro-inflammatory cytokines and 
chemokines, followed by the induction of anti-inflammatory mediators at later 





1.3.2.4 Melanocortin 4 receptor (MC4). 
Human MC4 is located on chromosome 18q22 and is composed of 332 amino 
acids with certain similarities to peptides that activate the MC1 (Table 1.2). 
Expression appears to be restricted to the CNS since detailed studies of various 
peripheral organs have failed to detect this receptor subtype (Gantz et al., 1993b, 
Chhajlani, 1996). MC4 is more widely distributed than MC3 within the CNS, being 
found in the cortex, thalamus, hypothalamus, brain stem and the spinal cord 
(Mountjoy et al., 1994).  The fact that PRO
12 of ACTH1-39, shared by α-MSH, is 
not present in ACTH4-10 or γ-MSH suggests that this amino acid residue could be 
critical for the binding of MC4 (Gantz et al., 1993b). Physiologically, MC4 
activation has been implicated in sexual dysfunction (Gantz and Fong, 2003), 
energy homeostasis, control of appetite (Butler and Cone, 2003) where the latter 
are of high interest within the pharmaceutical industry, due to the high demand 
for treatments of obesity.  
1.3.2.5 Melanocortin 5 receptor (MC5). 
MC5 was the last MC to be cloned (Gantz et al., 1994) and is located on 
chromosome 18p11.2, containing 325 amino acids (homo sapiens and mus 
musculus), with most potent agonists being α-MSH and ACTH1-39. Truncated 
peptides ACTH1-10 and ACTH4-13 have been found to provoke full activation of the 
receptor, although the effectiveness was considerably poorer when compared 
with α-MSH (Gantz et al., 1994). MC5 is widely expressed in peripheral tissues – 
liver, lung, thymus, testis, ovary, mammary glands, fat cells, bone marrow, skin, 
skeletal muscle, stomach and the duodenum (Gantz et al., 1994, Chhajlani, 
1996). mRNA expression has also been detected in the olfactory bulb, substantia 
nigra and striatum of the rat CNS (Griffon et al., 1994). In addition, the expression 
of MC5 has been reported in B-lymphocytes (Buggy, 1998) and T lymphocytes 
(Taylor and Namba, 2001), a fact that demonstrates a potential role in immuno-
modulation. Other hypotheses on its physiological participation includes: 
sebaceous secretion, water repulsion, thermal regulation and exocrine gland 
control (Chen et al., 1997). However, the exact role of MC5 within the body needs 





1.3.3 Melanocortin peptides. 
α-MSH corresponds to the first 13 N-terminal amino acid residues of ACTH1-39 
and is identical in all mammals from which it has been isolated so far (e.g. Mus 
musculus, Sus scrofa, Macaca mulata, Rattus norvegicus, Ovis aries, Camelus 
dromedarius, Equus caballus). The N-terminal serine residue of α-MSH is often 
N-acetylated and the valine at the C-terminus is almost always covalently linked 
to a carboxamide group, modifications, rendering α-MSH more potent and stable 
against exopeptidase activities (Lerner and McGuire, 1964). The structure of β-
MSH peptides of different vertebrates is more variable as compared to α-MSH. 
All β-MSH share 6 constant residues – Tyr5, His9-Phe10-Arg11-Trp-12 and Pro15 
and have an acidic iso-electric point (pI), as compared to α-MSH, which has 
higher pI. Conversely, γ-MSH sequence is not found in POMC precursor 
molecule of all vertebrate species. It is a dodecapeptide named Lys-γ1-MSH or 
just γ-MSH, and in its longer form (22-31 aa) is termed γ3-MSH. Significant 
sequence variations of the C-terminal sequence has been identified between 
species, whilst the N-terminal domain highly conserved (with Tyr2, His6-Phe7-
Agr8-TRP9 and Phe12 being the invariant residues in all species). γ-MSH is 
processed from γ3-MSH by cleavage at the dibasic residue pair RR (Figure 1.6), 
and contains an N-terminal lysine and carboxamide group that has been most 
likely generated similarly to those of α-MSH.  
In addition to these endogenous melanocortin receptor agonists, two naturally 
occurring antagonists have been confirmed: the Agouti signalling protein (ASP) 
and agouti-related protein (AGRP). Agouti’s gene, which encodes a 131 aa 
protein containing a signal sequence, controls the relative amounts of eumelanin 
and phaeomelanin pigments in mammals. Lu and colleagues noticed that Agouti, 
produced in hair follicles, acts on follicular melanocytes to inhibit α-MSH elicited 
eumelanin production (Lu et al., 1994). What is more, it has been proven that 
agouti is a high-affinity antagonist to both MC1 and MC4 and acts by preventing 
α-MSH from activating adenylate cyclase (Lu et al., 1994), thus a role in 
inflammation has been proposed (Catania et al., 2004). It is now wildly known 
that ASP (the human equivalent of mouse agouti) is broadly distributed, with 





(Wilson et al., 1995, Voisey and van Daal, 2002). Contrary, AGRP, is specifically 
expressed in the CNS – the neuronal cell bodies of the posterior hypothalamus in 
particular (Catania et al., 2004) and has been demonstrated to be an antagonist 
of MC3 (Ollmann et al., 1997). Additionally, AGRP blocked the anti-inflammatory 
effects of the selective MC3 agonist D[TRP]8-γ-MSH in a murine model of urate 
crystal peritonitis (Getting et al., 2006).  
1.3.4 Synthetic melanocortins. 
The melanocortin peptides are implicated in the regulation of pigmentation, 
adrenal function, memory, feeding behaviour, inflammation and more, as 
described previously (see section 1.3.2).  Molecular cloning and sequencing of 
the melanocortin receptors has boosted systematic studies for investigation of 
the molecular mechanisms implicated in these functions. Synthetic and non-
peptide development have enhanced our understanding of the biological 
functions of MCs in different tissues. The complexity and the wide expression 
distributions of the receptors, together with the high sequence homology has 
impeded the identification of all of their biological effects and has hindered the 
development of selective agonists and antagonists (Grieco et al., 2002). 
Identification of endogenous and synthetic peptides have been utilised to 
evaluate the pathophysiological role of the various MCs in different tissues. 
Extensive investigations led to the identification of the minimum fragment needed 
for activation of the MCs – HFRW, except MC2 (Wikberg et al., 2000). A number 
of peptides and non-peptide compounds have been developed over the last 20 
years with varying degrees of selectivity to help elucidate the roles played by 
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1.3.4.1 Melanocortin receptor agonists. 
[Nle4D-Phe7]-α-MSH (NDP-α-MSH) was one of the first synthesised analogues of 
α-MSH to display efficacy in inflammatory models (Sawyer et al., 1980), 
however, due to its length, the economic reality of bringing this peptide to market 
led to the development of smaller compounds. Given the short half-life and size 
of the peptide, smaller fragments were developed, including the potent MC3/4 
lactam-based heptapeptide super agonist melanotan II (MTII: Ac-Nle-c[Asp-
DPhe-Lys]-NH2;, EC50 = 2.8 nM) (Hadley et al., 1998) shown to be effective in 
models of murine obesity (Fan et al., 1997) and gouty arthritis (Getting et al., 
1999, 2001).  
Further identification of the natural agonists of the MC3 led to the discovery that 
Tryptophan substitution at position 8 into the natural sequence of γ-MSH leads to 
a selective compound termed D[TRP]8-γ-MSH  (D[TRP]8-γ-MSH: H-Tyr-Val-Met-
Gly-His-Phe-Arg-DTrp-Asp-Arg-Phe-Gly-OH; EC50= 0.33 nM), which has been 
recognized to have a 300-fold and 250-fold improvement in selectivity for the 
MC3 over MC4 and MC5, compared to the naturally occurring γ-MSH (EC50 = 5.9 
nM; Grieco et al., 2000).  
These findings highlighted that those amino acids changes within the polypeptide 
of α-MSH lead to the development of increasingly selective compounds. The 
discovery of the synthetic selective MC1 agonists MS05 (Ser-Ser-Ile-Ile-Ser-His-
Phe-Arg-Trp-Gly-Lys-Pro-Val-NH3) and MS09 (Ser-Ser-Ile-Ile-Ser-His-DPhe-Arg-
Trp-Gly-Lys-Pro-Val-NH2) occurred following screening of peptide phage display 
library (Martignoni et al., 1997) with MS09 being more potent, but less selective 
than MS05 (Wikberg et al., 2000). These compounds potently down-regulate the 
expression and secretion of selectin (E-selectin), vascular cell adhesion molecule 
(VCAM), and intracellular endothelial cell adhesion molecules (ICAM) in human 
dermal vascular endothelial cells treated with TNF-α. In addition, they down-
regulate IL-1β induced NF-κB activation in these cells (Brzoska et al., 1999). The 
octapeptide 154N-5 (Met-Phe-Arg-DTrp-Phe-Lys-Pro-Val-NH2), which showed a 
high degree of HTB-14, HEK293, Jurkat, TNP-1 cell-lines, primary human cells 





1.3.4.2 Melanocortin antagonists. 
Development of SHU9119 is one of the major breakthroughs in melanocortin 
pharmacology. Substitution of the bulky aromatic amino acid DNal(2’) into 
position 7 of ACTH1-39 led to the discovery of the antagonist at MC3 and MC4 with 
the structure Ac-Nle-c[Asp-His-DNal(2’)-Arg-Trp-Lys]-NH2 (Hruby et al., 1995). 
SHU9119 has allowed many groups to dissect the role of MC3 in diseases 
ranging from arthritis to cardiovascular pathologies, and also in models of obesity 
as it has been shown to be an antagonist at MC3/4 in murine model of obesity 
(Fan et al., 1997; Butler et al., 2000) and models of acute inflammation 
(Hartmayer et al., 1997; Neumann-Andersen et al., 2001; Hill et al., 2006; Adachi 
et al., 1999; Getting et al., 1999, 2001). Other substitutions into positions 6 to 15 
of ACTH1-39 have yielded the MC4 antagonist HS014 (Schioth et al., 1999), which 
blocked cAMP induced by α-MSH in MC4-transfected COS-1 cells.  The selective 
cyclic MC4 antagonist HS024 (Kask et al., 1998) has an enhanced 10-fold 
potency compared to HS014 (Schioth et al, 1999) and has been demonstrated to 
stimulate food intake in rats (Kask et al., 1998). In order to investigate further the 
role of His6 in the core tetrapeptide of the melanocortin peptides, Grieco and 
colleagues designed, synthesized and characterized new cyclic lactam ligands 
with several modifications and the most important variant was the substitution of 
the Histidine residue at position 6 in SHU9119 with a Pro and Hyp (Grieco et al., 
2002). This led to the discovery of the full agonists at MC5 – PG901 (Ac-Nle-
c[Asp-Pro-DNal(2’)-Arg-Trp]-Lys-NH2, EC50 = 0.072 nM), approx. 40 times more 
active than the superagonist MTII (EC50 = 2.8 nM), and PG911 (Ac-Nle-c[Asp-
Hyp-DNal(2’)-Arg-Trp]-Lys-NH2, EC50= 0.031 nM), which was synthesized by 
placing a Hyp residude at position 6). The His-Hyp substitution at position 6 of 
SHU9119 caused a remarkable agonistic activity of PG911 at MC5. In addition, 
both peptides showed noteworthy antagonistic activities on MC3 and MC4, 







1.3.5 Melanocortin peptides molecular mechanism of action. 
The main intracellular signalling mechanism of stimulated melanocortin receptors 
is cAMP production via MC/Gs coupled to adenylate cyclase (Wikberg et al., 
2000). However, the peptides have been shown to not only elicit cAMP increase, 
but also stimulate p38 pathway, extracellular signalling kinases (ERK; p44/42) 
(Mandrika et al., 2001), PKC and NF-κB transcription factors AP-1 and NF-κB as 
outlined in Figure 1.8 (Konda et al., 1994, Kalden et al., 1999, Ichiyama et al., 
1999). The binding of melanocortins to its corresponding receptor is thought to 
activate protein kinase A (PKA), which has four main effects. First, PKA 
activation induces the phosphorylation of the cAMP-responsive-element-binding 
protein (CREB), which, owing to its high affinity for the co-activator CREB-binding 
protein (CBP), prevents the association of CBP with p65 (which is a key 
component of (NF-κB). Second, activated PKA inhibits IκB kinase (IKK), which 
stabilizes the IκB inhibitor and prevents nuclear translocation of p65. Third, PKA 
activation inhibits MAPK/ERK kinase kinase 1 (MEKK1) phosphorylation and 
activation, and the subsequent activation of p38 and TATA-binding protein (TBP). 
TBP need to be phosphorylated in order to be able to bind to the TATA box and 
to form an active trans-activating complex with CBP and NF-κB (Gonzalez-Rey et 
al., 2007). A reduction in the amounts of nuclear p65, CBP and phosphorylated 
TBP inhibits the formation of the conformationally active trans-activating complex 
that is required for the transcription of most cytokine and chemokine 
genes. Fourth, inhibition of MEKK1 by PKA subsequently deactivates Jun kinase 
(JNK) and c-Jun phosphorylation. The composition of the activator protein 1 
(AP1) complex changes from the transcriptionally active c-Jun–c-Jun, to the 
transcriptionally inactive c-Jun–c-Fos or CREB (Gonzalez-Ray et al., 2007). 
The final consequence is that the transcriptional machinery, which is perfectly 
assembled to the gene promoters of several inflammatory mediators (examples 
shown in red box) after the signalling of TNF-α through TNFR1, is significantly 
disrupted by treatment with melanocortin peptides. In addition to these effects of 
melanocortin peptides there is another mechanism of action that has been 
proposed. In human MC3 transfected HELA cells, activation of cAMP-dependent 
PKA in the presence of α-MSH was shown to exert an inhibitory effect on the 
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Figure 1.8 Molecular mechanism and transcription factors involved in the anti-
inflammatory effects of melanocortin peptides.   
The binding of melanocortins to its corresponding receptor increases cAMP and is thought to 
activate protein kinase A (PKA), which has four main effects. a) First, PKA activation induces the 
phosphorylation of the cAMP-responsive-element-binding protein (CREB) prevents the 
association of CBP with p65. b) The activated PKA hinders IκB kinase (IKK), which stabilizes the 
IκB inhibitor and stops nuclear translocation of p65. c) PKA activation prevents MAPK/ERK 
kinase kinase 1 (MEKK1) phosphorylation and activation, and activation of p38 and TATA-binding 
protein (TBP). Non-phosphorylated TBP is unable to bind to the TATA box and to form dynamic 
trans-activating complex with CBP and NF-κB. A reduction in the amounts of nuclear p65, CBP 
and phosphorylated TBP inhibits the formation of the conformationally active trans-activating 
complex that is required for the transcription of most cytokine and chemokine genes. d) Fourth, 
inhibition of MEKK1 by PKA subsequently deactivates JUN kinase (JNK) and cJUN 
phosphorylation. The composition of the activator protein 1 (AP1) complex changes from the 
transcriptionally active cJun–cJun, to the transcriptionally inactive JunB–cFos or CREB. e) The 
final consequence is that the transcriptional machinery is significantly disrupted by treatment with 





1.4 Role of melanocortin peptides in arthritic pathologies. 
1.4.1 Osteoarthritis. 
Current treatment regimes for OA largely focus on exercise, surgery for joint 
replacement, and the treatment of symptoms, e.g., relieving pain with analgesics, 
rather than treating the underlying causes of the disease (Ettinger and Afable, 
1994, Chen et al., 2008, Franklin et al., 2010) 
Only a handful of studies so far have evaluated the therapeutic potential of ACTH 
and melanocortin peptides in OA. This may seem somewhat surprising at first 
glance given the number of studies suggesting therapeutic potential of these 
peptides in both pre-clinical models and human patient samples from RA and 
gouty arthritis patients. However, this could stem from the fact that whilst 
inflammation is considered causal to both RA and gouty arthritis, it is not 
generally accepted to be a major contributor to the development of OA.  
Catania and colleagues evaluated the presence of systemic and synovial α-MSH 
in patients with OA and RA to evaluate whether changes in levels correlated with 
disease progression. α-MSH was detected in the synovial fluid of both OA and 
RA patients, with levels that were much lower in OA than RA (Catania et al., 
1994). Of interest, however, was the observation that synovial levels of α-MSH 
were higher than plasma, suggesting a local production of this peptide (Catania 
et al., 1994). This could indicate that activation of resident cells within the joints 
cause the release of α-MSH, which in turn switches off disease progression in an 
auto or paracrine fashion. Again, given that inflammation is only considered to be 
a component of OA rather than a causal factor, this could explain why much 
lower levels of α-MSH are found in OA rather than RA patients.  One potential 
mechanism for the articular cartilage degradation observed in OA may be due to 
TNF-α induced expression of MMPs, which can be down-regulated by α-MSH. In 
the human chondrosarcoma cell line HTB-94 (SW1353), α-MSH has been shown 
to down-regulate TNF-α induced expression of MMP13 mRNA and protein (Yoon 
et al., 2008). Studies with the pharmacological inhibitor SB203580, a p38 MAPK 
inhibitor, showed that α-MSH inhibited MMP13 by modulating p38 MAPK 





Although α-MSH has been shown to decrease TNF-α induced MMP expression, 
the parent hormone ACTH can cause terminal differentiation of chondrocytes and 
subsequent cartilage degeneration (Evans et al., 2004). Rodent chondrocytes 
and chondrocyte cell-lines express MC3, matrix deposition was concentration 
dependently elevated in the presence of ACTH. These data highlight that the 
melanocortin system promotes chondrocyte phenotype development and their 
differentiation into mature chondrocytes, leading to an elevation in intracellular 
free calcium (Evans et al., 2005). 
1.4.2 Rheumatoid arthritis.  
RA is a complex pathology affecting many systems outside of the joints, with 40 
% of RA deaths due to cardiovascular disease. Therapeutic intervention in RA is 
a leading cause of complications, for example NSAIDs may cause elevated blood 
pressure (Getting et al., 2009) and glucocorticoids increase cardiovascular 
problems by accelerating the rate of pathologies such as arterial thickening and 
narrowing (Getting et al., 2009). Methotrexate on the other hand may also 
promote heart disease by increasing levels of homocysteine. As a result of these 
complications and the fact that NSAIDs are contraindicated in the elderly due to 
high possibility of kidney failure, the progress of novel endogenous therapeutics 
is indispensable.   
The role of melanocortin peptides in rheumatoid arthritis has not been fully 
ascertained yet. Catania et al. detected increased concentration of α-MSH in the 
synovial fluid of patient suffering from RA, juvenile arthritis, but not OA, that were 
greater than that detected in the plasma (Catania et al., 1994; Grässel et al., 
2009) suggesting local production of the peptide, i.e. that the anti-cytokine 
molecule α-MSH is produced within a site of inflammation. This increase in α-
MSH within synovial fluid also suggests the possibility of an endogenous anti-
inflammatory loop maintaining a homeostatic balance within the joint and 
controlling the host inflammatory response. Joint concentrations of α-MSH in 
these patients were directly proportional to the degree of inflammation, whilst 






Utilising the adjuvant-induced arthritis model, α-MSH was shown to modulate 
weight loss, arthritic score, joint damage, and swelling, characteristic features of 
the disease. This effect on preventing weight loss was in contrast to that 
observed by the glucocorticoid prednisolone, which caused significant weight 
loss in these animals (Ceriani et al., 1994). The inflamed joint is characterised not 
only by infiltrating leukocytes, but also by activated resident bone/cartilage cells, 
such as osteoclasts and chondrocytes. Some evidence exists to suggest 
melanocortin receptor expression on these cells (Yoon et al., 2008). In situ 
hybridization shows that all MCs are expressed on chondrocytes in the mouse 
femoral bone and mRNA signals for all MCs, except MC1, were detected on 
primary rat osteoclasts, which also expressed the POMC gene (Zhong et al., 
2005), thereby suggesting the possibility that POMC peptides generated by these 
cells could act in an autocrine/paracrine manner through their corresponding 
MCs. α-MSH has been shown to inhibit TNF-α-induced MMP13 by modulating 
p38 and NF-κB signaling in human chondrosarcoma cell-line HTB-94 (Yoon et 
al., 2008). These findings indicate that α-MSH may be beneficial in arthritic 
conditions.   
1.4.3 Gouty arthritis. 
ACTH1-39 was first shown to have clinical efficacy in gout in the 1950s, although 
no mechanism of action was described for its effects (Gutman and Yu, 1950). 
Long-term administration of ACTH1-39 causes a number of side effects, including 
suppression of the HPA axis, and thus its use was superseded by other 
therapies. Current treatments for gout focus largely on the use of colchicines, 
allopurinol and NSAIDs, which cause a number of side effects, including peptic 
ulceration, gastric problems, and are poorly tolerated in the elderly and patients 
with renal insufficiency (Ritter et al., 1994), a potential reason why there is a 
renewed interest in the use of ACTH1-39. Another reason is the fact that ACTH 
demonstrates a greater efficacy than conventional glucocorticoids in controlling 
gout (Ritter et al., 1994). The authors suggested the existence of another 
mechanism of action other than the well-characterised stimulation of ACTH/MC2 
expressed on the adrenal gland (Ritter et al., 1994). Therefore, anti-inflammatory 





hope that they may have a better safety profile. Utilising murine models of gout, it 
has been demonstrated that smaller fragments of the POMC gene, including the 
peptides α-MSH, β-MSH, and ACTH4-10, could reduce urate crystal–induced 
neutrophil migration, and pro-inflammatory cytokine and chemokine release 
(Getting et al., 1999). Of specific interest are the anti-inflammatory effects of 
these peptides, which occur in a corticosterone-independent manner and thus 
there is no reflex stimulation of the HPA axis.  
These findings mirror those observed for ACTH4-10 in rat skin inflammation, 
where it was shown to inhibit prostaglandin generation and oedema formation 
(Gecse et al., 1980). The biological efficacy of these peptides was shown to 
occur via MC3 expression on peritoneal macrophages with subsequent elevations 
in cAMP. Further confirmation of the role of MC3 in mediating the anti-
inflammatory effects of these peptides was highlighted when pre-treatment of 
mice with the MC3/4 antagonist SHU9119 led to an attenuation of their efficacy. 
Based on these findings, a hypothesis was proposed that MC3 could be a novel 
therapeutic target for modulating the anti-inflammatory effects of the 
melanocortins, at least in this model of monosodium urate crystal deposition 
(Getting et al., 1999). Further studies promote this hypothesis with natural and 
synthetic agonists of the MC3, γ2-MSH  (Gecse et al., 1980) and MTII (Fan et al., 
1997) respectively, attenuating inflammation both in vivo and in vitro (Getting et 
al., 2001). In a rodent model developed to mimic certain aspects of the human 
pathology, urate crystals were injected into the knee joint, which led to migration 
of neutrophils preceded by the release of IL-1β and IL-6. Local and systemic 
administration of the parent hormone ACTH1-39 resulted in significant inhibition of 
all parameters associated with joint inflammation (swelling, arthritic score, 
neutrophil migration) (Getting et al., 2002).  
1.4.4 Role of melanocortins in other inflammatory pathologies.  
In addition to the anti-inflammatory properties discussed above, melanocortins 
have been shown in various in vitro and in vivo experiments to possess 
modulatory roles in inflammation. In vitro, α-MSH can reduce the T-lymphocyte 
co-stimulatory molecule CD86 in LPS stimulated monocytes (Bhardwaj et al., 





2000) and THP-1 cells (Taherzadeh et al., 1999) and inhibit NO synergistically 
elicited by LPS and IFN-γ in a MØ cell-line (Star et al., 1995, Mandrika et al., 
2001). Supporting data were also shown in vivo in models of endotoxemia 
(Delgado Hernandez et al., 1999), inflammatory bowel diseases (Rajora et al., 
1997b) and experimental heart transplant (Gatti et al., 2002), where melanocortin 
peptide treatment caused the reduction of NO and TNF-α.  
Interestingly, α-MSH has been shown to modulate the elevation, production and 
release of the anti-inflammatory cytokine IL-10 in human peripheral blood 
mononuclear cells, thus promoting further the inhibition of pro-inflammatory 
cytokines induced by MØ (Bhardwaj et al., 1996). The importance of α-MSH-
induced IL-10 in mediating anti-inflammatory responses was further 
substantiated in vivo, where the suppressive effect of α-MSH on airway 
inflammation is no longer observed in IL-10 knockout mice (Raap et al., 2003).  
A remarkable facet of melanocortin biology is their ability to regulate peripheral 
acute inflammation following central administration. It was shown in brain 
ventricle injection that pre-treatment with α-MSH and ACTH11-13 reduced ear and 
hind paw oedema induced by local injection of IL-1, IL-8, leukotriene B4 and 
platelet-activating factor (Ceriani et al., 1994, Macaluso et al., 1994). When spinal 
cord trans-section was performed, these anti-oedema effects caused by central 
α-MSH injection was abolished, indicating that intact descending inhibitory neural 
















1.5 Aims of the study and hypothesis. 
The aims of this thesis were to examine the expression and functionality of 
melanocortin receptor MC1 and MC3 in human C-20/A4 cell-line and primary 
bovine articular chondrocytes. Another aim was to ascertain their anti-
inflammatory, anti-apoptotic and chondroprotective effect on pro-inflammatory 
cytokine production following stimulation of in vitro cultures (C-20/A4 cell-line and 
primary articular chondrocytes) with TNFα/ mechanical impact of chondrocytes in 
situ and to investigate their effect on the production of anti-inflammatory proteins.  
• To investigate the response of chondrocytes to inflammatory stimuli and 
the effect on pro-inflammatory cytokine (IL-1β IL-6, IL-8 and MCP-1), 
degradive matrix metalloproteinase (MMP1, MMP3 and MMP13) and 
cartilage ECM matrix component (collagen type I and type II) production.  
• To study the effect of classical anti-inflammatory drugs glucocorticoids 
(dexamethasone) and NSAIDs (indomethacin) on expression and release 
of IL-6, IL-8 and MMPs from activated chondrocytes. 
• To ascertain melanocortin receptor expression, production and 
functionality in chondrocytes and determine whether melanocortin 
peptides can inhibit pro-inflammatory cytokines, and/or MMP production 
and induce anti-inflammatory proteins in cell-line and primary 
chondrocytes. 
• To evaluate the protective properties of melanocortin peptides against 
TNF-α-induced apoptosis and caspases activity.  
• To investigate the response of chondrocytes to lowered extracellular 
osmolarity, e.g. pro-inflammatory cytokines and degradive enzymes and 
the effect of melanocortin peptides on these parameters. 
• To characterise the cytoprotective and anti-inflammatory effect of 















































2.1 Materials and suppliers.  
2.1.1 Chemical and reagents. 
Table 2.1. Chemicals and Biochemicals used for tissue culture.  
Name Supplier Catalogue No. 
Ascorbic acid Sigma-Aldrich Company Ltd., Poole, UK A4403 
Foetal Bovine Serum (FBS) Invitrogen, Paisley,  UK 16170078 
GIBCO® DMEM + Glutamax™-1 
 Invitrogen, Paisley, UK 31966 
Pen/Strep Solution (+5000 U/ml 
Penicillin, +5000 µg/ml 
Streptomycin) 
Sigma-Aldrich Company Ltd., 
Poole, UK P0781 
Sodium Chloride Fisher Scientific, Leicestershire, UK S13160/65 
Trypsin-EDTA Invitrogen, Paisley, UK 25300 
 
 
Table 2.2. Chemicals and biochemicals used in protein extractions, SDS-PAGE 
and Western blots.  
Name Supplier Catalogue No. 
Acryl Amide Bio-Rad Laboratories Ltd., Hertfordshire, UK. 161-0100 
Ammonium Persulfate Bio-Rad Laboratories Ltd., Hertfordshire, UK 161-0700 
β-mercaptoethanol Sigma-Aldrich Company Ltd., Poole, UK P0781 
Bio-Rad Protein Assay (Bradford 
solution) 
Bio-Rad Laboratories Ltd., 
Hertfordshire, UK 04693159001 
Bis-acrylamide Bio-Rad Laboratories Ltd., Hertfordshire, UK. 161-0154 
Coomassie© brilliant blue R250 Sigma-Aldrich Company Ltd., Poole, UK 25300 
Dithiotreitol (DTT) Fisher Scientific, Leicestershire, UK BP172-25 
Glycine, aminoacetic acid Fisher Scientific, Leicestershire, UK BPE381 
Glycerol Sigma-Aldrich Company Ltd., Poole, UK 49779 




Sigma-Aldrich Company Ltd., 
Poole, UK T9281 
NuPAGE® MOPS SDS Running 
Buffer 20x Invitrogen, Paisley, UK NP0001 
NuPAGE® Transfer Buffer 20x 
 Invitrogen, Paisley, UK NP0006 
NuPAGE® Novex 10% Bis-Tris 






NuPAGE® Novex LDS Sample 
Buffer 4x Invitrogen, Paisley, UK NP0007 
Ponceau S Staining Solution Sigma-Aldrich Company Ltd., Poole, UK P3504 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich Company Ltd., Poole, UK A4403 
Trizma®  Base Sigma-Aldrich Company Ltd., Poole, UK T1503 




Table 2.3 Reagents used in ELISAs. 
Name Supplier Catalogue No. 
3, 3’,5,5’ –Tetramethylbenzidine 
tablets 
Sigma-Aldrich Company Ltd., 
Poole, UK T5525 
Bovine albumin serum (BSA; 
fraction V, minimum 98%) 
Sigma-Aldrich Company Ltd., 
Poole, UK A2153 
Dimethyl Sulfoxide (DMSO) Fisher Scientific, Leicestershire, UK D4121 
Hydrogen Peroxide (30%) Fisher Scientific, Leicestershire, UK H1550 
Phosphate Buffer Saline (PBS) 
tablets Oxoid LPD, Hertfordshire BR0014G 
Phosphate Citrate Buffer  Sigma-Aldrich Company Ltd., Poole, UK P4809 
Sodium acetate Fisher Scientific, Leicestershire, UK S210-500 




Table 2.4 Primers used in this study. 
Name Supplier 
β-actin forward and reverse Eurofins MWG Operon, London, UK 
Collagen I forward and reverse Eurofins MWG Operon, London, UK 
Collagen II forward and reverse Eurofins MWG Operon, London, UK 
IL-6 forward and reverse Eurofins MWG Operon, London, UK 
IL-8 forward and reverse Eurofins MWG Operon, London, UK 
MMP1 forward and reverse Eurofins MWG Operon, London, UK 
MMP3 forward and reverse Eurofins MWG Operon, London, UK 





MC1 forward & reverse primers Applied Biosystems UK, Cheshire, UK 
MC3 forward & reverse primers Applied Biosystems UK, Cheshire, UK 
MC5 forward & reverse primers Applied Biosystems UK, Cheshire, UK 
 
 
Table 2.5. Antibodies used in this study. 
Name Supplier Cat. No. 
 
α-Tubulin Mouse mAb (clone B-5-
1-2) 




Cleaved Caspase-3 (Asp175) 
(5P1) Rabbit mAb 




Goat anti-rabbit horseradish 
peroxidase (HRP)-conjugated IgG 




Goat anti-mouse horseradish 
peroxidase (HRP) conjugated IgG 
Dako Cytomation Ltd., 
Cambridgeshire, UK. 
P0447 
Heme oxygenase(HO)-1 rabbit 
pAb 
 
Bioquote Ltd. (supplier for 






Table 2.6 Commercial Kits used in this study.  
Commercial Kits Supplier Cat. No. 
cAMP Biotrak™ EIA system  GE Healthcare UK Ltd., Buckinghamshire, UK RPN2251 
Caspase-Glo® 3/7 
 




DuoSet® ELISA Development 
systems 
 
R&D Systems® Europe Ltd., 
Abingdon, UK N/А 
 
GoTaq Green Mastermix 2x 
 
 












GE Healthcare UK Ltd., 
Buckinghamshire, UK 
740933.50 
Parameter™ PGE2 Assay 
 







Table 2.7. Additional materials and chemicals used in this study.  
Materials Company Cat. No. 
α-MSH; ACTH1-13 
Sigma–Aldrich Inc. 








































Kind gift by Prof. Paolo Grieco, 



















FUJI Medical X–Ray Film 
 




Full–range Rainbow™ Molecular 
Weight Marker 
 




Hybond™–C Extra Nitrocellulose 
membrane 
 




Hydrochloric acid (HCl) 
 
VWR International (supplier for 































Pierce® ECL Western Blotting 
Substrate 
Thermo Scientific,  
Surrey, UK 32209 
Propidium Iodide (PI) Invitrogen, Paisley, UK P1304MP 
RNase inhibitor 
 
Promega UK Ltd.,  
Southampton, UK 
N2611 
RQ1 RNase-free DNase 
 

























Zymosan Type A Sigma–Aldrich Inc. Poole, UK Z4250 
 
2.1.2 Software. 
Table 2.8. Software used in this study. 
Software Company 
Image J Bitplane AG, Zurich, Switzerland  
Imaris 7.1.1 Imaris 
Microsoft Office 2008 Microsoft, USA 
GraphPad Prism  GraphPad Software, San Francisco, USA 
OmniGraffle Pro 5.02 Washington, USA 
Leica TCS SP1/SP2 Leica Microsystems (UK) Ltd., Milton Keynes UK 






2.2.1 Cell line storage and resuscitation.  
C-20/A4 is a human chondrocytic cell line, derived from juvenile costal 
chondrocytes (Finger et al., 2004). C20/A4 chondrocytes were stored in liquid 
nitrogen in 1.0 ml aliquots of 1.0 x 106 cells/ml in Dulbecco Modified Eagle 
Medium (DMEM) supplemented with 50.0 % FCS and 20% DMSO.  Prior to cell 
culture, cells were rapidly thawed at 37ºC in a water bath and pre-warmed 
complemented medium (DMEM + Glutamax supplemented with 50 U/ml 
Penicillin, 50 µg/ml Streptomycin and 10% FCS) added to dilute the toxicity of the 
DMSO. The resulting cell suspension was centrifuged at 2000 rpm for 10 min and 
supernatant discarded, thus removing DMSO. The cell pellet was then 
resuspended in complete medium, transferred into 25 cm2 flasks and incubated 
in humidified incubator with 95% air : 5% CO2 to allow cell proliferation.  
2.2.2 Cell line culture and maintenance. 
Cell culture media was replaced at 4-day intervals whereby media were removed 
by aspiration and replaced by fresh complemented DMEM. At 80 % confluence, 
chondrocytes were subcultured by lifting the cells from their substrate using 0.05 
% Trypsin-EDTA and centrifuging of detached adherent cells at 2000 rpm for 10 
min. The resulting cell pellet was resuspended and seeded in new culture flasks 
(1.0 x 103 cells/cm2) for continuous culture or in various (6-, 24-, or 96-) well 
plates (1.0 x 105 cell/cm2) as appropriate for experimentation. Cells were 
incubated at 37 ºC in a humidified atmosphere supplied with 95% air : 5% CO2. 
Cell line passage numbers used in all experiments were between 1 and 10. 
2.2.3 Cartilage removal and chondrocyte isolation.  
Fresh metacarpal or metatarsal phalangeal joints of 18 – 21 month old female 
animals were obtained with permission from the local abattoir and were dissected 
under aseptic conditions on the day of slaughter. Full depth articular cartilage, 
excluding subchondral bone, was removed carefully from the load bearing 
surfaces of the metacarpal phalangeal joints and cartilage explants cultured in 





(used within 96h). Osmolarity was measured using Vapro™ vapour pressure 
osmometer and accurate to ± 5 mOsm (Kerrigan and Hall, 2008). 
For chondrocyte isolation, cartilage explants were incubated for ~18h at 37ºC 
with 0.8 mg/ml Collagenase in DMEM 380 mOsm (Bush and Hall, 2001). The 
osmolarity of the DMEM was raised by addition of 3.14 mg/ml filter-sterilized 
NaCl (using 2.0 µm filter) to limit cell swelling upon chondrocytes released from 
the matrix (Hall et al., 1996b). Digest material was passed through a tea strainer, 
and 20.0 µm nylon filters (Falcon) to remove undigested material and any large 
cell clumps. Chondrocytes were washed 3x by centrifugation (8 min, 20º C, 600g) 
in DMEM (380 mOsm/kg:H2O). For stimulation of freshly isolated bovine 
chondrocytes (P0 – passage 0), chondrocytes were seeded at 1.0 x 105 cells/cm2 
in 25 cm2 plastic flasks in the same serum-free 380 mOsm DMEM for 2 – 24 h to 
allow for cell attachment.  
For long-term culture of primary bovine chondrocytes, cells were isolated as 
described above and following the third wash, chondrocytes were resuspended 
in ‘complemented’ DMEM (380 mOsm/kg:H2O; 10% FCS, 50 µg/ml ascorbic acid, 
50 U/ml Penicillin, 50 µg/ml Streptomycin; pH 7.4; Kerrigan et al., 2008). Media 
was replaced when required and chondrocytes were subcultured up to passage 3 
(P3; 21 days). Briefly, supplemented media was removed and chondrocytes were 
lifted from the plastic using Trypsin-EDTA 0.05%. The suspension was diluted 
1:2.5 in DMEM (380 mOsm) prior to washing by centrifugation (3x). 
Subsequently, cells were seeded as described above in plastic flasks with 
various sizes (depending on the experimental needs).  
2.2.4 Application of single impact to bovine articular cartilage explants. 
A vertical drop tower was used to deliver single blunt impact to individual 
cartilage explants under aseptic conditions. The impacting weight and the base 
were made of hard nylon with smoothly polished surface as previously described 
(Bush et al., 2005). The individual cartilage explants were carefully positioned 
with the synovial surface uppermost, and exposed to single blunt impact with a 
weight of 137 g dropped from a height of 10 cm, equivalent to 1.14 N, 6.47 kPa 





explants were discarded. The cartilage pieces were then removed from the drop 
tower and returned to the 10 cm2 dishes for 6 h when the chondrocytes were 
incubated for 30 min with Calcein-AM and visualised under confocal laser 
scanning microscopy (CLSM). Human knee forces are approximately 12.0 kPa, 
significantly higher than the ones used here (Matthews et al., 1977), but it has to 
be noted that the articular cartilage explant did not have the support of the 
underlining bone, or the protection of the synovial fluid available in vivo. 
Therefore, the impact tower was used for injuring the cartilage and not as a 
model of forces found in vivo. 
Explants of bovine articular cartilage were incubated for 30 min with or without 
melanocortin peptides α-MSH and D[TRP]8-γ-MSH (3.0 µg/ml) prior to single 
impact and then incubated for 6 h. Explants were then incubated with the 
fluorescent indicators Calcein-AM (5.0 µM) and Propidium Iodide (1.0 µM) 
permitting the measurement of cell viability using CLSM. 
Cell viability of in situ chondrocytes was investigated by CLSM and cytokine 
release (IL-1β, IL-6, IL-8, MCP-1) from cartilage explants by ELISA. Tissue was 
viewed by placing the cartilage piece in a new dry dish and viewing 
perpendicularly to the articular (synovial) surface. A small amount of 
cyanoacrylate glue was applied to a small corner of the explant, at a distant point 










2.2.5 Confocal Microscopy.  
2.2.5.1 Confocal Microscopy Imaging. 
Images were taken using an upright Leica TCS NT CLSM (Leica Microsystems, 
Milton Keynes, UK) and Leica Software. The following parameters were adopted 
for the acquisition of the images (Kerrigan and Hall, 2005). 
 
• Grey resolution of 8 bit 
• Pinhole: 1.00 airy unit, matched to the diameter of objective used 
• Beam splitter 488/543/633 
• Laser speed 400 Hz 
• Dipping lens HCX APO L U-V-1 63.0x 90 W 
 
During the incubation of cartilage explants with Calcein-AM and PI, the molecules 
diffused through the matrix into the cells.  
Calcein-AM is non-fluorescent when outside the cell. It is cell membrane 
permeable and once in the cell, the molecule undergoes enzymatic cleavage by 
intracellular esterase’s, a process, which releases the fluorophore – Calcein. It is 
comparatively membrane impermeable and therefore is trapped within the cells. 
After excitation of the dye with a 488 nm argon laser (emission at 525 nm), 
Calcein fluoresced, providing useful indication of cytoplasmic space in the living 
cells. Propidium Iodide (PI) is membrane impermeable and only when bound to 
nucleic acids, it fluoresced red (excitation at 525 – 535 nm and emission = 650 – 
670 nm), therefore indicating the presence of dead cells. When cartilage was 
impacted, it was possible to observe cell death, as dying cells lost their green 
fluorescence rapidly as it leaked out of cell membranes upon impact. Instead, 
they fluoresced red, as the PI entered the cell through the leaky membrane and 
bound to the nucleic acids.  
Chondrocytes in cartilage explants were viewed by an upright Leica TCS SP2 
CLSM (Leica Microsystems, Milton Keynes, UK) with low power magnification of 
x10 air objective lenses for cell viability measurements. Laser power and detector 





bleaching (Bush and Hall, 2001a,b). Scanning speed was 0.6 Hz with double 
frame integration, double line averaging for 1024x1024 pixel image.  
2.2.5.2 Image analysis.  
Confocal microscopy collects a series of planar images comprised of voxels (3D 
pixels). Each voxel contains information about its relative position and intensity. 
To be able to correctly portray a cell, it was essential to ascertain the correct 
boundaries of each individual cell. Images of chondrocytes loaded with Calcein-
AM showed strong homogenous fluorescence that differed tremendously from 
the emission of the surrounding matrix/DMEM media, which shows negligible 
fluorescence under the conditions used for this thesis.  
In order to determine cell viability prior to and post impact, CLSM data were 
imported into and analysed using Imaris 7.1.1 Spots feature. Based on the 
average diameter of viable cells (green) and “dead” cells (red), in the cartilage 
explant, spot analysis was used to calculate the total number of cells and the 
number of viable cells within the area of observation. For spots analysis, the 
optimum threshold for Calcein-AM and PI was calculated by selecting a smaller 
area with a known number of cells and different threshold values from 0 – 100% 
were applied in increments of 10 %. Using the resulted linear regression formula, 
the correct cell number was determined with a threshold percentage of 20 % for 
Calcein-AM-stained cells (viable cells) and 60 % for PI-stained cells (dead cells) 









Figure 2.1 Schematic representation of 3D image reconstitution using Imaris 7.1.1.  
A series of images were taken using upright Leica CLSM along the z-axis of 
chondrocytes adherent to the surface of a plastic 10 cm2 culture dish (A). The images 
were imported in Imaris 7.1.1 and reconstituted (B) to give a 3D view of the observed 
cells (volume objects; C). Using the Surfaces visualization feature of the software, the 
correct cell boundaries above the background cut-off were identified by a computer-
generated representation of a specified grey value range in the data set. It creates an 








Figure 2.2 Optimisation of spot analysis. 
Cartilage explants were stained with Calcein-AM (5.0 µM) and Propidium Iodide (1.0 µM) 
and imaged under CLSM. An area of visually countable cells (Panel B) was cropped 
from the 3D CLSM image (Panel A) and spot analysis was applied to the cropped 
section (Panel C) for both the viable (green) and non-viable (red) cells by altering the 
baseline threshold in 10 % increments from 0-100 %. Actual cell number was used to 












2.2.6 Cell-line and primary bovine chondrocyte stimulation. 
2.2.6.1 In vitro cell stimulation with various inflammogens. 
Primary bovine chondrocytes Po and C-20/A4 chondrocytes seeded in 96-well 
plates were stimulated with TNF-α (20.0 – 80.0 pg/ml), LPS (0.1 – 10.0 µg/ml), 
MSU crystals (0.1 – 10.0 µg/ml), H2O2 (0.01% - 1.0%). Both control and 
stimulated chondrocytes were incubated for various time periods, outlined in 
figure legends, in humidified incubator at 37ºC, 95% : 5% air : CO2. Cells were 
analysed for MTT reduction to assay cell viability and media collected for Griess 
nitrite accumulation assay and cytokine ELISAs (for detailed protocols, see: 
sections 2.3.4; 2.3.1 and 2.3.2 respectively).  
2.2.6.2 Chondrocyte drug treatment. 
2.2.6.2.1 In vitro melanocortin agonist treatment of human C-20/A4 and 
primary P0 bovine articular chondrocytes. 
C-20/A4 cell line or primary bovine P0 chondrocytes were seeded in 6- 24- or 96-
well plates and incubated for 24h at 37ºC in humidified incubator at 37ºC, 95% : 
5% air : CO2 to allow cell adhesion to the culture substrate. Culture medium was 
then replaced with serum-free DMEM medium and chondrocytes incubated in 
different conditions for various time points (outlined in the respective figure 
legends). Chondrocytes were treated with a panel of melanocortin peptides – α-
MSH, D[TRP]8-γ-MSH, PG901, PG911, or SHU9119 in a concentration range 
(0.1 – 30.0 µg/ml) for 2 – 24 h in serum-free DMEM ± TNF-α (60.0 pg/ml) for C-
20/A4 cells or for 6 h only (P0 bovine cells). The cells in the 24-well plates and 
96-well plates were analysed for MTT and cell-culture media were collected for 
cytokine ELISA experiments.  
In separate experiments, cells were treated with α-MSH, D[TRP]8-γ-MSH (3.0 
µg/ml) or SHU9119 (10.0 µg/ml) ± TNF-α (60.0 pg/ml) for 6 h. For protein 
expression and RNA extraction, cells were removed from the 6-well plates with a 
cell scraper and the respective experiment was performed as described in 





analysed by MTT assay for cell viability, and cell-culture media were collected for 
cytokine ELISA experiments.  
Alternatively, cells were treated with α-MSH, D[TRP]8-γ-MSH (3.0 µg/ml) ± 
SHU9119 (10.0 µg/ml) + TNF-α (60.0 pg/ml) for 6 h and the media from 24-well 
plates were used for cytokine ELISA measurements. Cells plated in 6-well plates 
were used for RNA extraction.  
2.2.6.2.2 In vitro dexamethasone and Indomethacin treatment of human C-
20/A4 chondrocytes.  
To investigate the effect of classical anti-inflammatory drugs in this system, two 
widely used drugs were chosen dexamethasone (glucocorticoid) and 
Indomethacin (NSAID). Human C-20/A4 chondrocytes were pre-treated for 30 
min with 1.0 µM of either dexamethasone or indomethacin and then stimulated 
with TNF-α (60.0 pg/ml) for 0 – 24 h. Total RNA was extracted and reverse 
transcribed into cDNA. Conventional PCR was employed to investigate the 
transcription levels of IL6 and IL8 at time point 6 h. From the same experimental 
set-up, cell-free supernatants were collected at time points 0, 2, 4, 6 and 24 h 
and analysed for IL-6 and IL-8 protein release via commercially available 
ELISAs.  
2.2.6.2.3  In situ cartilage explants treatment with melanocortin peptides 
and dexamethasone.  
Cartilage explants were obtained as explained earlier (Section 2.2.3) and treated 
with PBS, dexamethasone (1.0 µM) or melanocortin peptides – α-MSH/D[TRP]8-
γ-MSH (3.0 µg/ml) for 6 h prior to confocal microscopy for evaluation of their 
effect on chondrocyte viability. From the same experimental set-up, cell free 
supernatants were collected to evaluate basal release of IL-1β, IL-6 and IL-8 and 
to compare that to the effect of the abovementioned agents.  
Alternatively, in order to evaluate and compare the protective properties of the 
melanocortin peptides and steroids on mechanically injured cartilage explants, 
the cartilage pieces were incubated for 30 min with PBS (control), 





µg/ml) for 30 mins prior to cartilage impact (using drop tower as explained in 
section 2.2.4). The cartilage explants were then returned to their vials 
immediately, whereby they were incubated for additional 6 h at 37ºC prior to 
confocal microscopy visualization for identification of the effect of the treatments 
on cell death and changes in chondrocyte morphology. Cell-free supernatants 
were collected at that time-point in order to evaluate: 1.) the effect of mechanical 
trauma on pro-inflammatory cytokine production by the injured chondrocytes, and 
2.) the therapeutic, anti-inflammatory effect of dexamethasone, α-MSH and 
D[TRP]8-γ-MSH on chondrocytes following mechanical trauma.  
2.2.7 mRNA and protein analysis 
2.2.7.1 RNA purification and quantification. 
Total RNA was extracted from primary and cell-line chondrocytes using the 
commercially available NucleoSpin® RNA II Kit. Cell culture medium was 
aspirated and the cells washed with PBS, prior to trypsinizing them using 0.05 % 
Trypsin. Cell suspension was centrifuged at 3000 rpm for 5 min and 
subsequently lysed by incubation of the cell pellet with 350 µl buffer RA1 
(containing 3.5 µl β-ME), which contains large amounts of chaotropic ions, 
therefore immediately inactivating RNases, creating appropriate binding 
conditions favoring adsorption of RNA to the silica membrane. The viscosity of 
the lysate was reduced by centrifugation at 13,000 rpm for 1 min. RNA binding 
conditions were adjusted by the addition of 350 µl of 70 % EtOH to the filtrated 
lysate and mixed by vortexing (2 x 5 s). The mixture was then loaded onto a 
NucleoSpin RNA II Column and RNA bound to the silica membrane by 
centrifuging the lysate at 13,000 rpm for 1 min. 350 µl Membrane Desalting 
Buffer were applied to the membrane and centrifuged at 13,000 rpm for 1 min, 
improving the efficacy prior to rDNase digestion by salt removal.  
Contaminating DNA bound to the silica membrane, was removed by rDNase 
solution, directly applied to the membrane during the preparation and incubated 
at room temperature for 15 min. The sample was washed with buffer RA2 to 
inactivate the rDNase and subsequently washed twice with buffer RA3. Pure 





The concentration of samples was then determined by measuring the 
absorbance at A230, A260 and A280 using NanoDrop® ND-1000 UV-Vis 
Spectrophotometer, which enables highly accurate analyses of extremely small 
samples with remarkable reproducibility. Readings were deemed significant if 
A260 ≥ 0.1 (1 absorbance unit at 260 nm corresponds to 40.0 µg/ml RNA). The 
A260/A280 and the A260/A230 ratios provided an estimate of the purity of the RNA, 
which was considered uncontaminated if both absorbance ratios were in the 
range of 1.9 – 2.1.  
2.2.7.2 Complementary DNA (cDNA) synthesis. 
cDNA was synthesized by mixing 1.0 µg of DNase-treated total RNA, PolyT and 
Random Primers in a total volume of 20.0 µl (Promega) using the ImpromII 
Reverse Transcription System. Briefly, RNA and the oligonucleotides were 
incubated at 70˚C for 5 min to allow denaturation of RNA secondary structures 
and primers were hybridized to the RNA by cooling the samples to 4ºC for 5 min. 
Reaction buffer, MgCl2, dNTPs and Reverse Transcriptase (RT) were then added 
















2.2.7.3 Polymerase Chain Reaction (PCR). 
Polymerase chain reaction (PCR) is a method used to amplify a specific DNA 
sequence in vitro by repeated cycles of synthesis with specific primers and 
thermostable DNA polymerase (Saiki et al., 1988). Specific primers are 
complementary to sequences that lie on opposite strands of the template DNA 
and flank the segment of DNA to be amplified. Template DNA was first denatured 
by heating the reaction to 95ºC in the presence of a large molar excess of each 
of the two primers and dNTPs. The reaction mixture was cooled to allow the 
primers to anneal to their target sequences, and subsequently the annealed 
primers extended at 72ºC by Taq DNA polymerase.  
Primer sequences for each gene, together with their specific Tm and the resulting 
fragment size are outlined in Table 2.9. Synthetic oligonucleotides were 
purchased from MWG Biotech AG, Ebersberg, Germany. Cycles of denaturation, 
annealing, and DNA synthesis were repeated 25 times as outlined below (Table 
2.10). The PCR with Taq polymerase was used for gene screening procedures, 
where the expression of key genes was checked with specific primers. 
GoTaq®Green Master Mix (Promega) and cDNA amplification performed with 






















β-actin_FWD GTC CCG GCA TGT GCA A 16 54.3 
550 
β-actin_REV AGG ATG TTC ATG AGG TAG T  19 52.4 
MC1R_FWD GCT GGA CAA TGT CAT TGA CG 20 57.3 
497 
MC1R_REV AGT TCT TGA AGA TGC AGC C  19 54.5 
MC3R_FWD GTC TTT CCT GTG AGC AGC A  19 56.7 
820 
MC3R_REV CCA GCA GAA GAT GAA CAC  18 53.7 
MC5R_FWD GCC ATC ACG CCG GCA TC 17 58.7 
340 
MC5R_REV GAG ACA TGA AGC GAG AGC 18 71.6 
GAPD_FWD_BOV AGA ACG GGA AGC TTG TCA TC 20 57.0 
743 
GAPD_REV_BOV TGA GCT TGA CAA AGT GGT CGT 21 58.0 
MC1R_FWD_BOV CCA CCC TCC CCT TCA CCC TGG 21 67.6 
301 
MC1R_REV_BOV CAT TGT CCA GCT GCT GCA CCA CG 23 66.0 
MC5R_FWD_BOV GTC CAG AAT GCA TCC TCA CTA TGT GAG G 28 66.6 642 
MC5R_REV_BOV CAG GGT GAT GGC GCC CTT CAC G 22 68.0 
IL6_FWD CTC AGC CCT GAG AAA GGA GA 20 59.4 
450 
IL6_REV TGC AGG AAC TCC TTA AAG CTG 21 57.9 




IL8_REV TTA TGA ATT CTC AGC CCT CTT CAA 
AAA 
27 58.9 




MMP1_REV AAG GTT AGC TTA CTG TCA CAC ACG 
CTT 
27 63.4 











MMP9_FWD TGT ACG GAC CCG AAG C 16 54.3 
322 
MMP9_REV CCG TCC TTA TCG TAG TCA G 19 56.7 
MMP13_FWD GTG GTG TGG GAA GTA TCA TCA 21 57.9  
330 MMP13_REV GCA TCT GGA GTA ACC GTA TTG 17 57.9 
COL1A1-FWD ACA TGC CGA GAC TTG AGA CTC A 22 60.3 
86 COL1A1-REV CGA TCC ATA GTA CAT CCT TGG TTA 
GG 
26 62.2 
COL2A1-FWD AGC AGG TTC ACA TAT ACC GTT CTG 24 60.6 
73 















































6.5 N/A Final 
Elongation  
10:00 72 





2.2.7.4 DNA separation by agarose electrophoresis.  
Linear double-stranded DNA-fragments were separated by an electric field due to 
the fact that the migration of DNA varies as the reciprocal of the logarithm of the 
base-pairs number (Meyers et al., 1976). Upon addition of ethidium bromide, 
which is intercalated into GC–pairs, DNA becomes fluorescent and can be 
visualized under UV-light. Agarose gels (2.0 %) were prepared in TBE buffer (40 
mM Tris-acetate, 1.3 mM EDTA–Na, 0.47 mM CH3COOH). Agarose gels (2 %) 
were prepared in TBE–buffer and DNA samples loaded onto the gel together with 
positive (β–actin) and negative controls and separated at 80–150 V. DNA 
fragments’ size was determined by comparing to a DirectLoad™Step Ladder 50 
bp (Sigma-Aldrich, Poole, Dorset, UK), suitable to estimate the size of DNA 
fragments in the range of 50–3000 bp. After electrophoresis the gel was stained 
in ethidium bromide (10.0 µg/ml) in TBE-buffer for 5-15 min. and visualized under 
UV light 
2.2.7.5 Protein extraction. 
There are two broad categories for complementary analytical applications of 
extracted proteins: identification and quantification studies and functional studies, 
including enzymatic assays and binding studies. Here, quantification studies 
have been carried out in order to determine the amount of proteins following 
stimulation of chondrocytes with various agents. Quantity determination is based 
on protein sequencing or antibody binding and does not require preservation of 
secondary, tertiary and quaternary structures.  
Following stimulation of C-20/A4 cells with various stimuli (detailed explanation in 
2.2.6.2) cell supernatants were removed and 0.5 ml of hot lysis buffer (10% v/v 
glycerol, 62.5 mM Tris–HCl – pH 6.8, 2% SDS, 100 mM DTT; 65º C) was added 
to each well. Cells were removed by scraping them off the plate using a cell 
scraper and lysate was collected and passed through a 25 gauge needle in order 
to disrupt the cell membranes. This method denatures the proteins by 
solubilisation with the anionic detergent Sodium Dodecyl Sulphate (SDS). Protein 





Concentrations of the protein extracts were determined at A280 using NanoDrop® 
ND-1000 UV-Vis Spectrophotometer. Briefly, the spectrophotometer was blanked 
with 2 µl Hot Lysis Buffer and 2.0 µl of each of the protein samples applied and 
the concentration and purity measured.  
2.2.7.6 Sodium Dodecyl Sulphate – Polyacryl Amide Gel electrophoresis: 
SDS-PAGE.  
SDS binds to proteins with a constant ratio of 1.4:1 (µg/µg) and thereby confers 
negative charges to the proteins, which increases proportionally to size and leads 
to linearization of the protein. Depending on the size of the molecules to be 
separated, electrophoresis is usually performed using either agarose (large 
molecules) or polyacrylamide (small molecules) gels. PAGE gels are generated 
by radical polymerization of acryl amide (AA) and bis–acryl amide (BA) catalysed 
by radicals set free from ammonium persulphate. 
A discontinuous electrophoretic gel/buffer system was employed using the 
electrophoresis apparatus Novex® Minicell (Invitrogen, Paisley) for SDS–PAGE. 
Readymade NuPAGE® 10 % Bis–Tris gels of 1.0 mm x 10 wells were used. 
Protein samples (40 µg/lane) were mixed 1:4 in NuPAGE® Novex LDS Sample 
Buffer (4x; Invitrogen, Paisley; containing 4.0 % v/v β–ME), boiled for 5 mins at 
100°C and loaded onto the NuPAGE® 10.0 % Bis–Tris gels. Full Range Rainbow 
Molecular Weight Marker (Invitrogen, Paisley) was used as a molecular weight 
marker. The upper buffer electrophoresis chamber was filled with 200 ml of 1x 
NuPAGE® Novex MOPS SDS Running buffer (20x; Invitrogen, Paisley) and the 
electrophoresis run at 200 V (constant), 100 mA/gel for 30 mins until the tracking 
dye reached the bottom of the separating gel.). The gel was washed three times 
with ddH2O and then incubated for 30 mins in GelCode Blue Stain Reagent to 
visualize proteins.  
2.2.7.7 Western Blot. 
Following electrophoresis by SDS–PAGE, proteins were electrotransferred to 
0.45 microns Hybond™–C Extra nitrocellulose membrane (Amersham 





NuPAGE® Novex Transfer buffer (20x; Invitrogen, Paisley) with added 10.0% v/v 
CH3OH in an XCell II™ Blot Module (Invitrogen, Paisley).  
Following electrotransfer, protein migration onto the membrane was checked 
using Ponseau S Staining Solution (0.1% w/v Ponseau S, 5.0 % v/v CH3COOH). 
This is a rapid and reversible staining method for locating protein bands on 
Western blots. 
The membrane was then blocked for ≥30 mins at room temperature with 10 ml of 
5 % w/v skimmed milk in TBST buffer (block solution) block solution (1% v/v 1.0 
M Tris–HCL pH 8.0, 3.0 % 5.0 M NaCl, 0.5% v/v Tween–20 in ddH2O). 
Subsequently, the membrane was washed 3 x 5 mins in TBST buffer and 
incubated for 1.5 h at room temperature (or overnight at 4°C) with specific to the 
protein of interest primary antibody as detailed below (Table 2.11) in milk–TBST 
solution.  The unbound antibody was then removed by washing the membrane 3 
x 5 mins in TBST solution at room temperature. The membrane was then 
incubated with milk–TBST solution containing secondary antibody (polyclonal 
goat anti–mouse Immunoglobulins/HRP, polyclonal goat anti–rabbit 
Immunoglobulins/HRP) at a dilution 1:2000 v/v at room temperature for ≥ 45 mins 
(Table 11). Following incubation the membrane was washed in TBST for 3 x 5 
mins at room temperature.  
Proteins were then visualized using a chemiluminescent detection method to 
detect peroxide labelled secondary antibody using Pierce® ECL Western Blotting 
Substrate, according to manufacturer instructions. Briefly, Pierce® ECL Western 
Blotting Substrate (1:1 Pierce® ECL Reagent 1: Pierce® ECL Reagent 2) was 
directly applied to the membrane and incubated at room temperature for 5 min, 
after which the membrane was dried and positioned in a film–developing 
Hypercassette™ (Amersham Pharmacia Biotech, Buckinghamshire, UK). In a 
dark room, the membrane was exposed to FUJI Medical X–Ray film for 1–2 sec 
at room temperature. The film was subsequently developed by incubation for 3 
mins in KODAK GBX developer/replenisher solution (Sigma–Aldrich, Poole), 
subsequent washing in ddH2O and then fixation in KODAK GBX fixer/replenisher 
solution (Sigma–Aldrich, Poole). Densitometric analysis was performed on the 










Dilution Conditions Secondary Antibody Dilution 
α-tubulin 
1:2000 
1h at RT Goat anti-mouse HRP-conjugated IgG 
1:2000 
MC1 18 h at 4 °C 
Goat anti-rabbit HRP-conjugated IgG MC3 18 h at 4 °C 




1:2000 18 h at 4 °C Goat anti-rabbit HRP-conjugated IgG 1:2000 
 
 
In most instances, the membranes were re-probed for the detection of other 
proteins or secondary proteins such as the standard housekeeping protein α-
tubulin. This was achieved by stripping bound antibodies on the nitrocellulose 
membrane with the commercially available Pierce Restore PLUS Western Blot 
Stripping Buffer (Thermo Fisher Scientific Inc.) at room temperature for 15 min at 
37ºC for high affinity antibodies. The membranes were then washed in TBST 3 x 
5 min and subsequently blocked in 5 % milk blocking solution for 30 mins at room 
temperature prior to immuno-blotting. Sufficient removal of antibodies was 
ensured by incubating the stripped membranes with Pierce® ECL Western 
Blotting Substrate and consequently exposing them to films.  
 
2.3 Biochemical and analytical methods. 
2.3.1 Griess nitrite accumulation assay. 
Griess reaction assay (Bartholomew, 1984) is a colorimetric method for 
determination of iNOS activity in cells following stimulation, it essentially identifies 
nitrite accumulation within cell culture medium. The assay is based on a chemical 
reaction utilising sulphanilamide and N–1–napthylethylenediamine (NED) under 
acidic condition (H2PO4), whereby nitrite interacts with sulphanilamide in a 
diazotization reaction forming a diazonium species. Following this the diazonium 





spectrophotometrically at the dual wavelength of 560 nm and 630 nm, Thereby, 
provides an indication of nitrite presence in the culture medium. 
Cell-free culture supernatants (100 µl) were collected from the experimental plate 
and transferred to a 96 well plate before an equal volume of Griess reagent (1:1 
mixture of 1.0 % w/v sulphanilamide in 5.0 % aqueous H2PO4 and 0.1 % w/v 
aqueous NED) was added to each well. The plate was incubated for 10 min at 
room temperature for colour development. Following incubation the absorbance 
of the samples was measured at wavelength of A540 nm.  
Quantification of NO2- levels was achieved by comparing the experimental results 
to a calibration curve. Only standard curves (0 – 1000 µM sodium nitrite in 
complete medium) with correlation coefficient R2 ≥ 0.98 were used to analyze 
experimental data, as to ascertain that the fitted model explains at least 98 % of 
the variation in the response variable x (Figure 2.3). 
 
 


























Figure 2.3 Example of a typical Griess nitrite accumulation assay standard curve.  
Absorbance values for each sample were measured at 540 nm and nitrite accumulations 





2.3.2 Cytokine ELISA.  
C-20/A4 and primary chondrocytes were treated at different concentrations with a 
panel of pro–inflammatory stimuli as describe in section 2.2.6.2. Cell-free 
supernatants were analysed for pro-inflammatory cytokines (IL–1β, IL–6, IL–8, 
IL–10 MCP–1). The method of cytokine detection was performed using 
commercially available ELISA kits (R&D Systems). Firstly, a 100 µl capture 
antibody specific to the analyte of interest was bound to a 96–well plate overnight 
in order to create a solid phase. Excess, unbound antibodies were washed off 
with Wash Buffer and incubated with 300 µl blocking reagent (1% BSA dissolved 
in PBS) in order to reduce any unspecific binding. The plate was further washed 
prior to the addition of 100 µl standards, controls and samples were incubated for 
2 h to allow the analyte to bind to the capture antibody, any unbound analyte was 
removed by washing. A detection antibody (100 µl) was then added that binds to 
a different epitope and incubated for 2 h. Unbound detection antibody was 
removed by washing and 100 µl Streptavidin–HRP added for 20 mins. The plate 
was then washed and 100 µl of substrate solution TMB/H2O2 added and 
incubated for 20 mins. Colour development occurred over this period and was 
proportional to the amount of bound analyte. The colour development was 
stopped with the addition of 2N H2SO4 and intensity of the colour measured at 
A450 nm with wavelength correction. Quantification of cytokine levels was 























































































Figure 2.4 Represntative ELISA calibration curves generated using IL-1β  (A), IL-6 
(B), IL-8 (C), MCP-1 (D) and IL-10 (E).  
The standard curves were calculated using a computer-generated 4-PL curve fit. Only 
standard curves with correlation coefficient R ≥ 0.98 were used to analyse experimental 
data, as to ascertain that the fitted model explains at least 98 % of the variation in the 





2.3.3 Cyclic AMP (cAMP) detection assay. 
In functional studies, the alteration of Gi- and Gs-coupled GPCRs is normally 
examined by detecting the concentration of cAMP. cAMP is the intracellular 
signalling molecule 3’–5’–cyclic adenosine monophosphate. It modulates 
intracellular processes by binding to the regulatory units of different protein 
kinases, thus activating their catalytic subunits. That causes initiation of protein 
phosphorylation, an event that alters the functionality of the targeted enzymes 
and/or transcription factors. cAMP is formed by a chemical reaction catalysed by 
adenylate cyclase, which converts ATP to cAMP and inorganic phosphate and is 
triggered or inhibited as a result of direct interaction with G-protein α–subunits. 
Gs and Gi–coupled GPCR activation/inhibition with various agonist or 
antagonists would therefore result in increase or inhibition of cAMP production, 
which can be detected using the cAMP assay.  
In order to determine if the melanocortin agonists are able to cause cAMP 
accumulation within chondrocytes, cAMP Biotrak EIA system was used. Human 
chondrocytic cells C-20/A4 were re–suspended to 1.0 x 105 cells/ml and plated in 
96–well plates overnight to allow adherence. Medium was then replaced with 1.0 
µM IBMX (90.0 µL), and cells then incubated for 30 mins with media, 
melanocortin peptides or Forskolin (3.0 µM). The media was removed and 100 µl 
lysis buffer 1B was added to each well, the plate was then placed on a plate 
shaker for 10 mins to allow for lysis. The lysate standards (0–3200 fmol), 
substrate blank (B), non–specific c binding (NSB) and samples (100 µl each) 
were then prepared and added to the plate. Antiserum was added to each well 
except the NSB and blank wells and incubated at 3 – 5°C for exactly 2 h. Then 
50.0 µl cAMP –peroxidase conjugate was added to all wells except the blank and 
incubated at 3 – 5 ºC for 1 h. Plate was then washed with wash buffer and 150 µl 
of enzyme substrate was added into all wells, and the plate incubated for 30 mins 
at room temperature. The colorimetric reaction was then stopped by adding 100 
µl Stop 1.0 M H2SO4 into each well and mixing. The OD was determined at A450 
cAMP accumulation levels were then calculated by comparing the experimental 






















Figure 2.5 Representative Calibration Curve for cAMP accumulation.  




2.3.4 MTT cell proliferation assay. 
MTT cell proliferation assay measures mitochondrial function as an indication of 
cell viability (Mosmann, 1983). The assay is often used to determine the 
cytotoxicity of potential medicinal agents and toxic materials, since those would 
stimulate or inhibit cell viability and growth. The principle of this assay is to 
assess the ability of mitochondrial succinate dehydrogenase for metabolizing the 
yellow soluble form of MTT (3-(4,5-Dimethyl–2–thiazolyl)–2,5–diphenyl–2H–
tetrazolium bromide, a yellow tetrazole) by reducing it to purple insoluble 
formazan in living cells (Figure 2.6) (Mosmann, 1983). The amount of formazan 
produced is directly proportional to the number of active cells and thus can be 
measured spectrophotometrically to quantify the formazan product.  
Briefly, chondrocytes were treated with or without pro–inflammatory stimuli ± a 
range of melanocortin peptides/ anti–inflammatory drugs for 1 – 72h, supernatant 





10X) was added to each well and cells incubated for 2 h at 37ºC. MTT solution 
was then discarded and the resulting formazan deposits were dissolved in DMSO 
for 15 min prior to absorbance measurement at A570 and A630. Samples containing 
only DMEM + C-20/A4 chondrocytes represented 100 % viability (positive 




Figure 2.6 General reaction scheme for the reduction of MTT to formazan by 






























2.3.5 Caspase-Glo 3/7 apoptosis assay. 
The Caspase-Glo® 3/7 assay is a homogenous luminescent assay that 
measures caspase-3 and caspase-7 activities. These caspases belong to a 
family of cysteine/aspartic acid-specific proteases, which plays key effector roles 
in mammalian cells apoptosis (Nicholson and Thornberry, 1997, Thornberry and 
Lazebnik, 1998, Garcia-Calvo et al., 1999).  
In order to detect cell apoptosis following various treatments of the cells, C-20/A4 
cells were plated at 2.0 x 104/well in 96-well plates with 100 µl of DMEM medium 
supplemented with 1 % Pen/Strep and incubated for 24 h to allow adherence. 
Cells were treated with various agents (pro-inflammatory stimuli ± relevant drug) 
for 6 h and caspase 3 and 7 activity was then evaluated according to the 
manufacturer’s protocol (Promega).  
100 µl of Caspase-Glo 3/7 Reagent was added negative control cells or treated 
cells in DMEM medium. The blank reaction was used to measure background 
luminescence associated with the C20/A4 cell culture system and the Caspace-
Glo reagent. The negative control reactions were prepared in order to detect and 
record basal levels of caspase activity in the C-20/A4 cell culture system.  
Content was mixed gently on a plate shaker at 300-500 rpm for 30 sec and left at 
room temperature to incubate for 1 h, following which luminescence was 
measured using plate-reading luminometer.  
 
2.4 Data analysis and statistics. 
For both in vitro and in situ studies, experiments were performed in triplicates 
unless stated otherwise in the individual figure legends. Bovine articular 
chondrocytes were extracted and pooled together from 3 – 4 animal joints per 
experiment (N=3/4) and performed also in triplicate. Data are reported as mean ± 
standard error of the mean (SEM) unless otherwise stated. Significant differences 
were determined by One-way/Two-way analysis of variance (ANOVA), followed 
by Dunnet’s post-test, or Bonferroni’s multiple comparison tests as appropriate 
using GraphPad Prism 5.0, (GraphPad Software, CA, USA). Values of p≤ 0.05 



























3.1 Effect of pro-inflammatory stimuli on C-20/A4 
chondrocyte function.  
It is increasingly appreciated that mediators typically associated with 
inflammatory arthritis, such as catabolic cytokines and nitric oxide are produced 
by chondrocytes in OA. The role these mediators play in the progression of 
cartilage degradation during OA is an area of intense investigation.  
In this thesis, I have evaluated whether human C-20/A4 chondrocytes might be 
used as a surrogate model for evaluating the effect of anti-inflammatory drugs 
including the effect of melanocortin peptides on inflammatory mediator release 
from activated chondrocytes. I have investigated the cells response to 
inflammatory stimuli (TNF-α, LPS, Zymosan, H2O2 and MSU crystals) on 
synthesizing and releasing pro-inflammatory mediators, such as nitric oxide and 
various catabolic cytokines and chemokines including IL-1β, IL-6, IL-8 and MCP-
1.  
3.1.1 Effect of TNF-α, LPS, H2O2 and MSU crystals on nitrite 
concentration and cell viability.  
Initially, it was investigated whether a panel of stimuli (TNF-α, LPS, Zymosan, 
H2O2 and MSU crystals) were able to cause activation of the iNOS gene and this 
was determined by measuring the release of nitrate from stimulated 
chondrocytes. Nitric oxide is an important signalling molecule that acts in many 
tissues to regulate a diverse range of physiological processes. Cytotoxicity as a 
result of a substantial NO-formation is an established apoptosis initiating factor 
(Brune et al., 1999). Following stimulation, chondrocyte viability was assessed by 
MTT assay to ascertain the effect of the inflammatory stimuli on this parameter.   
C-20/A4 chondrocytes were plated in monolayer in DMEM media (50.0 U/ml 
Penicillin, 50.0 µg/ml Streptomycin) for 24 h prior to stimulation with TNF-α (20.0 
– 80.0 pg/ml), LPS (0.1 – 10.0 µg/ml), H2O2 (0.01 – 1.0 %) or MSU crystals (0.1 – 
1.0 µg/ml) for 6 h. Cell free supernatants were collected and analysed for nitrite 
release by Griess assay. In unstimulated cells there was a basal release of nitrite 





value. In initial experiments C-20/A4 chondrocytes were stimulated with high 
concentrations of H2O2 to determine whether C-20/A4 chondrocytes produce 
nitrite compared to unstimulated control cultures.  
H2O2 caused a concentration-dependent increase in NO release, where 0.01%, 
0.1% and 1.0% H2O2 led to 139.28 ± 6.24 µM, 175.67 ± 7.18 µM and 210.12 ± 
10.31 µM respectively (p≤ 0.001), thereby indicating that the chondrocytes can 
release substantial quantities of nitrite when stimulated (Figure 3.1 A). After 
validating the ability of C-20/A4 cells to respond to oxidative stress by activating 
iNOS, we tested the response of the chondrocytes to TNF-α, LPS and MSU 
crystals stimulation.  
 
Figure 3.1 B demonstrates the effect of TNF-α (20.0 – 80.0 pg/ml) on nitrite 
formation. Stimulation of the human cell-line chondrocytes led to a significant 
release of nitrite, whereby TNF-α (20.0 pg/ml) caused 19.18 ± 6.79 µM, which 
was not substantially altered upon increasing the concentrations, however, 
maximal release was observed at 80.0 pg/ml (20.86 ± 6.33 µM, p≤ 0.05 vs. 
control). Next, it was evaluated whether the observed effect was due to the 
particular stimulus being used; therefore nitrite release in the presence of LPS 
(0.1 – 10.0 µg/ml) was examined (Figure 3.1) and significant alterations were 
detected: 36.35 ± 7.95 µM, 30.35 ± 9.64 mM and 24.99 ± 7.21 µM for 1.0, 3.0 
and 10.0 µg/ml LPS respectively (p≤ 0.05 for all concentrations tested). 
Conversely, MSU crystals (30 – 1000 ng/ml) did not cause a significant increase 
in nitrite release compared to unstimulated controls (p> 0.05; Figure 3.1 D).  
Following identification of C-20/A4 chondrocytes capability to produce NO, cell 
viability was assessed by MTT assay in the presence of these stimuli, thereby 
confirming the cytotoxicity of the given stimulus in this cell-line model. To ensure 
that cell death could be measured in C-20/A4 chondrocytes, cells were 
stimulated with 0.01 %, 0.1 % and 1.0 % H2O2, which caused a concentration-
dependent decrease in cell viability with 82.25 ± 4.66 %, 87.14 ± 4.23 % and 
92.80 ± 1.29 % cell death respectively (p<0.001; Figure 3.2A). Similarly, TNF-α 
(20.0 – 80.0 pg/ml) caused a significant concentration-dependent decline in C-





4.09 % reduction in viability (p≤ 0.05). Analogous effects were noted following 
40.0 pg/ml (11.8 ± 3.4%, n.s.), whilst at higher concentrations (60.0 pg/ml) there 
was 27.58 ± 2.85% (p≤ 0.01) rate of cell death, which was slightly increased at 
80.0 pg/ml to 30.22 ± 1.18 % (p≤ 0.001) compared to untreated cells (Figure 3.2 
B). C-20/A4 chondrocytes were then stimulated with LPS, which caused a 23.29 
± 3.14 % (p≤ 0.001), 19.24 ± 2.83 % (p≤ 0.001) and 17.42 ± 3.23 % (p≤ 0.01) cell 
death at 1.0, 3.0, and 10.0 µg/ml concentrations respectively.  
MSU crystals (30 – 1000 ng/ml) did not alter cell viability of C-20/A4 
chondrocytes compared to unstimulated cells. This finding, combined with the 
observation that it did not induce nitrite release led to discontinuation of further 




























































Figure 3.1.  The effect of inflammatory stimuli on nitric oxide production from C-
20/A4 chondrocytes.  
C-20/A4 chondrocytes (1.5 x 105 cells/cm2) were plated in serum-free DMEM and 
stimulated with H2O2 (0.01 – 1.0 %; Panel A), TNF-α (20.0 – 80.0 pg/ml; Panel B), LPS 
(1.0 – 10.0 µg/ml; Panel C) or MSU crystals (0.1 – 1.0 µg/ml; Panel D) for 6 h. Cell-free 
supernatants were then collected and analysed for nitrite release via Griess assay. 
Dotted line represents basal release of nitrite (1.23 ± 1.21 µM). Data are presented as 
Mean ± SEM of n=9 experiments, assessed in triplicate.  *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001 







































































Figure 3.2.  The effect of inflammatory stimuli on C-20/A4 chondrocytes viability.  
C-20/A4 chondrocytes (1.5 x 105 cells/cm2) were plated in serum-free DMEM (280 and 
stimulated with H2O2 (0.01 – 1.0 %; Panel A), TNF-α (20.0 – 80.0 pg/ml; Panel B), LPS 
(1.0 – 10.0 µg/ml; Panel C) or MSU crystals (0.1 – 1.0 µg/ml; Panel D) for 6 h. Cell 
viability was then determined via MTT reduction assay. Dotted line represents control 
sample cell viability – untreated cells (100%). Data are presented as Mean ± SEM of n=9 










3.1.2 Detection of pro-inflammatory cytokines release following 
stimulation of C-20/A4 chondrocytes with TNF-α and LPS.  
The importance of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6 IL-8 in 
the induction of catabolic processes in chondrocytes has been recognized 
(Pelletier et al., 1991, Shinmei et al., 1991, Lotz et al., 1992, Reboul et al., 1996, 
Melchiorri et al., 1998, Shlopov et al., 2000, Fernandes et al., 2002, Schuerwegh 
et al., 2003, Rai et al., 2008, Goldring et al., 2008). The major source of pro-
inflammatory cytokines in OA has been thought to be activated synovium or 
infiltrating inflammatory cells, however strong evidence exists that chondrocytes 
can also release these mediators and drive the inflammatory response within the 
joint (Goldring, 2000; Goldring et al., 2011). In order to investigate whether 
human C-20/A4 chondrocytes are capable of releasing pro-inflammatory 
cytokines, cells were stimulated with TNF-α and LPS and mRNA and protein 
levels of pro-inflammatory cytokines were determined.  
3.1.2.1 Effect of TNF-α and LPS on IL6 and IL8 mRNA expression in 
C20/A4 chondrocytes. 
In initial experiments, the effect of TNF-α (60.0 pg/ml) and LPS (1.0 µg/ml) was 
investigated on IL6 and IL8 mRNA expression levels following 0 – 48 h 
incubation periods. Total RNA was extracted from stimulated and non-stimulated 
cells and conventional RT-PCR amplification reactions with specific primers for 
IL6 and IL8 genes (Table 2.9) were used. Gene expression was visualized on 2 
% agarose gels, run in conjunction with β-actin (Figure 3.5 A).  RT-PCR showed 
that C-20/A4 chondrocyte respond to TNF-α (60.0 pg/ml), a concentration 
chosen from previous experiments to cause a sub-maximal rate of cell death and 
nitrite release, thereby substantially increasing IL6 and IL8 expression in time-
dependent manner (Figure 3.3 A). Maximal mRNA levels of IL6 and IL8 were 
detected 2 h post-stimulation gradually decreased in the period between 6 – 48 
h, as determined by densitometric analysis (Figure 3.3 B and C).  Incubation 
period of 6 h was chosen as suitable for subsequent experiments as it led to sub-
maximal release of IL6 and IL8, thereby allowing for the concentration dependent 





in IL6 and IL8 with densitometric quantification showing a 53-fold increase in 
expression of IL6 peaking at 40.0 pg/ml  TNF-α (Figure 3.4 A), and a 9-fold 
increase in IL8 compared to control (Figure 3.4 B and C).  
In order to clarify the response of C-20/A4 chondrocytes to LPS, the effect of 
various concentrations on pro-inflammatory cytokine expression was 
investigated. LPS induced a concentration-dependent increase in the expression 
of IL6 and IL8 (Figure 3.4 C and D), whereby chondrocytes were notably 
activated following concentrations as low as 0.1 µg/ml, and reaching a 72-fold 
increase in IL6 and 13.5-fold increase in IL8 expression at 1.0 µg/ml compared to 
untreated controls (p≤ 0.001). Each value was normalized to the respective β-







Figure 3.3. Densitometric quantification of IL6 and IL8 expression in C-20/A4 
chondrocytes treated with TNF-α  (60.0 pg/ml) for 0-48 h.  
C-20/A4 chondrocytes were stimulated with TNF-α (60.0 pg/ml) at time 0 and total RNA 
extracted 0-48 h post-stimulation. PCR amplification with the respective primers for IL6 
and IL8 was used to detect and quantify gene expression on 2% agarose gels in 
triplicates with β-actin used as internal control (Panel A). Comparison of 
densitometrically quantified IL6 (Panel B) and IL8 (Panel C) shown in arbitrary units, 
each value normalized to the respective β-actin expression. Data are presented as Mean 






Figure 3.4. Densitometric quantification of IL6 and IL8 expression in C-20/A4 cells 
treated with TNF-α  (20.0 – 80.0 pg/ml) and LPS (0.1 – 1.0 µg/ml) for 6 h.  
C-20/A4 chondrocytes were stimulated with TNF-α (20.0 – 80.0 pg/ml) and LPS (0.1 – 
1.0 µg/ml) at time 0 and total RNA extracted 6 h post stimulation. PCR amplification with 
the respective primers for IL6 and IL8 was used to detect and quantify gene expression 
on 2 % agarose gels in triplicates with β-actin used as internal control (Panel A). 
Comparison of densitometrically quantified IL6 (Panel B and C) and IL8 (Panel D and E) 
shown in arbitrary units, each value normalized to the respective β-actin expression. 






3.1.2.2 Effect of TNF-α and LPS on IL-6 and IL-8 cytokine release from 
C20/A4 chondrocytes. 
Following identification of TNF-α and LPS ability to induce IL6 and IL8 
expression in C-20/A4 chondrocytes, the effect of various concentrations of these 
stimuli over a time course was investigated, thereby confirming the genuine 
translation of IL6 and IL8 mRNA to protein. C-20/A4 chondrocytes were 
stimulated with TNF-α (20.0 – 80.0 pg/ml) and LPS (1.0 – 10.0 µg/ml) for 0, 2, 6 
and 24 h and cell-free supernatants were collected and analysed. Stimulation for 
2 h with TNF-α (20.0 – 80.0 pg/ml) resulted in well-defined bell-shaped curve 
effect in IL-6 release, peaking at 60.0 pg/ml (99.23 ± 13.81 pg/ml; p≤ 0.05) and 
decreasing thereafter with 80.0 pg/ml leading to 74.55 ± 17.89 pg/ml (p≤ 0.05; 
Figure 3.5 A). Lower concentrations of TNF-α failed to illicit significant IL-6 
release at this time-point as compared to control (DMEM treated cultures). 
Subsequently, a longer, 6 h incubation period was employed to investigate IL-6 
production from chondrocytes in response to TNF-α, with 20.0 pg/ml and 40.0 
pg/ml of TNF-α caused 45.52 ± 8.3 pg/ml and 59.64 ± 2.4 pg/ml of IL-6 
respectively (p≤ 0.05; Figure 3.5 B). As previously seen, maximal release 
following 2 h of stimulation was caused by 60.0 pg/ml of TNF-α with 117.1 ± 
26.09 pg/ml (p≤ 0.05), which slightly decreased following treatment with 80.0 
pg/ml TNF-α (84.31 ± 5.69 pg/ml; p≤ 0.05). Analogous effects were observed at 
24 h, when a bell-shaped release of IL-6 was detected with 20.0 pg/ml and 40.0 
pg/ml causing 52.79 ± 2.60 pg/ml and 63.30 ± 6.97 pg/ml of IL-6 respectively (p≤ 
0.05). Increasing the concentrations led to the detection of a maximal release of 
154.30 ± 10.32 pg/ml (p≤ 0.01) detected at 60.0 pg/ml, which decreased at 80.0 
pg/ml TNF-α (139.34 ± 11.48 pg/ml (p≤ 0.01; Figure 3.5 C).  
The effect of LPS (0.1 – 10.0 µg/ml) was subsequently determined and confirmed 
to cause a concentration-dependent increase in IL-6 at 2 h compared to 
untreated control cultures (Figure 3.5 D). Concentrations lower than 1.0 µg/ml did 
not cause statistically significant difference compared to control values (p≤ 0.05), 
but higher concentrations of LPS led to 73.467± 13.83 pg/ml, 176.85 ± 23.5 pg/ml 
and 152.34 ± 6.44 pg/ml of IL-6 production (p≤ 0.05) for 1.0, 3.0 and 10.0 µg/ml 





treated with LPS for 6 h; however, here, in accordance with RT-PCR detected 
levels, 0.1 µg/ml and 0.3 µg/ml of LPS caused a significant increase in IL-6 
production, leading to 61.33 ± 7.11 pg/ml and 68.67 ± 10.33 pg/ml respectively 
(p≤ 0.05; Figure 3.5 E). At 24 h post-stimulation LPS (0.1 – 10.0 µg/ml), a 
maximal release of 134.93 ± 14.72 pg/ml of IL-6 was recorded following 
stimulation with LPS (3.0 µg/ml; p≤ 0.01; Figure 3.5 F) There was no significant 
difference between the potency of the various concentrations probably due to a 
plateau, which is reached at concentrations this high. 
Consequently the translation of IL-8 mRNA to protein was determined. C-20/A4 
chondrocytes were stimulated with TNF-α and LPS for 0, 2, 6 and 24 h and a 
bell-shaped response was recorded regardless of the time-point. The results, 
reported in Figure 3.6 A, demonstrated the lack of efficacy of low concentrations 
of TNF-α (20.0 and 40.0 pg/ml) at short incubation periods (2 h) in the 
chondrocyte system. However, 2 h-stimulation with 60.0 pg/ml and 80.0 pg/ml of 
TNF-α caused significant IL-8 production with 130.23 ± 9.5 pg/ml and 142.65 ± 
12.5 pg/ml respectively (p≤ 0.05), (Figure 3.6 A). These amounts were compared 
to basal levels of IL-8 synthesis (63.34 ± 5.32 pg/ml). TNF-α caused a bell-
shaped response in IL-8 production at 6 h post-simulation, peaking at 60.0 pg/ml 
(205.90 ± 27.1 pg/ml; p≤ 0.01), and slowly decreasing following stimulation with 
80.0 pg/ml of TNF-α (145.68 ± 4.72 pg/ml; p≤ 0.01; Figure 3.6B). In contrast to 
the effect at 20.0 and 40.0 pg/ml of TNF-α at 2h, these concentrations led to 
significant increase in IL-8 production following 6 h incubation (120.38 ± 3.67 
pg/ml and 131.8.41 pg/ml; p≤ 0.05; Figure 3.6 B) compared to control (72.65 ± 
7.34 pg/ml). Lastly, TNF-α effect at 24 h was determined with 20.0 and 40.0 pg/m 
leading to 348.57 ± 53.23 pg/ml and 391.36 ± 35.7 pg/ml of IL-8 respectively (p≤ 
0.01), compared to control (79.33 ± 15.65 pg/ml).  
LPS (0.1 – 10.0 µg/ml), being a bacterial lipopolysaccharide has been shown to 
cause joint and cartilage inflammation (Lotz et al., 1992). At all concentrations 
and time-points tested it caused a significant increase in IL-8 production. At 2 h, 
6 h and 24 h there was a concentration-dependent increase leading to a maximal 
release of IL-8 at 3.0 µg/ml with 189.5 ± 25.46 pg/ml, (p≤ 0.05), 243.53 ± 18.31 





concentrations caused similarly significant amounts of IL-8, but were not different 
from one another within the incubation period (Figure 3.6 D-F).  
 
Figure 3.5 Effect of pro-inflammatory stimuli on IL-6  release from C20/A4 
chondrocytes.  
C-20/A4 chondrocytes were stimulated with TNF-α (20.0 – 80.0 pg/ml; Panel A – C) or 
LPS (0.1 – 10.0 µg/ml; Panel D – F) and cell-free supernatants collected at 0, 2, 6 and 
24 h. IL-6 release was then determined by ELISA. Data are presented as Mean ± SEM 










Figure 3.6. Effect of pro-inflammatory stimuli on IL-8 release from C20/A4 
chondrocytes. 
C-20/A4 chondrocytes were stimulated with TNF-α (20.0 – 80.0 pg/ml; Panel A – C) or 
LPS (0.1 – 10.0 µg/ml; Panel D – F) and cell-free supernatants collected at 0, 2, 6 and 
24 h. IL-8 production was then determined by ELISA. Data are presented as Mean ± 
SEM of n=4 independent experiments repeated in triplicate, *p≤0.05, **p≤0.01 vs. Time 






3.1.2.3 Effect of TNF-α and LPS on IL-1β and MCP-1 cytokine release 
from C-20/A4 chondrocytes. 
In separate experiments C-20/A4 chondrocytes were stimulated with different 
concentrations of TNF-α (20.0 – 80.0 pg/ml) and LPS (1.0 – 10.0 µg/ml) for 0, 2, 
6 and 24 h and cell-free supernatants were analysed for IL-1β and MCP-1 by 
ELISA. Given that IL-1β is considered to be active locally within cartilage and 
leads to matrix destruction, IL-1β levels were measured (Attur et al., 2000; 
Fernandes et al., 2002; Kapoor et al., 2011). In addition, to assess chondrocyte 
contribution to the chemotactic environment of inflamed joints the intracellular 
content of the CC (IL-1β) and CXC chemokine (MCP-1) was investigated, with 
specific interest in MCP-1 production (Villager et al., 1992; Borzi et al., 1999). 
TNF-α and LPS caused a significant increase in IL-1β release (p≤ 0.05) 
compared to unstimulated control cells. Treatment with TNF-α caused a 
significant concentration-dependent increase in IL-1β at 2, 6 and 24 h post-
stimulation.  
Following 2 h stimulation, the lower concentrations (20.0 and 40.0 pg/ml) of TNF-
α didn’t cause significant up-regulation in IL-1β production, consistent with the 
results obtained for IL-6 and IL-8. The maximal release of 16.74 pg/ml at this time 
point was induced by 80.0 pg/ml (p≤ 0.05; Figure 3.7 A), and these observations 
were confirmed at 6 h, where 80.0 pg/ml caused 28.35 ± 3.25 pg/ml IL-1β to be 
released (p≤ 0.05; Figure 3.7 B), However, at 6 h, 40.0 pg/ml and 60.0 pg/ml of 
TNF-α also led to significant increase in the concentration of IL-1β, 15.73 ± 1.1 
pg/ml and 24.37 ± 8.69 pg/ml respectively (p≤ 0.05). IL-1β was not detectable at 
24 h following stimulation with 80.0 pg/ml, however at 60.0 pg/ml, a small but 
detectable amount of IL-1β was observed (14.61 ± 3.1 pg/ml, p≤ 0.05; Figure 3.7 
C).   
LPS (3.0 µg/ml) stimulation of C-20/A4 chondrocytes for 2 h caused the maximal 
release of IL-1β for this time point with 17.23 ± 2.86 pg/ml (p≤ 0.05; Figure 3.7 
D). Following 6 h stimulation, LPS caused a concentration-dependent bell-
shaped response, with 1.0 µg/ml causing 26.55 ± 10.31 pg/ml of IL-1β to be 





with all concentrations causing similar amounts of IL-1β to be released (p≤ 0.05; 
Figure 3.7 F). 
Next, TNF-α (20.0 – 80.0 pg/ml) effect was evaluated on MCP-1 production, 
where stimulation for 2 h (Figure 3.8 A) did not yield statistically significant 
increases in MCP-1 compared to basal levels (46.18 ± 14.21 pg/ml; p≤ 0.05). 
TNF-α (20.0 pg/ml) did not cause any significant change in MCP-1 levels 
regardless of the incubation periods (p> 0.05) evaluated, however, with 
increasing concentrations of the cytokine at 6 h (Figure 3.8 B), there was a 
significant increase in MCP-1 production of 69.39 ± 4.21 pg/ml (p≤ 0.05), 101.2 ± 
16.37 pg/ml (p≤ 0.05) and 119.92 ± 8.74 pg/ml (p≤ 0.05) for TNF-α 40.0 pg/ml, 
60.0 pg/ml and 80.0 pg/ml respectively. MCP-1 levels at 24 h following 
stimulation with TNF-α (40.0 – 80.0 pg/ml; Figure 3.8 C) followed a  bell-shaped 
curve, where 40.0, 60.0 and 80.0 pg/ml TNF-α causing 70.43 ± 5.23 pg/ml (p≤ 
0.05), 101.34 ± 12.09 (p≤ 0.05) and 93.324 ± 6.42 pg/ml (p≤ 0.05) respectively 
compared to basal production (39.29 ± 11.28 pg/ml).  
Subsequently, LPS was evaluated and found to stimulate significant rise in MCP-
1 release with a maximal response achieved at 3.0 and 10.0 µg/ml following 6 h 
incubation (Figure 3.8 E), with 68.34 ± 4.52 pg/ml and 70.11 ± 3.32 pg/ml 
respectively compared to untreated controls (46.18 ± 14.21 pg/ml). At 2 h post-
stimulation (Figure 3.8 D), MCP-1 release was lower 25.29 ± 2.38 pg/ml (0.3 
µg/ml; p≤ 0.05), 41.34 ± 12.23 pg/ml (1.0 µg/ml; p≤ 0.05), 23.55 ± 6.89 pg/ml (3.0 
µg/ml, p≤ 0.05) and 32.43 ± 12.48 pg/ml (10.0 µg/ml; p≤ 0.05). Incubation periods 
longer than 6 h did not induce statistically significant increases in MCP-1 release 
from C-20/A4 chondrocytes compared to basal levels (39.31 ± 8.89; p≤ 0.05; 















Figure 3.7. Effect of pro-inflammatory stimuli on IL-1β   release from C20/A4 
chondrocytes.  
C-20/A4 chondrocytes were stimulated with TNF-α (20.0 – 80.0 pg/ml; Panels A – C) or 
LPS (0.1 – 10.0 µg/ml; Panels D – F) and cell-free supernatants collected at 0, 2, 6 and 
24 h and IL-1β determined by ELISA. Data are presented as Mean ± SEM of n=4 







Figure 3.8. Effect of pro-inflammatory stimuli on MCP-1 release from C20/A4 
chondrocytes. 
C-20/A4 chondrocytes were stimulated with TNF-α (20.0 – 80.0 pg/ml; Panel A – C) or 
LPS (0.1 – 10.0 µg/ml; Panel D – F) and cell-free supernatants collected at 0, 2, 6 and 
24 h and analysed for MCP-1  by ELISA. Data are presented as Mean ± SEM of n=4 









3.1.2.4 Time dependent release of pro-inflammatory cytokines following 
C-20/A4 chondrocyte stimulation.  
In order to fully understand the response of C-20/A4 chondrocytes to 
inflammogens, they were stimulated with TNF-α at 60.0 pg/ml and LPS at 1.0 
µg/ml (the most potent concentrations identified from previous experiments) for a 
longer time course investigation including incubation periods of up to 72 h. Cell-
free supernatants were collected at each individual time point and subsequently 
analysed for IL-6 and IL-8 release by ELISA.  
Cultured C-20/A4 cells had a basal release of IL-6 (21.09 ± 18.49 pg/ml) and IL-8 
(72.65 ± 13.32 pg/ml). TNF-α (60.0 pg/ml) and LPS (1.0 µg/ml) caused a 
significant time-dependent increase in IL-6 (Figure 3.9 A, B) and IL-8 (Figure 3.9 
C, D), with maximal production detected at 48 h post-incubation, with 154.30 ± 
10.32 pg/ml and 159.65 ± 20.86 pg/ml (p≤ 0.001) of IL-6 following TNF-α and 
LPS stimulation respectively. Maximal release of IL-8 was detected at 48 h 
(558.90 ± 11.34 pg/ml, p≤ 0.001), whilst following LPS stimulation it was detected 
at 72 h (378.79 ± 46.86 pg/ml, p≤ 0.001). Release of these pro-inflammatory 
cytokines following 2 h of incubation with TNF-α (60.0 pg/ml) and LPS (1.0 µg/ml) 
caused significant increases of 99.23 ± 13.81 pg/ml (p≤ 0.05) and 73.47 ± 13.82 
(p≤ 0.05) of IL-6 and 130.23 ± 9.50 pg/ml (p≤ 0.05) and 172.64 ± 14.97 pg/ml (p≤ 
0.01) IL-8 respectively. At later time-points there was an increase in these 
cytokines, such that following 4 h stimulation with LPS there was a marked up-
regulation of IL-6 and IL-8 with 112.0 ± 11.3 pg/ml (p≤ 0.05) and 219.45 ± 12.22 
pg/ml for IL-6 and IL-8 respectively. Incubation of chondrocytes with TNF-α (60.0 
pg/ml) and LPS (1.0 µg/ml) for 6 h caused 117.1 ± 26.1 pg/ml and 135.99 ± 
20.13 pg/ml release of IL-6, for the two inflammogens respectively, and 205.92 ± 
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Figure 3.9. Effect of TNF-α  and LPS on IL-6 and IL-8 release in C-20/A4 cells over 
0-72 h period.  
C-20/A4 chondrocytes were stimulated with TNF-α (60.0 pg/ml; dark blue bars) or LPS 
(1.0 µg/ml; light blue bars) and cell-free supernatants collected at 0 – 72 h. IL-6 (Panel 
A, B) and IL-8 (Panel C, D) were then determined by ELISA. Data are presented as 
Mean ± SEM of n=7 independent experiments repeated in triplicate, *p≤ 0.05, **p≤ 0.01, 






3.1.3 Effect of TNF-α and LPS on MMP1, MMP3 and MMP13 expression 
in C20/A4 chondrocytes. 
OA is increasingly characterised by release of pro-inflammatory cytokines and 
other mediators of the host inflammatory response and cartilage degradation 
initiated by MMPs. Generally, collagenase expression induced by TNF-α is 
thought to be NFκB-dependent, a pathway also used by TLRs (Zhang et al., 
2008). Initially, the effects of TNF-α and LPS (TLR4 ligand) were investigated on 
MMP1, MMP3 and MMP13 expression by C20/A4 chondrocytes. The effect of 
TNF-α (20.0 – 80.0 pg/ml) and LPS (0.1 – 1.0 µg/ml) on MMPs levels were at 
first evaluated following 6 h stimulation of C-20/A4 chondrocytes and the total 
RNA extracted from stimulated and non-stimulated cells was analysed for 
transcription of these genes by RT-PCR.  
LPS and TNF-α caused increases in MMP1 (Figure 3.10 A) and MMP13 (Figure 
3.11 A) and decreased expression of MMP3 in C-20/A4 cells at 6 h. (Figure 3.12 
A). TNF-α (20.0 – 80.0 pg/ml) caused significant increases in MMP1 expression 
(Figure 3.10 B), with 20.0 pg/ml causing 1.5-fold increase compared to basal 
(0.21 ± 0.02 au to 0.33 ± 0.04 au, p≤ 0.05). Increased concentrations of TNF-α 
(40.0 and 60.0 pg/ml) led to a plateau effect of 8-fold up-regulation of MMP1 with 
expression levels of 1.66 ± 0.22 au and 1.71 ± 0.11 au respectively (p≤ 0.01 for 
both concentrations), whilst 80.0 pg/ml of TNF-α caused a slightly less profound 
but similar increase to 1.52 ± 0.23 au representing 7-fold increase in expression 
(p≤ 0.01). LPS stimulation caused a bell-shaped response with a significant 
increase in MMP1 expression at 0.1 µg/ml (8-fold increase; 1.78 ± 0.21 au, 
p<0.01) and at 1.0 µg/ml (7-fold increase; 1.47 ± 0.1 au, p≤ 0.01), with a maximal 
12-fold up-regulation detected following stimulation with 0.3 µg/ml LPS (2.18 ± 
0.3 au, p≤ 0.01; Figure 3.10 C).  
Densitometric analysis of MMP13 expression showed a concentration dependent 
increase in expression (Figure 3.11 A), whilst no detection was observed in non-
stimulated C-20/A4 chondrocytes. TNF-α (20.0 and 40.0 pg/ml) caused an 
increase in MMP13 expression to 0.057 ± 0.03 au and 0.1 ± 0.02 au, respectively 





0.34 ± 0.07 au respectively (p≤ 0.001; Figure 3.11 B). Similarly, LPS (0.1 – 1.0 
µg/ml) at all concentrations led to significant increases in MMP13 expression 
levels (Figure 3.11 C), with 0.1 µg/ml causing 0.13 ± 0.003 au and higher 
concentrations causing 0.205 ± 0.002 au and 0.2 ± 0.03 au (p≤ 0.001 both) 
expression for 0.3 µg/ml and 1.0 µg/ml respectively.  
MMP3 was then evaluated as it has been shown to be highly expressed in 
healthy hip cartilage, and significantly reduced in osteoarthritic hip cartilage 
(Kevorkian et al., 2004). Both TNF-α and LPS significantly reduced MMP3 levels 
(Figure 3.12 A). TNF-α stimulation caused a bell-shaped inhibition in MMP3 
expression with 60.0 pg/ml, with a 46% down-regulation of the protease 
expression from 0.580 ± 0.051 au to 0.31 ± 0.05 au (p≤ 0.05; Figure 3.12 B). 
Treatment with LPS caused a concentration dependent decrease in MMP3 
expression with 1.0 µg/ml causing a complete inhibition in expression compared 
to untreated controls (p≤ 0.001). Lower concentrations of LPS caused significant 
inhibition with 0.1 µg/ml and 0.3 µg/ml leading to 64% and 77% down-regulation 
of MMP3 expression (0.21 ± 0.04 and 0.13 ± 0.06 au, p≤ 0.01) compared to 
control cultures (Figure 3.12 C).  
Following identification of MMP1, MMP3 and MMP13 mRNA expression at 6 h, 
the effect of TNF-α in a time-dependent manner was investigated. C-20/A4 
chondrocytes were stimulated with TNF-α (60.0 pg/ml) for 0 – 48 h. MMP1 was 
markedly increased in a time-dependent manner (Figure 3.13 A). Unlike IL6 and 
IL8 expression, which peaked at 2 h post-stimulation, TNF-α stimulation of 
MMP1 did not cause significant change in expression at this time point (0.31 ± 
0.04 au compared to untreated 0.22 ± 0.03 au). However, at 6 h there was a 
marked 8-fold increase to 1.71 ± 0.11 au (p<0.001). The expression of MMP1 
continued to increase over the time course to 2.12 ± 0.22 au (p≤ 0.001) at 24 h 
and was reduced at 48 h (1.72 ± 0.23 au, 8-fold; p≤ 0.001; Figure 3.13 B).  
Similarly, MMP13 expression was unchanged following 2 h stimulation with TNF-
α (0.021 ± 0.022 au; p>0.05); however, expression was significantly increased at 
6 h with a 11.5-fold increase in expression compared to 2 h (p<0.001; Figure 





expression of MMP13 with 0.29 ± 0.03 au and 0.34 ± 0.07 au at 24 h and 48 h 
post-incubation respectively.  
Treatment of C-20/A4 with TNF-α (60.0 pg/ml) caused a significant reduction of 
MMP3. It was significantly reduced by 55% down to 0.26 ± 0.05 au (p≤ 0.01) at 2 
h, by 36% down to 0.37 ± 0.42 au (p≤ 0.05) and at 24 h the expression of MMP3 
was down-regulated to 0.31 ± 0.05 au, a 46% decrease (p≤ 0.05) as compared to 
untreated controls (0.580 ± 0.051 au). At 48 h post stimulation, there was a slight 







Figure 3.10. Densitometric quantification of MMP1 expression in C-20/A4 cells 
treated with TNF-α  (20.0 – 80.0 pg/ml) and LPS (0.1 – 1.0 µg/ml) for 6 h.  
C-20/A4 chondrocytes were stimulated with TNF-α (20.0 – 80.0 pg/ml) or LPS (0.1 – 1.0 
µg/ml) at time 0 and total RNA extracted 6 h post stimulation. PCR amplification with the 
respective primers for MMP1 was used to detect and quantify gene expression on 2 % 
agarose gels in triplicates with β-actin used as internal control (Panel A). Comparison of 
densitometrically quantified MMP1 expression by TNF-α (Panel B) and LPS (Panel C) 
shown in arbitrary units, each value normalized to the respective β-actin expression. 






Figure 3.11. Densitometric quantification of MMP13 expression in C-20/A4 cells 
treated with TNF-α  (20.0 – 80.0 pg/ml) and LPS (0.1 – 1.0 µg/ml) for 6 h.  
C-20/A4 chondrocytes were stimulated with TNF-α (20.0 – 80.0 pg/ml) or LPS (0.1 – 1.0 
µg/ml) at time 0 and total RNA extracted 6 h post stimulation. PCR amplification with the 
respective primers for MMP13 was used to detect and quantify gene expression on 2 % 
agarose gels in triplicates with β-actin used as internal control (Panel A). Comparison of 
densitometrically quantified MMP13 expression by TNF-α (Panel B) and LPS (Panel C) 
shown in arbitrary units, each value normalized to the respective β-actin expression. 







Figure 3.12. Densitometric quantification of MMP3 expression in C-20/A4 cells 
treated with TNF-α  (20.0 – 80.0 pg/ml) and LPS (0.1 – 1.0 µg/ml) for 6 h.  
C-20/A4 chondrocytes were stimulated with TNF-α (20.0 – 80.0 pg/ml) or LPS (0.1 – 1.0 
µg/ml) at time 0 and total RNA extracted 6 h post stimulation. PCR amplification with the 
respective primers for MMP3 was used to detect and quantify gene expression on 2 % 
agarose gels in triplicates with β-actin used as internal control (Panel A). Comparison of 
densitometrically quantified MMP3 expression by TNF-α (Panel B) and LPS (Panel C) 
shown in arbitrary units, each value normalized to the respective β-actin expression. 







Figure 3.13. Densitometric quantification of MMP1, MMP3 and MMP13 expression 
in C-20/A4 cells treated with TNF-α  (60.0 pg/ml) for 0-48 h.  
C-20/A4 chondrocytes were stimulated with TNF-α (20.0 – 80.0 pg/ml) at time 0 and total RNA 
extracted 0-48 h post stimulation. PCR amplification with the respective primers for MMP1, MMP3 
and MMP13 were used to detect and quantify gene expression on 2 % agarose gels in triplicates 
with β-actin used as internal control (Panel A). Comparison of densitometrically quantified MMP1 
(Panel B), MMP3 (Panel C) and MMP13 (Panel D) expression by TNF-α shown in arbitrary units, 
each value normalized to the respective β-actin expression. Dotted line represents basal 
expression levels. Data are presented as Mean ± SEM of four independent experiments *p≤ 0.05, 





3.1.4 Effect of TNF-α on COL2A1 and COL1A1 expression. 
In healthy articular cartilage, chondrocytes are actively maintaining the steady-
state expression of collagens and proteoglycans. Articular chondrocytes are 
sensitive to various growth factors and cytokines, which either enhance or reduce 
the synthesis of type II collagen, a marker of normal function of articular 
chondrocytes (Goldring et al., 1994). In osteoarthritis, cytokines including IL-1β, 
IL-6, IL-8, and TNF-α, produced by osteoarthritic chondrocytes significantly up-
regulate matrix metalloproteinases (MMPs) gene expression, and decrease the 
synthesis of tissue specific macromolecules, such as collagen II, therefore 
inhibiting the chondrocyte’s compensatory synthesis pathways required to 
restore the integrity of the degraded extracellular matrix (Pelletier et al., 1991, 
Goldring et al., 1994b, Shlopov et al., 1997, Shlopov et al., 2000, Goldring et al., 
2011).  
Human C-20/A4 chondrocytes were found to respond to TNF-α in a time and 
concentration-dependent manner, by producing large amounts of the above-
mentioned pro-inflammatory cytokines and significantly up-regulating 
collagenases 1 and 3. Next, in order to further investigate whether stimulation 
with TNF-α induces conditions resembling the events observed in OA 
chondrocytes, we investigated its effect on COL1A1, COL2A1 expression and 
additionally calculated the COL2A1:COL1A1 ratio to study the effect of TNF-α on 
the chondrocytic phenotype of the C-20/A4 cells. The results showed that 
expression of COL2A1, a marker for normal function of articular chondrocytes, 
was significantly down-regulated after TNF-α (60.0 pg/ml) treatment, in 
comparison to unstimulated cultures of C-20/A4 chondrocytes. The inflammogen 
caused a 66.7 % reduction in mRNA expression of collagen type II from 0.754 ± 
0.08 au to 0.24 ± 0.012 au (p≤ 0.01) and 49 % reduction in COL1A1 expression 
from 2.25 ± 0.16 au to 1.121 ± 0.05 au (p≤ 0.01), as calculated following 
densitometric analysis (Figure 3.14 B) of the PCR product bands with the correct 
size (Figure 3.14 A).  
Despite the large drop in overall collagen production, there was only slight, 
insignificant change in the indicator of differentiation COL2A1:COL1A1 ratio, as 







Figure 3.14 Quantification of the effect of TNF-α  on COL1A1 and COL2A1 
expression.  
C-20/A4 chondrocytes were treated with TNF-α (60.0 pg/ml) and total RNA extracted 6 h 
post stimulation. PCR amplification with the respective primers for COL1A1 and COL2A1 
was used to detect and quantify gene expression on 2 % agarose gels in triplicates with 
β-actin used as internal control (Panel A). Comparison of densitometrically quantified 
COL1A1 and COL2A1 expression (Panel B) is shown in arbitrary units (au), each value 
normalized to the respective β-actin expression. Comparison of COL2A1:COL1A1 ratio 
prior and after stimulation with TNF-α is shown in Panel C. Data are presented as Mean 





3.2 Effect of classical anti-inflammatory drugs on 
inflammatory mediator release from C-20/A4 
chondrocytes 
To determine whether inflammatory pathways were modulated in the presence of 
classical anti-inflammatory drugs, the effect of the non-steroidal anti-inflammatory 
drug indomethacin and glucocorticoid dexamethasone on stimulated 
chondrocytes was evaluated. Indomethacin is an indol derivative that’s a non-
selective COX-1 and COX-2 inhibitor with anti-inflammatory, analgesic, and 
antipyretic effects (Hart and Boardman, 1963). Dexamethasone is a potent 
synthetic member of the glucocorticoid class of steroid drugs. It acts as an anti-
inflammatory and immunosuppressant drug and is 20-30 times more potent than 
the naturally occurring cortisol and 4-5 times more potent than prednisone 
(Vayssiere et al., 1997). Dexamethasone and indomethacin are used to treat 
many inflammatory and autoimmune diseases including osteoarthritis and 
rheumatoid arthritis.  
3.2.1 Effect of indomethacin on IL-6 and IL-8 mRNA and protein in C-
20/A4 chondrocytes. 
C-20/A4 cell cultures were treated with 1.0 µM indomethacin for 30 min prior to 6 
h incubation with TNF-α (60.0 pg/ml). Total RNA was extracted and PCR 
analysis performed using specific primers for the amplification of IL-6 and IL-8 
(Table. 2.9). A significant decrease was observed in IL-6 and IL-8 expression 
following treatment with indomethacin (1.0 µM; Figure 3.15 A) with a significant 
61.4 %, (p≤ 0.001) and 78.6 % (p≤ 0.001) down-regulation of IL-6 and IL-8 
respectively as determined by densitometric quantification compared to β-actin 
(Figure 3.15 B).  
Subsequently, its effect on IL-6 and IL-8 protein levels was determined. C-20/A4 
chondrocytes were pre-treated with 1.0 µM indomethacin for 30 min prior to 
stimulation with TNF-α (60.0 pg/ml) and cell-free supernatants collected and 
analysed for IL-6 and IL-8 by ELISA.  Indomethacin completely abrogated the 
release of the pro-inflammatory cytokines IL-6 and IL-8 bringing it down to basal 






Figure 3.15. Densitometric quantification of the effect of indomethacin on TNF-α-
mediated IL-6 and IL-8 gene expression.  
C-20/A4 chondrocytes were pre-treated for 30 min with PBS or indomethacin (1.0 µM) 
prior to stimulation with TNF-α (60.0 pg/ml) and total RNA extracted 6 h post stimulation. 
PCR amplification with the respective primers for IL6 and IL8 was used to detect and 
quantify gene expression on 2 % agarose gels in triplicates with β-actin used as internal 
control (Panel A). Comparison of densitometrically quantified IL6 and IL8 expression by 
TNF-α (Panel B) shown in arbitrary units, each value normalized to the respective β-
actin expression. Data are presented as Mean± SEM of four independent experiments 








Figure 3.16. Effect of Indomethacin on TNF-α-mediated IL-6 and IL-8 release.   
C-20/A4 chondrocytes were pre-treated for 30 min with PBS or Indomethacin (1.0 µM) 
prior to stimulation with TNF-α (60.0 pg/ml) and cell-free supernatants collected at 6 h 
post stimulation. IL-6 (Panel A) and IL-8 (Panel B) expression by TNF-α were then 
determined. Data are presented as Mean± SEM of n=4 independent experiments 








3.2.2 Effect of dexamethasone on IL-6 and IL-8 mRNA and protein on 
C20/A4 chondrocyte. 
In order to investigate the effect of dexamethasone on the expression of pro-
inflammatory cytokines IL6 and IL8 in TNF-α treated C-20/A4 chondrocytes, cells 
were pre-treated with 1.0 µM dexamethasone for 30 mins before stimulation with 
TNF-α (60.0 pg/ml) and incubated for 6 h. PCR analysis was performed using 
specific primers for the amplification of IL6 and IL8 (Table. 2.9). Pre-treatment of 
C-20/A4 cells with 1.0 µM dexamethasone led to a significant 72.6 % down-
regulation of IL6 and IL8 by 83 % compared to control (Figure 3.17).  This effect 
at the mRNA level was confirmed at the protein level with a complete abrogation 












Figure 3.17. Densitometric quantification of the effect of dexamethasone on TNF-
α-mediated IL6 and IL8 gene expression.  
C-20/A4 chondrocytes were pre-treated for 30 min with PBS or dexamethasone (1.0 µM) 
prior to stimulation with TNF-α (60.0 pg/ml) and total RNA extracted 6 h post stimulation. 
PCR amplification with the respective primers for IL6 and IL8 was used to detect and 
quantify gene expression on 2% agarose gels in triplicates with β-actin used as internal 
control (Panel A). Comparison of densitometrically quantified IL6 and IL8 expression by 
TNF-α (Panel B) shown in arbitrary units, each value normalized to the respective β-
actin expression. Data is presented as Mean ± SEM of n=4 independent experiments 






Figure 3.18. Effect of Dexamethasone on TNF-α-mediated IL-6 and IL-8 protein 
release.  
C-20/A4 chondrocytes were pre-treated for 30 min with PBS or dexamethasone (1.0 µM) 
prior to stimulation with TNF-α (60.0 pg/ml) and cell-free supernatants collected at 6 h 
post stimulation. TNF-α stimulated IL-6 (Panel A) and IL-8 (Panel B) production was 
then determined. Data are presented as Mean ± SEM of n=4 independent experiments 











3.2.3 Effect of indomethacin on MMP1, MMP3 and MMP13 gene 
expression.  
The effect of indomethacin on the regulation of MMP1, MMP3 and MMP13 gene 
expression in non-stimulated and TNF-α stimulated C-20/A4 chondrocytes was 
investigated (Figure 3.19) 
C-20/A4 cells were pre-treated with 1.0 µM Indomethacin for 30 min prior to 
stimulation with TNF-α (60.0 pg/ml) for 6 h. Total RNA was extracted and PCR 
analysis performed using specific primers for the amplification of MMP1, MMP3 
and MMP13 (Table. 2.9; Chapter 2). Following gel electrophoresis of the PCR 
reactions on 2 % agarose gels, the correct bands (Figure 3.19 A) were quantified 
densitometrically and a significant decrease in the proteinases expression (p≤ 
0.01) was detected with a >75 % inhibition of the interstitial collagenase MMP1, 
67% reduction in MMP13 and a 49 % down-regulation of MMP3 expression 
compared to TNF-α stimulated controls (Figure 3.19 B).  
3.2.4 Effect of dexamethasone on MMP1, MMP3 and MMP13 gene 
expression. 
Following identification of the anti-cytokine properties of dexamethasone, its 
effect on the expression of MMP1, MMP3 and MMP13 in non-stimulated and 
TNF-α-treated C-20/A4 chondrocytes was investigated (Figure 3.20). 
C-20/A4 cells were pre-treated with 1.0 µM dexamethasone for 30 minutes prior 
to stimulation with TNF-α (60.0 pg/ml) for 6 h. Total RNA was extracted and PCR 
analysis performed using specific primers for the amplification of MMP1, MMP3 
and MMP13 (Table. 2.9,). A significant decrease in the proteinases expression 
(p≤ 0.01) was detected with a >75 % inhibition of MMP1, 42 % reduction in 
MMP13 and a 49 % down-regulation of MMP3 expression compared to TNF-α 












Figure 3.19. Effect of Indomethacin on TNF-α-mediated MMP1, MMP3 and MMP13 
expression.  
C-20/A4 chondrocytes were pre-treated for 30 min with PBS or indomethacin (1.0 µM) 
prior to stimulation with TNF-α (60.0 pg/ml) at time 0 and total RNA extracted 6 h post 
stimulation. PCR amplification with the respective primers for MMP1, MMP3 and MMP13 
were used to detect and quantify gene expression on 2 % agarose gels in triplicates with 
β-actin used as internal control (Panel A). Densitometrically quantified MMP1, MMP3 
and MMP13 expression by TNF-α alone or in presence of Indomethacin shown in 
arbitrary units, each value normalized to the respective β-actin expression (Panel B).   







Figure 3.20. Effect of Dexamethasone on TNF-α-mediated MMP1, MMP3 and 
MMP13 expression.  
C-20/A4 chondrocytes were pre-treated for 30 min with PBS or dexamethasone (1.0 µM) 
prior to stimulation with TNF-α (60.0 pg/ml) at time 0 and total RNA extracted 6 h post 
stimulation. PCR amplification with the respective primers for MMP1, MMP3 and MMP13 
were used to detect and quantify gene expression on 2 % agarose gels in triplicates with 
β-actin used as internal control (Panel A). Densitometrically quantified MMP1, MMP3 
and MMP13 expression by TNF-α alone or in presence of dexamethasone shown in 
arbitrary units, each value normalized to the respective β-actin expression (Panel B). 





3.3 Effect of melanocortin peptides treatment on C-20/A4 
activation. 
3.3.1 Expression of MC1, MC3 and MC5 mRNA and protein on C-20/A4 
chondrocytic cells. 
Melanocortin peptides (e.g. α-MSH) have been shown to possess anti-pyretic 
and anti-inflammatory functions via activation of a family of seven 
transmembrane receptors termed melanocortin receptors of which five have been 
identified (MC1-5, Getting et al., 2009). Expression of MC1, MC3 and MC5 by 
C20/A4 chondrocytes was determined. 
 
Total RNA was extracted from the cells and reverse-transcribed into cDNA via 
RT-PCR. PCR amplification reactions were used to assay for MC1, MC3 and MC5 
expression. MC1 and MC3 were highly expressed on C-20/A4 chondrocytes, with 
detection of specific bands corresponding to the expected size 493 bp and 820 
bp respectively. Very slight MC5 expression was also detected at the expected 
size of 340 bp. All samples were run alongside β-actin as an internal control 
(Figure 3.21). 
 
Following identification of MC1 and MC3 mRNA, protein levels of these receptors 
were determined by employing Western Blotting. Protein extracts were prepared 
and examined for MC1 and MC3 protein expression. Western Blotting confirmed 
the presence of both of the melanocortin receptors in human C-20/A4 
chondrocytes at the expected size of 35 and 40 kDa for MC1 and MC3 
respectively. C-20/A4 cells expressed lower levels of MC3 compared to MC1 
receptor after both were compared and normalized to the internal control α-








Figure 3.21. Endogenous expression of MC1, MC3 and MC5 by C-20/A4 
chondrocytic cell-line.  
C-20/A4 chondrocytes were grown to confluence and RNA extracted.  PCR amplification 
with the respective primers for MC1, MC3 and MC5 were used to detect and quantify 
gene expression on 2 % agarose gels in triplicates with β-actin used as internal control. 
Densitometrically quantified MC1, MC3 and MC5 shown in arbitrary units, each value 
normalized to the respective β-actin expression. Data are presented as Mean ± SEM of 







Figure 3.22. Detection of MC1 and MC3 protein in human C-20/A4 chondrocytic 
cells.  
Protein detection was performed using mouse anti-α-Tubulin mAb, rabbit anti-MC1 mAb 
and rabbit anti-MC3 mAb (1:2000). Bands with sizes corresponding to MC1 (35 kDa), 
MC3 (40 kDa) and α-tubulin (55 kDa) were detected and melanocortins receptor 















3.3.2 cAMP accumulation in C-20/A4 chondrocytes following 
melanocortin peptide stimulation. 
Following identification of MC1, MC3 and MC5 mRNA and MC1, MC3 protein, a 
panel of melanocortin peptides was evaluated to ascertain receptor functionality 
by determining intracellular cAMP accumulation within the C20/A4 chondrocytes. 
C-20/A4 cells were treated with α-MSH, D[TRP]8-γ-MSH, SHU9119, PG910, 
PG911 or a direct adenylate cyclase stimulator, forskolin, used as positive control 
in all cases. Forskolin (3.0 µM) increased the intracellular cAMP level to 2227.44 
± 74.42 fmol/well, representing 9-fold increase over PBS-vehicle control (249.36 
± 10.56 fmol/well).  Treatment of C-20/A4 chondrocytes with the pan 
melanocortin receptor agonist α-MSH (1.0 – 30.0 µg/ml), for 30 mins caused a 
significant increase in intracellular cAMP at 3.0, 10.0 and 30.0 µg/ml by 
approximately 2-fold, 2.6-fold and 1.7-fold increase to 568.86 ± 22.74 fmol/well 
(p≤ 0.001), 638.6 ± 41.6 fmol/well (p≤ 0.001) and 429.1 ± 18.9 fmol/well (p≤ 0.05) 
respectively compared to the vehicle control level of 249.36 ± 10.56 fmol/well 
(Figure 3.23 A) 
Similarly, a drastic 3.2-fold increase in cAMP accumulation peaking at 800.83 ± 
30.0 fmol/well (p≤ 0.001) was recorded following treatment with 3.0 µg/ml of the 
highly selective MC3 receptor agonist D[TRP]8-γ-MSH (Figure 3.23 B).  A 
significant increase of 3-fold compared to vehicle control levels was observed at 
10.0 µg/ml (789.9 ± 49.15 fmol/well, p≤ 0.001) and 30.0 µg/ml (696.2 ± 27.59 
fmol/well, p≤ 0.001). In comparison, the MC3/4 receptor antagonist SHU9119 (1.0 
– 10.0 µg/ml) failed to induce a statistically significant cAMP response in C-20/A4 
cells at any of the concentrations tested (Figure 3.23 C).  
The MC5 full agonists PG901 and PG911 (1.0 –10.0 µg/ml) were then evaluated 
to determine whether MC5 was a functionally active receptor. Both are full 
agonists at the MC5 (EC(50) = 0.072 nM and 0.031 nM, respectively), but full 
antagonists at the MC3/4. However, no statistically significant cAMP formation 
was recorded following stimulation at any of the concentrations (Figure 3.23 D, 





Following identification that α-MSH and D[TRP]8-γ-MSH induced cAMP 
accumulation in C-20/A4 chondrocytes, the peptides were evaluated in the 
presence of the MC3/4 antagonist SHU9119 to determine if the cAMP 
accumulation occurred via these receptors (Figure 3.24). C-20/A4 chondrocytes 
were incubated with α-MSH and D[TRP]8-γ-MSH (0 – 30.0 µg/ml) alone or in the 
presence of SHU9119 (10.0 µg/ml).  
SHU9119 totally abrogated the effect elicited by D[TRP]8-γ-MSH, whilst cAMP 
formation triggered by α-MSH was only slightly reduced at 3.0 µg/ml (Figure 3.24 
B). SHU9119 inhibited the activation of the MC3 elicited by D[TRP]8-γ-MSH at all 
concentrations evaluated; where at 3.0 µg/ml of the antagonist, only slight 
inhibition resulted leading it to drop from 379.82 ± 15.29 fmol/well to 320.21 ± 
30.35 fmol/well (n/s, p> 0.05). The addition of the antagonist with 3.0 µg/ml 
D[TRP]8-γ-MSH caused the cAMP levels to fall from 800.83 ± 29.99 to 318.84 ± 
9.34 fmol/well, representing ~ 87 % reduction (p≤ 0.001).  
Similarly, SHU9119 (10.0 µg/ml) inhibition led to a >84 % reduction in cAMP 
accumulation elicited by 10.0 µg/ml D[TRP]8-γ-MSH (p≤ 0.01) with a reduction 
from 789.9 ± 49.2 fmol/well down to 338.04 ± 10.6 fmol/well cAMP accumulation 
for D[TRP]8-γ-MSH and D[TRP]8-γ-MSH + SHU9119 (10.0 µg/ml). Even the 
highest concentration of the selective MC3 agonist, had no effect when given 
simultaneously with the MC3/4 receptor antagonist: the concentration of cAMP 
was reduced from 696.21 ± 27.59 to 290.12, illustrating an 80 % reduction in 
cAMP accumulation (p≤ 0.001). cAMP levels triggered by  α-MSH, were not 
reduced by SHU9119,  except when the antagonist was added in conjunction 
with 3.0 µg/ml of α-MSH, when SHU9119 (10.0 µg/ml) led to 15.5% decrease in 
cAMP formation  from 568.86 ± 22.74 to 480.29 ± 35.3  (n.s., p> 0.05; Figure 







Figure 3.23. MC1, MC3, MC5 functionality determined by cAMP EIA.  
C-20/A4 chondrocytes were treated with 1.0-30.0 µg/ml α-MSH (A), [DTRP8]-γ-MSH (B) 
and with 1.0-10.0 µg/ml SHU9119 (C), PG-901 (D) and PG911 (E) for 30 min and cAMP 
(fmoles/well) accumulation determined by cAMP EIA. Dotted lines indicate basal 
accumulation in PBS-treated whilst dashed lines indicate maximal accumulation in 3.0 
µM FSK-treated C20/A4 cells. Data is Mean ± SEM of n=6 samples, n.s. p> 0.05, *p≤  









Figure 3.24.  SHU9119 prevents D[TRP]8-γ-MSH from activating MC3, but has no 
effect on MC1 functionality.  
C-20/A4 chondrocytes were treated with 1.0-30.0 µg/ml α-MSH (Panel A) and [DTRP8]-
γ-MSH (Panel B) alone or in the presence of SHU9119 (10 µg/ml) for 30 min and cAMP 
(fmoles/well) accumulation determined by cAMP EIA. Dotted lines indicate basal 
accumulation in PBS-treated, whilst dashed lines indicate maximal accumulation in FSK-
treated C20/A4 cells. Data is Mean ± SEM of n=6 samples, *p≤  0.05, ***p≤  0.01 vs. 





3.3.3 Modulation of pro-inflammatory mediator release and apoptosis 
by melanocortin peptides on TNF-α stimulated C20/A4 
chondrocytes. 
3.3.3.1 Effect of melanocortin peptides on basal release of pro-
inflammatory cytokines production from C-20/A4 chondrocytes.  
Following identification of functionally active MC1 and MC3 on C-20/A4 
chondrocytes, their effect on basal cytokine production was determined. C-20/A4 
chondrocytes were treated with α-MSH (3.0 µg/ml), D[TRP]8-γ-MSH (3.0 µg/ml) 
and SHU9119 (10.0 µg/ml), and the basal levels of production of the pro-
inflammatory cytokines IL-1β, IL-6, IL-8 and MCP-1 were determined by cytokine 
ELISAs (Table 3.3). Treatment of cells with melanocortin peptides did not cause 
significant alteration compared to control cultures treated with DMEM alone (p> 
0.05). 
 
Table 3.3 Effect of melanocortin derived peptides on basal levels of pro-
inflammatory cytokine release from C-20/A4 chondrocytes. 
Data are Means ± SEM of n=4 of three determinations.  
Interleukin(IL)-1β; IL-6, Interleukin(IL)-6, interleukin(IL)-8; MCP-1, monocyte chemoatractant 
protein-1 
 IL-1β  IL-6 IL-8 MCP-1 
DMEM Media 2.77± 0.44 21.09±18.5 72.65±4.78 46.18 ± 14.12 
α-MSH (3.0 µg/ml) 5.76±1.8 38.29±29.1 82.3±5.36 54.26 ± 11.11 
D[TRP]8-γ-MSH (3.0 µg/ml) 3.69±0.65 23.19±11.65 67.76±6.3 48.42± 7.1 





3.3.3.2 Attenuation of TNF-α-activated pro-inflammatory cytokines 
release from C-20/A4 chondrocytes by α-MSH and D[TRP]8-γ-
MSH.  
The identification of the melanocortin receptors’ functionality on C-20/A4 
chondrocytes and their non-cytotoxic effects, led to the evaluation of α-MSH and 
D[TRP]8-γ-MSH effect on pro-inflammatory cytokine release following TNF-α-
stimulation.  
The C-20/A4 cell-line was treated with α-MSH or D[TRP]8-γ-MSH in 
concentrations ranging from 0.3 – 30.0 µg/ml for 30 mins prior to stimulation with 
TNF-α, cell free supernatants were collected at 2, 6 and 24 h post-stimulation 
and pro-inflammatory cytokines IL-1β, IL-6 and IL-8 were determined by 
commercially available ELISAs.   
α-MSH led to a significant concentration-dependent decrease in IL-1β 
concentration with a maximal reduction detected at 3.0 µg/ml α-MSH with 88.6 ± 
3.2 % at 2 h (p≤ 0.001) and 84.8 ± 4.01 % at 6 h (p≤ 0.001) compared to TNF-α-
stimulated controls. The melanocortin peptide did not modulate IL-1β release at 
24 h post-stimulation (Figure 3.25 A). The MC3 agonist D[TRP]8-γ-MSH (3.0 
µg/ml) led to the maximal observed reduction of 72.73 ± 3.31 % at 6 h (Figure 
3.25 B). 
Evaluating the effects of α-MSH on IL-6 showed that after 6 h, α-MSH caused a 
concentration-dependant effect peaking at 3.0 µg/ml with 72.1 ± 2.3 % compared 
to TNF-α-stimulated controls. It was observed that higher concentrations did not 
elicit a significant effect. α-MSH did not exert any detectable effect at 24 h post-
stimulation, except when C-20/A4 chondrocytes were treated with low 
concentration of 0.3 µg/ml with 37 ± 3.4 % and 34.5 ± 4.6 % inhibition of IL-6 
respectively (p≤ 0.05). D[TRP]8-γ-MSH caused a concentration-dependent 
response observed at all time-points (Figure 3.26 B). The maximum effect at 2 h 
was observed following stimulation with 0.3 and 3.0 µg/ml with 75.0 ± 6.9 % and 
73.1 ± 3.5 % reduction respectively. At 6 h, 3.0 µg/ml were identified as the most 





synthesis respectively. The peptide was still effective at 24 h post stimulation with 
a pronounced concentration-dependent reduction of IL-6 concentration, peaking 
with 85 ± 2.0 % inhibition at 30.0 µg/ml (Figure 3.26 B). 
α-MSH inhibited IL-8 release in a concentration dependent manner at 2 and 6 h 
and was not effective at later time points (Figure 3.27 A). At 2 h, the greatest 
reduction in IL-8 synthesis was caused by 3.0, and 30.0 µg/ml of α-MSH with 
59.2 ± 5.5 % and 66.7 ± 9.85 % decrease respectively, while 0.3 had less effect 
leading to 47.2 ± 9.6 % down-regulation. There was a concentration dependent 
inhibition of IL-8, 6 h post stimulation, with a maximal reduction of 60.21 ± 2.1% 
caused by 3.0 µg/ml α-MSH.  
D[TRP]8-γ-MSH (0.3 µg/ml) failed to suppress the effect of TNF-α, except at 24 h 
post-stimulation, when it caused 51% decrease in the cytokine production (Figure 
3.27 B). The higher concentration of 3.0 µg/ml, led to significant down-regulation 
of IL-8 release regardless of the time point evaluated with a 67.32 ± 2.76%, 44.71 
± 5.14 % and 37.11 ± 2.4 % reductions at 2, 6 and 24h respectively. Following 
treatment of C-20/A4 chondrocyte with 30.0 µg/ml of D[TRP]8-γ-MSH a consistent 
decrease of 80.72 ± 2.13 % (p≤ 0.01), 64.72 ± 2.3 % (p≤ 0.001) and 69.89 ± 3.23 



























































































Figure 3.25.  Effect of α-MSH and D[TRP]8-γ-MSH on TNF-α  induced IL-1β  release 
from C-20/A4 cells.  
C-20/A4 chondrocytes were pre-treated for 30 min with PBS (Dotted line), α-MSH or 
D[TRP]8-γ-MSH (0.3 – 30.0 µg/ml) prior to stimulation with TNF-α (60.0 pg/ml; dashed 
line) and cell-free supernatants collected at 2, 6 and 24 h post stimulation and analysed 
for IL-1β by ELISA. Data are presented as Mean ± SEM of n=4 independent experiments 




















































































Figure 3.26.  Effect of α-MSH and D[TRP]8-γ-MSH on TNF-α  induced IL-6 release 
from C-20/A4 cell-line.  
C-20/A4 chondrocytes were pre-treated for 30 min with PBS (Dotted line), α-MSH or 
D[TRP]8-γ-MSH (0.3 – 30.0 µg/ml) prior to stimulation with TNF-α (60.0 pg/ml; dashed 
line) and cell-free supernatants collected at 2, 6 and 24 h post stimulation and analysed 
for IL-6 by ELISA. Data are presented as Mean ± SEM of n=4 independent experiments 





















































































Figure 3.27.  Effect of α-MSH and D[TRP]8-γ-MSH on TNF-α  induced IL-8 release 
from C-20/A4 cell-line.  
C-20/A4 chondrocytes were pre-treated for 30 min with PBS, α-MSH (Panel A) and 
D[TRP]8-γ-MSH (0.3 – 30.0 µg/ml, Panel B) prior to stimulation with TNF-α (60.0 pg/ml) 
and cell-free supernatants collected at 0, 2, 6 and 24 h post stimulation and analysed for 
IL-8 by ELISA. Data are presented as Mean ± SEM of n=4 independent experiments 





3.3.3.3 Effect of PG901 and PG911 on TNF-α stimulated pro-
inflammatory cytokines release from C-20/A4 chondrocytes.  
Following the finding that MC5 was not functionally active, the effects of the 
selective agonist PG901 and PG911 on cytokine release was evaluated to 
ensure that the anti-cytokine effects elicited by α-MSH were independent of MC5. 
C-20/A4 chondrocytes were pre-treated with PG901 or PG911 (3.0 or 10.0 µg/ml) 
prior to stimulation with TNF-α (60.0 pg/ml) and were incubated for 6 h. 
Subsequently, IL-1β, IL-6, IL-8 and MCP-1 release was determined by ELISA 
(Table 3.1). As previously observed (Figures 3.5, 3.6 and 3.8), TNF-α (60.0 
pg/ml) caused a significant release of these cytokines compared to control cells 
(†p≤ 0.05), IL-1β, IL-6 and MCP-1 were not inhibited by PG901 or PG911 at any 
concentration evaluated. However, a different scenario was observed with 
respect to IL-8 only PG911 (10.0 µg/ml) caused a 40.4 ± 23.3 % reduction; all 
other concentrations of PG911 and PG901 were inactive.  
 
Table 3.1 Effect of PG901 and PG911 on TNF-α  induced cytokine release from C-
20/A4 cell-line. 
 IL-1β  IL-6 IL-8 MCP-1 
Medium 2.77± 0.44 21.09±18.5 72.65±4.78 46.18 ± 14.12 
TNF-α  (60 pg/ml) 24.37±8.69† 280.6 ± 20.39† 202.82 ± 21.04† 101.2± 16.37† 
TNF-α  + PG901 
(3.0 µg/ml) 17.56 ± 1.03 231.29 ± 24.19 165.41 ± 23.81 84.6 ± 16.37 
TNF-α  + PG901 
(10.0 µg/ml) 19.43 ± 3.29 253.62 ± 26.46 144.84 ± 25.41 89.96 ± 18.91 
TNF-α  + PG911 
(3.0 µg/ml) 19.92 ±4.99 273.396 ± 48.21 181.37 ± 54.78 97.05 ± 5.29 
TNF-α  + PG911 
(10.0 µg/ml) 16.38 ± 2.01 244.29 ± 17.14 122.46 ± 18.47* 85.88 ± 6.05 
Data are Means ± SEM of n=4 of three determinations †, *p≤ 0.05.  






3.3.4 Effect of SHU9119 on α-MSH and D[TRP]8-γ-MSH modulation of 
pro-inflammatory cytokines from C-20/A4 chondrocytes.  
The effect of the MC3/4 antagonist SHU9119 on α-MSH and D[TRP]8-γ-MSH 
modulation of cytokine release was evaluated to determine whether MC1 or MC3 
were transmitting the anti-inflammatory effects of these peptides in the 
chondrocyte system. C-20/A4 chondrocytes were pre-treated with α-MSH or 
D[TRP]8-γ-MSH (3.0 µg/ml) ± SHU9119 (10.0 µg/ml) for 30 mins prior to 
stimulation with TNF-α (60.0 pg/ml) and total RNA and cell-free supernatants 
were collected at 6 h post-stimulation. Total RNA was extracted from the treated 
C-20/A4 chondrocytes and PCR amplification performed using IL6 and IL8 
specific primers (Table 2.9).   
3.3.4.1 Antagonistic effect of SHU9119 on IL6 and IL8 gene expression 
following α-MSH and D[TRP]8-γ-MSH stimulation 
Densitometric quantification (Figure 3.28 A) showed that α-MSH (3.0 µg/ml) 
significantly down-regulated TNF-α-induced IL6 and IL8 expression, therefore 
causing a 35 % drop in IL6 expression from 0.802 ± 0.025 to 0.517 ± 0.018 au 
(p≤ 0.05) and a 24.5 % down-regulation of IL-8 from 1.92 ± 0.1 au down to 1.45 ± 
0.028 au (p≤ 0.05), this effect was not blocked by SHU9119 (Figure 3.28 B and 
C).  
The MC3 agonist D[TRP]8-γ-MSH significantly inhibited the transcription of both 
IL6 and IL8 genes as shown by densitometric quantification (Figure 3.29 A) with 
a 27 % inhibition of IL6 expression from 0.802 ± 0.025 au to 0.585 ± 0.02 au (p≤ 
0.05) and 35.7 % reduction in IL8 transcription from 1.92 ± 0.1 to 1.234 ± 0.016 
au (p≤ 0.01). SHU9119 completely inhibited the effect of D[TRP]8-γ-MSH on IL6 
and IL8, such that IL6 expression was 0.94 ± 0.05 au and IL-8 was 1.85 ± 0.19 





3.3.4.2 Effect of SHU9119 on cytokine release from α-MSH and D[TRP]8-
γ-MSH pre-treated TNF-α-activated C-20/A4 chondrocytes.  
In order to further elucidate the function of the melanocortin peptides α-MSH and 
D[TRP]8-γ-MSH  on TNF-α stimulated cytokine production, the MC3/4 antagonist 
SHU9119 was used to selectively block the function of MC3. C-20A4 cells were 
pre-treated with 3.0 µg/ml of α-MSH or D[TRP]8-γ-MSH for 30 min prior to 
stimulation with TNF-α (60.0 pg/ml) for 6 h and IL-6, IL-8 and MCP-1 levels were 
detected by ELISA. α-MSH (3.0 µg/ml) caused a marked reduction in IL-6, 
causing a 72.13 ± 2.3 % (p≤ 0.01; Figure 3.30 A), 60.22% (p≤ 0.01) reduction in 
IL-8 production (Figure 3.30 B) and a 21.3 % reduction in MCP-1 (p≤ 0.05; Figure 
3.30C). These effects were not abrogated in the presence of SHU9119 (Figure 
3.30 A-C).  
The selective MC3 agonist D[TRP]8-γ-MSH inhibited IL-6 production by 68 % (p≤ 
0.01), 44.72 % (p≤ 0.01) reduction in IL-8 secretion and a 26 % (p≤ 0.01) 










Figure 3.28. Densitometric quantification of IL-6 and IL-8 mRNA expression in 
TNF-α-activated C-20/A4 chondrocytes treated with α-MSH and SHU9119 for 6 h.  
C-20/A4 chondrocytes were pre-treated for 30 min with α-MSH (3.0 µg/ml) ± SHU9119 
(10.0 µg/ml) prior to stimulation with TNF-α (60.0 pg/ml) and total RNA extracted 6 h 
post stimulation. PCR amplification with the respective primers for IL-6 and IL-8 was 
used to detect and quantify gene expression on 2 % agarose gels in triplicates with β-
actin used as internal control (Panel A). Comparison of densitometrically quantified IL-6 
and IL-8 expression following treatments (Panel B) shown in arbitrary units, each value 
normalized to the respective β-actin expression. Data are presented as Mean ± SEM of 






Figure 3.29. Densitometric quantification of IL-6 and IL-8 mRNA expression in 
TNF-α-activated C-20/A4 chondrocytes treated with D[TRP]8-γ-MSH and SHU9119 
for 6 h.  
C-20/A4 chondrocytes were pre-treated for 30 min with D[TRP]8-γ-MSH (3.0 µg/ml) ± 
SHU9119 (10.0 µg/ml) prior to stimulation with TNF-α (60.0 pg/ml) and total RNA 
extracted 6 h post stimulation. PCR amplification with the respective primers for IL-6 and 
IL-8 was used to detect and quantify gene expression on 2 % agarose gels in triplicates 
with β-actin used as internal control (Panel A). Comparison of densitometrically 
quantified IL-6 and IL-8 expression following treatments (Panel B) shown in arbitrary 
units, each value normalized to the respective β-actin expression. Data are presented as 






Figure 3.30. Effect of SHU9119 on IL-6, IL-8 and MCP-1 release from α-MSH and 
D[TRP]8-γ-MSH pre-treated C-20/A4 chondrocytes.   
C-20/A4 chondrocytes were pre-treated for 30 min with PBS, α-MSH (Panel A – C) or 
D[TRP]8-γ-MSH (3.0 µg/ml) alone (Panels D – F) or in the presence of SHU9119 (10.0 
µg/ml) prior to stimulation with TNF-α (60.0 pg/ml) and cell-free supernatants collected at 
6 h post stimulation and analysed for IL-6, IL-8 and MCP-1 by ELISA. Data are 
presented as Mean ± SEM of n=4 independent experiments repeated in triplicate, *p≤ 





3.3.4.3 Effect of SHU9119 on MMP1, MMP3 and MMP13 expression in α-
MSH D[TRP]8-γ-MSH and pre-treated TNF-α  activated 
chondrocytes. 
Following the identification of the anti-cytokines effects of α-MSH and D[TRP]8-γ-
MSH, their effect was evaluated on matrix metalloproteinases expression (Figure 
3.31A). α-MSH (3.0 µg/ml) caused a significant ~80 % down-regulation in the 
transcription of MMP1; densitometric quantification of the bands revealed that 
expression was reduced from 1.71 ± 0.11 au to 0.34 ± 0.04 au (p≤ 0.001; Figure 
3.31 B). MMP3 expression was reduced by α-MSH by 48 % from 0.37 ± 0.02 au 
(TNF-α-treated control cultures) to 0.19 ± 0.03 au (p≤ 0.01; Figure 3.31C), whilst 
MMP13 expression was inhibited by 66.7 % from 0.24 ± 0.01 au (TNF-α, 60.0 
pg/ml) to 0.083 ± 0.002 au  (Figure 3.31 D).  
This inhibition of MMP1, MMP3 and MMP13 was not modified in the presence of 
SHU9119. Nevertheless, when SHU9119 (10.0 µg/ml) was added together with 
α-MSH (3.0 µg/ml), there was a marked synergistic down-regulation of MMP13 
synthesis, with the combination causing a marked inhibition of 87.5 % (p≤ 0.001) 
compared to TNF-α treated controls and 57.8 % drop compared to samples pre-
treated with α-MSH alone (p≤ 0.05).  
Treatment of C-20/A4 chondrocytes with D[TRP]8-γ-MSH (3.0 µg/ml) led to a 
significant 88.9 % reduction in MMP1 expression (0.189 ±0.1 au; p≤ 0.001; 
Figure 3.32A) an effect blocked completely by co-administration of SHU9119 
(10.0 µg/ml; Figure 3.32 B). MMP3 was reduced by 76 % (0.098 ± 0.006 au; p≤ 
0.01) compared to TNF-α stimulated cultures (0.372 ± 0.012 au) an effect 
blocked by SHU9119 (10.0 µg/ml), returning the expression levels back to TNF-
α-stimulated levels (0.372 ± 0.012 au; Figure 3.32 C). A similar observation was 
noted for MMP13 gene expression, where D[TRP]8-γ-MSH (3.0 µg/ml) caused a 
91.7 % drop in transcription levels (0.02 ± 0.004 au; p≤ 0.001) as compared to 
TNF-α−treated controls (0.237 ± 0.008 au), an effect completely abolished by 







Figure 3.31. Densitometric quantification of MMPs mRNA expression in C-20/A4 
cells treated with α-MSH and SHU9119 for 6 h.  
C-20/A4 chondrocytes were pre-treated for 30 min with α-MSH (3.0 µg/ml) ± SHU9119 (10.0 
µg/ml) and stimulated with TNF-α (60.0 pg/ml). Total RNA was extracted at 6 h post 
stimulation and PCR amplification with the respective primers for MMP1, MMP3 and MMP13 
was used to detect and quantify gene expression on 2 % agarose gels in triplicates, with β-
actin used as internal control (Panel A). Comparison of densitometrically quantified MMP1, 
MMP3 and MMP13 expression for α-MSH ± SHU9119 (Panel B, C and D) shown in arbitrary 
units, each value normalized to the respective β-actin expression. Data is presented as 






Figure 3.32. Densitometric quantification of MMPs mRNA expression in C-20/A4 
cells treated with D[TRP]8-γ-MSH and SHU9119 for 6 h.  
C-20/A4 chondrocytes were pre-treated for 30 min with D[TRP]8-γ-MSH (3.0 µg/ml) ± 
SHU9119 (10.0 µg/ml) and stimulated with TNF-α (60.0 pg/ml). Total RNA was extracted at 
6 h post stimulation and PCR amplification with the respective primers for MMP1, MMP3 and 
MMP13 was used to detect and quantify gene expression on 2 % agarose gels in triplicates 
with β-actin used as internal control (Panel A). Comparison of densitometrically quantified 
MMP1, MMP3 and MMP13 expression for [DTRP]8-γ-MSH ± SHU9119 (Panel B, C and D) 
shown in arbitrary units, each value normalized to the respective β-actin expression. Data is 





3.3.5 Evaluation of the effect of melanocortin peptides on anti-
inflammatory protein synthesis and release from C-20/A4 
chondrocytes. 
Human chondrocytes from healthy and osteoarthritic cartilage have been 
previously shown to express both IL-10 as well as the IL-10 receptor (IL10R; 
Iannone et al., 2001). IL-10 has potent anti-inflammatory properties, repressing 
the expression of inflammatory cytokines such as TNF-α, IL-6 and IL-1β by 
activated cells. Direct stimulation of OA chondrocytes with IL-10 has been shown 
to inhibit the activation of chondrocytes by TNF-α and therefore to down-regulate 
the expression of MMP1 and MMP13 (Shlopov et al., 2000). In addition, IL-10 
has been shown to induce HO-1, which is implicated in the protection against 
tissue damage and is repressing pro-inflammatory cytokines such as TNF-α. 
Therefore, following identification of the anti-inflammatory properties of α-MSH 
and D[TRP]8-γ-MSH on TNF-α stimulated C20/A4 chondrocytes, their effect on 
the production of these anti-inflammatory proteins was next evaluated. 
3.3.5.1 Effect of melanocortin peptides alone on IL-10 release from C-
20/A4 chondrocytes. 
IL-10 protein levels in cell-free supernatants were determined by ELISA following 
stimulation of C-20/A4 chondrocytes with a panel of melanocortin peptides (α-
MSH, D[TRP]8-γ-MSH, PG901, PG911 all at 3.0 µg/ml and SHU9119 (10.0 
µg/ml) for 0, 2, 6 and 24 h.  
Figure 3.33 A and B demonstrates the time-dependent increase in IL-10 release 
peaking at 6 h following α-MSH (3.0 µg/ml) and D[TRP]8-γ-MSH (3.0 µg/ml) 
treatment. At time 0 there was almost no basal release of IL-10 (1.625 ± 0.92 
pg/ml). However, following stimulation with α-MSH and D[TRP]8-γ-MSH for 2 h, 
there was a significant 15.5-fold (25.28 ± 2.25 pg/ml, *p≤ 0.05) and 12-fold (19.96 
± 3.25 pg/ml; *p≤ 0.05) increase in IL-10 production for both peptides 
respectively. IL-10 levels steadily increased to 37.9 ± 4.13 pg/ml and 25.92 ± 2.3 
pg/ml following stimulation with α-MSH and D[TRP]8-γ-MSH for 6 h respectively. 
At 24 h post-treatment, α-MSH and D[TRP]8-γ-MSH treatment caused IL-10 





pg/ml and 19.23 ± 4.76 pg/ml, *p≤ 0.05 both peptides). At all time points 
SHU9119, PG901 and PG911 (10.0 µg/ml) failed to induce any significant 
increase in IL-10 above basal production at time 0h (Figure 3.33 C-E).  
3.3.5.2 Effect of melanocortin peptides on IL-10 production from TNF-α-
activated C-20/A4 chondrocytes.  
Pre-treatment of TNF-α−activated C-20/A4 chondrocytes with α-MSH (0.3 – 30.0 
µg/ml) for 2h caused a concentration-dependent increase in IL-10, peaking with 
37.5 ± 2.83 pg/ml following addition of 3.0 µg/ml α-MSH. Concentrations higher 
than 3.0 µg/ml didn’t cause significant increases in IL-10 compared to untreated 
controls (1.625 ± 0.919 pg/ml).  At 6 h post stimulation α-MSH caused a 
significant increase in IL-10 production at 0.3 – 3.0 µg/ml (*p≤ 0.05) compared to 
untreated controls (5.34 ± 3.34 pg/ml). The maximal response of 48.42 ± 3.21 
pg/ml was elicited by 0.3 µg/ml α-MSH, although this was not significantly 
different compared to 3.0 µg/ml (43.83 ± 2.24 pg/ml, p≤ 0.05; Figure 3.34). IL-10 
release was subsequently evaluated at 24 h, in order to determine if this 
induction was maintained over a longer time frame. At this time-point a different 
scenario was observed with concentrations of 3.0 and 30.0 µg/ml able to cause 
detectable IL-10 release. The maximal response at this time-point was elicited by 
30.0 µg/ml α-MSH (50.19 ± 4.12 pg/ml).  
Given that the pan-melanocortin agonist α-MSH caused increases in IL-10 the 
MC3 agonist D[TRP]8-γ-MSH (0.3 - 30.0 µg/ml) was subsequently evaluated prior 
to stimulation with TNF-α (60.0 pg/ml). The MC3 agonist caused a marked 
release of IL-10 at 2, 6 and 24 h post stimulation, with concentrations of 3.0 and 
30.0 µg/ml proving to be the most effective. D[TRP]8-γ-MSH (30.0 µg/ml) caused 
a maximal release of 34.12 ± 2.52 pg/ml of IL-10 at 2 h, compared to untreated 
controls (1.625 ± 0.919 pg/ml; *p≤ 0.05). At 6 h post stimulation 3.0 and 30.0 
µg/ml of D[TRP]8-γ-MSH significantly increased IL-10 release with a peak of 
24.94 ± 2.15 pg/ml at 3.0 µg/ml. At 24 h a concentration-dependent increase in 
IL-10 release was observed with a maximal release of 37.33 ± 0.83 pg/ml at 3.0 







Figure 3.33. Time dependent release of IL-10 from C20/A4 cells following treatment 
with α-MSH, D[TRP]8-γ-MSH, SHU9119, PG901 and PG911.  
C-20/A4 chondrocytes were treated α-MSH (3.0 µg/ml, Panel A), D[TRP]8-γ-MSH (3.0 
µg/ml; Panel B), SHU9119 (10.0 µg/ml; Panel C), PG901 (3.0 µg/ml; Panel D) or PG911 
(3.0 µg/ml; Panel E) and cell-free supernatants collected at 0, 2, 6 and 24 h. IL-10 was 
then determined by ELISA. Data are presented as Mean± SEM of n=4 independent 








































































Figure 3.34 Effect of α-MSH and D[TRP]8-γ-MSH on IL-10 release from TNF-α-
activated C-20/A4 chondrocytes.  
C-20/A4 chondrocytes were treated with α-MSH or D[TRP]8-γ-MSH (0.3 – 30.0 µg/ml) for 
30 min prior to TNF-α (60.0 pg/ml) stimulation. Cell-free supernatants were collected at 
for 2, 6 and 24 h and analysed for IL-10 by ELISA. Data are presented as Mean ± SEM 






3.3.5.3 Determination of HO-1 release from C-20/A4 cells following 
melanocortin peptide stimulation.  
HO-1 release from C-20/A4 chondrocytes treated with vehicle (DMEM), α-MSH 
or D[TRP]8-γ-MSH (3.0 µg/ml) alone or in presence of TNF-α (60.0 pg/ml) was 
investigated via Western Blot and the results are shown in Figure 3.35. C-20/A4 
chondrocytes were treated with melanocortin peptides for 6 h either alone or 
given 30 min prior to stimulation with TNF-α and samples collected 6 h later.  
Western Blot analysis identified basal production of HO-1 (0.50 ± 0.04 au), which 
was significantly increased following treatment with TNF-α (60.0 pg/ml) for 6 h to 
1.02 ± 0.01 au (p≤ 0.001). The treatment of chondrocytes with α-MSH (3.0 µg/ml) 
alone caused a significant 3-fold increase in HO-1 production (1.39 ± 0.04 au; p≤ 
0.001), compared to the media-treated controls and a 36 % increase when 
compared to TNF-α alone (p≤ 0.01). The combination of α-MSH and TNF-α 
caused a significant increase in HO-1 with a 6-fold increase in HO-1 (2.64 ± 0.14 
au, p≤ 0.001) compared to untreated controls and an approximate 3-fold increase 
when compared to TNF-α-stimulated samples (p≤ 0.001).  
A similar observation was made following treatment of the cells with the MC3 
agonist D[TRP]8-γ-MSH (3.0 µg/ml), which caused a 3-fold increase in HO-1 
expression, raising it to 1.37 ± 0.02 au (p≤ 0.01) compared to untreated controls 
and 34 % increase compared to HO-1 production by TNF-α-stimulated 
chondrocytes (p≤ 0.01). Combination of the MC3 agonist with TNF-α caused the 
highest increase in HO-1 (2.87 ± 0.12 au, p≤ 0.001) protein with a ~ 7-fold 
increase compared to media-treated samples, and a ~ 3-fold increase, compared 
to TNF-α stimulated samples. The expression of α-Tubulin standards was found 
to be consistent with all treatments. HO-1 production was normalized to the 












Figure 3.35. Effect of α-MSH and D[TRP]8-γ-MSH on HO-1 protein levels in human 
C-20/A4 chondrocytic cell line.  
Cultures of C-20/A4 chondrocytes were treated for 6 h with: Lane 1: DMEM medium, 
Lane 2: TNF-α (60 pg/ml), Lane 3: α-MSH (3.0 µg/ml), Lane 4: D[TRP]8-γ-MSH (3.0 
µg/ml), Lane 5: α-MSH + TNF-α (60 pg/ml), Lane 6: D[TRP]8-γ-MSH (3.0 µg/ml) + TNF-α 
(60.0 pg/ml). Bands with sizes corresponding to HO-1 (32 kDa) and α-tubulin (55 kDa) 
were detected by Western blotting. The image is representative of four individual 
experiments (Panel A). Comparison of densitometrically quantified HO-1 expression by 
human C-20/A4 cell-lines is shown in arbitrary units (Panel B). Data are presented as 
Mean ± SEM of n=4 experiments. †p≤ 0.01, **p≤ 0.01, ***p≤ 0.001 vs. cultures treated 






3.3.6 Effect of melanocortin peptides on chondrocyte apoptosis. 
3.3.6.1 Effect of α-MSH and D[TRP]8-γ-MSH on basal caspase 3/7 activity 
Substantial evidence supports that chondrocyte death, due to inflammation 
and/or injury is an important risk factor predisposing to osteoarthritis and one that 
exacerbates the disease progression, as chondrocytes are unable to reproduce 
and compensate for the lost cells (Sharif et al., 2004; Lopez-Armada et al., 
2006). We have shown that melanocortins do not cause any statistically 
significant increase in the production of pro-inflammatory cytokines from C-20/A4 
(Table 3.3), and in order to investigate their effect on chondrocyte apoptosis, we 
employed Caspase-Glo®-3/7 assay to measure any changes in caspase-3/7 
activity following treatment.  
C-20/A4 chondrocytes were treated with vehicle (DMEM), α-MSH or D[TRP]8-γ-
MSH (0.1 – 30.0 µg/ml) for 6 h and caspase-3/7 activity was determined 
according to the manufacturer’s instructions (Promega UK Ltd., UK).  Both α-
MSH and D[TRP]8-γ-MSH (0.1 – 30.0 µg/ml), were did not activate caspase-3/7 
apoptotic pathway (Figure 3.36), however α-MSH caused a moderate non-


































Figure 3.36. The effect of α-MSH and D[TRP]8-γ-MSH on caspase 3/7 activity of 
untreated C-20/A4 chondrocytes.  
C-20/A4 chondrocytes were plated at 2.0 x 104 cells/well, and treated with DMEM or 
D[TRP]8-γ-MSH (0.1 – 30.0 µg/ml) for 30 min prior to stimulation with TNF-α (60.0 pg/ml) 
for 6 h. Caspase-3/7 activity was determined by Caspase-3/7 Glo Assay (Promega, UK) 
Dotted line symbolizes Caspase 3/7 activity following PBS treatment (control). Data are 





3.3.6.2 Melanocortin peptides inhibit caspase-3 production, caspase-3/7 
activity and cell death of TNF-α-activated C-20/A4 chondrocytes. 
C-20/A4 chondrocytes were treated with TNF-α (60.0 pg/ml) to establish levels of 
caspase-3 activity (Figure 3.37). Western blot analysis against cleaved 
(activated) caspase-3 (Asp-175) showed 0.52 ± 0.045 au basal production 
(DMEM) of cleaved caspase-3, which upon stimulation with TNF-α led to 0.65 ± 
0.24 au thereby representing a significant 24 % increase in production (p≤ 0.05). 
Upon pre-treatment of the cells with MC pan-agonist α-MSH and the selective 
MC3 agonist D[TRP]8-γ-MSH, there was significant reduction in the synthesis of 
activated caspase-3 compared to the levels caused by TNF-α, with a 50 % (0.32 
± 0.012 au) and 42 % (0.37 ± 0.03) reduction for α-MSH (3.0 µg/ml) and 
D[TRP]8-γ-MSH  (3.0 µg/ml) respectively (p≤ 0.01).  
In order to investigate the involvement of the specific melanocortin receptors, 
SHU9119 (10.0 µg/ml) was utilized to specifically block MC3. When used in 
conjunction with α-MSH it did not block the effect of the peptide however, the 
antagonist did cause a slight (~8.7 %; n.s. p>0.05) synergistic inhibition in the 
production of activated caspase-3 (0.27 ± 0.02 au) compared to the effect of α-
MSH + TNF-α alone.  
The opposite effect was observed when SHU9119 was given in conjunction with 
the selective MC3 agonist D[TRP]8-γ-MSH, whereby it markedly hindered 
D[TRP]8-γ-MSH from activating its receptor (Figure 3.37). The combination led to 
significant ~25 % increase in cleaved caspase-3 production (0.47 ± 0.01 au; p≤ 
0.01) compared to the effect of D[TRP]8-γ-MSH  without the antagonist (0.37 ± 
0.3 au).  
Cell viability was evaluated using MTT proliferation assay (Figures 3.38, 3.39). C-
20/A4 chondrocytes were treated with DMEM, α-MSH or D[TRP]8-γ-MSH (0.1 – 
30.0 µg/ml) ± TNF-α (60.0 pg/ml) for 6 h with cell viability determined via MTT 
assay and caspase-3/7 activity determined by Caspase-3/7® Glo Assay. TNF-α 
(60.0 pg/ml) caused a 26 % cell death as determined by MTT Assay, which was 





maximal inhibition of cell death was achieved at 1.0 and 3.0 µg/ml of α-MSH, and 
3.0 and 10.0 µg/ml D[TRP]8-γ-MSH  (p≤ 0.01).  
Treatment of the C-20/A4 chondrocytes with TNF-α increased caspase-3/7 
activity 5.7-fold compared to DMEM, but was attenuated in the presence of α-
MSH and D[TRP]8-γ-MSH in a concentration-dependent manner (p≤ 0.01; Figure 
3.38). Pre-treatment of cells with the MC3/4 antagonist SHU9119 fully reversed 












































Figure 3.37. Western Blot detection and densitometric quantification of Cleaved 
caspase-3 protein levels in human C-20/A4 chondrocytic cell line.  
Cultures of C-20/A4 chondrocytes were treated for 6 h with: Lane 1: DMEM medium, 
Lane 2: TNF-α (60 pg/ml), Lane 3: α-MSH (3.0 µg/ml), Lane 4: D[TRP]8-γ-MSH (3.0 
µg/ml), Lane 5: α-MSH + TNF-α (60 pg/ml), Lane 6: D[TRP]8-γ-MSH (3.0 µg/ml) + TNF-α 
(60 pg/ml). Bands with sizes corresponding to Cleaved caspase-3 (Asp175; 17, 19 kDa) 
and α-tubulin (55 kDa) were detected by Western blotting. The image is representative 
of 4 individual experiments (Panel A). Comparison of densitometrically quantified 
Cleaved caspase-3 (Asp175) expression by human C-20/A4 cell-lines is shown in 
arbitrary units (au, Panel B). Data are presented as Mean ± SEM of n=4 experiments: 










































































































Figure 3.38.  The effect of α-MSH on cell viability and caspase 3/7 activity on TNF-
α-activated C-20/A4 chondrocytes.  
C-20/A4 chondrocytes were plated at 2.0 x 104 cells/well, and treated with PBS or α-
MSH (0.1 – 30.0 µg/ml) for 30 min prior to stimulation with TNF-α (60.0 pg/ml) for 6 h. 
Cell viability was determined via MTT reduction assay (Panel B) and caspase-3/7 activity 
determined by Caspase-3/7 Glo Assay (Panels A and B). Dashed (red) line represents 
control sample cell viability – untreated cells as determined by MTT (100%); Dotted line 
symbolizes Caspase 3/7 activity following DMEM treatment (control). Data are presented 
as Mean ± SEM of n=4 experiments, assessed in triplicate.  *p≤ 0.05, **p≤ 0.01, **p≤ 













































































































Figure 3.39. The effect of D[TRP]8-γ-MSH on cell viability and caspase 3/7 activity 
on TNF-α-activated C-20/A4 chondrocytes.  
C-20/A4 chondrocytes were plated at 2.0 x 104 cells/well, and treated with PBS or 
D[TRP]8-γ-MSH (0.1 – 30.0 µg/ml) for 30 min prior to stimulation with TNF-α (60.0 pg/ml) 
for 6 h. Cell viability was determined via MTT reduction assay (Panel A) and caspase-
3/7 activity determined by Caspase-3/7 Glo Assay (Panel A and B). Dashed (red) line 
represents control sample cell viability – untreated cells (100%); Dotted line symbolizes 
Caspase 3/7 activity following PBS treatment (control). Data are presented as Mean ± 
SEM of n=4 experiments, assessed in triplicate.  *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001 vs. vs. 













































Figure 3.40. The effect of α-MSH and D[TRP]8-γ-MSH on cell viability following 
TNF-α  activation.  
C-20/A4 chondrocytes were plated at 2.0 x 104 cells/well, and pre-treated with a-
MSH/D[TRP]8-γ-MSH (0.1 – 30.0 µg/ml) ± SHU9119 (10.0 µg/ml) for 30 min prior to 
stimulation with TNF-α (60.0 pg/ml) for 6 h. Cell viability was determined via MTT 
reduction assay. Dashed line represents TNF-a (60.0 pg/ml) treated control cell viability 
– 74.13%. Data are presented as Mean ± SEM of n=4 experiments, assessed in 





3.3.7 Effect of hypo-osmolarity on C-20/A4 chondrocyte function.   
Cartilage hydration plays an important role in the physiology of healthy 
chondrocytes. Highly hydrated proteoglycans inflate the cartilage tissue and thus 
it confers an ability to resist compressive forces (Hall, 1998). However, during 
osteoarthritis, matrix metalloproteinases are significantly over-expressed, driving 
the major degradation of collagen that occurs during OA (Kevorkian et al., 2004, 
Kobayashi et al., 2005).  The damaged collagen network allows the charged 
proteoglycans to attract more water, which leads to dilution of the charged ions in 
the extracellular space and misbalance of osmolarity compared to the 
chondrocytic cytoplasm, thereby increased water-flow into the cell and altered 
metabolism (Maroudas, 1976, Bush and Hall, 2001a, Bush and Hall, 2005).  As it 
is very difficult to mimic these conditions in situ and in vivo, the effect of 
hypotonic media (140 mOsm:H2O) on chondrocyte function was investigated in 
C-20/A4 chondrocyte system. The production of pro-inflammatory cytokine 
production and expression of matrix metalloproteinases was investigated 
following treatment of the chondrocytes with hypo-osmotic (140 mOsm) DMEM 
culture media.  
3.3.7.1 Effect of hypo-osmolarity on pro-inflammatory cytokines release 
and MMPs expression in C-20/A4 chondrocytes.  
C-20/A4 chondrocytes stimulated with TNF-α (60 pg/ml) showed increased pro-
inflammatory cytokine expression and release (IL-1β, IL-6, IL-8) and significant 
rise in MMP1 and MMP13. Here, an in vitro model, was designed to mimic the 
hypo-osmolarity in osteoarthritic cartilage in order to investigate its effects on the 
production of the catabolic pro-inflammatory cytokines IL-6 and IL-8, and the 
detrimental collagenases 1 and 3.   
C-20/A4 chondrocytes were grown in hypotonic media (140 mOsm) for 0, 24 and 
72 h and IL6 and IL8 expression determined using semi-quantitative PCR 
amplification reactions with the appropriate primers (Table 2.9). PCR products 
were visualised on 2 % agarose gel and the results were normalised to internal 
control β-actin (Figure 3.41 A). The resulting bands were analysed by 





mRNA levels. Cells incubated for 24 h in 140 mOsm DMEM media released 37-
fold more IL6 compared to control cultures and with increasing the time-periods 
to 72 h, the expression of IL6 increased to 42-fold compared to cells incubated in 
normal 280 mOsm DMEM (Figure 3.41). Similarly, IL8 expression was 
significantly increased following incubation with hypo-osmotic solution. The 
treatment of C-20/A4 cells with hypo-osmotic solution for 24 h caused a 8-fold 
up-regulation of IL8 expression, which continued to increase to 10-fold at 72 h 
post-stimulation.   
Changes in protein levels of IL-6 and IL-8 were investigated following incubation 
of the cells in 140 mOsm DMEM for 24 and 72 h by ELISA (Figure 3.42). C-20/A4 
cells were incubated with 140 mOsm DMEM media for 24 or 72 h. Cell-free 
supernatants were collected and analysed for IL-6 and IL-8 production by 
commercially available IL-6 and IL-8 ELISAs according to manufacturer’s 
instructions (R&D Systems, UK). There was a significant time-dependent 
increase in the concentration of IL-6 as compared to time 0. C-20/A4 
chondrocytes responded to decreased osmolarity of the extracellular space 
(DMEM) with a release of 150 ± 12.66 pg/ml and 192.34 ± 7.83 pg/ml of IL-6 
following incubation with the hypo-osmotic medium for 24 and 72h respectively 
(p≤ 0.001 for both values) compared to time 0 (21.09 ± 18.5 pg/ml). Similar 
observations were made for IL-8 production following incubation with 140 mOsm 
DMEM media for 24 and 72h, which yielded 394.32 ± 15.60 pg/ml and 376.10 ± 
11.38 pg/ml respectively (p≤ 0.001), compared to the untreated control cells 
(72.65 ± 4.78 pg/ml). There was slight but insignificant reduction in IL-8 































































Figure 3.41. Densitometric quantification of IL-6 and IL-8 expression in C-20/A4 
cells incubated in hypotonic (140 mOsm) DMEM media for 24 h and 72 h. 
C-20/A4 chondrocytes were stimulated with hypotonic media (140 mOsm) at time 0 and 
total RNA extracted at 0 h, 24 h and 72 h post stimulation. PCR amplification with the 
respective primers for IL6 and IL8 was used to detect and quantify gene expression on 2 
% agarose gels in triplicates with β-actin used as internal control (Panel A). Comparison 
of densitometrically quantified IL-6 (Panel B) and IL-8 (Panel C) shown in arbitrary units, 
each value normalized to the respective β-actin expression. Data are presented as Mean 








Figure 3.42 Time dependent effect of hypo-osmotic (140 mOsm) DMEM media on 
IL-6 and IL-8 protein release. 
C-20/A4 chondrocytes were treated with hypotonic media (140 mOsm) at time 0 and 
cell-free supernatants were collected at 0, 24 and 72 h post stimulation. Supernatants 
were then analysed by commercially available ELISA for IL-6 and IL8 production. Data 
are presented as Mean ± SEM of n=3 independent experiments repeated in triplicate, 
**p≤ 0.01, ***p≤ 0.001) vs. Time 0. 
 
The effect of hypotonic media on MMP1, MMP3 and MMP13 expression was 
determined using PCR amplification reactions with the appropriate primers (Table 
2.9). The PCR products were visualised on 2 % agarose gel and the results were 
normalised to internal control β-actin (Figure 3.43 A). Densitometric analysis 
showed that upon incubation of C-20/A4 chondrocytes with 140 mOsm DMEM 
media for 24 h and 72 h, MMP1 expression was significantly elevated with 0.49 ± 
0.12 au (2.3-fold increase; p≤ 0.05) at 24 h and a 4-fold increase at 72 h (0.932 ± 
0.0263 au; p≤ 0.001 vs. Time 0 h). Interestingly, MMP3 expression was 
increased slightly following 72 h compared to non-treated cells (0.714 ± 0.04 au, 
1.23-fold; p≤ 0.05 vs. Time 0), whilst no significant changes were observed at 24 
h. MMP13, a collagenase that is expressed in neither non-stimulated C-20/A4 
cells, (as shown on Figure 3.43 B), nor in healthy human cartilage, was 
significantly up-regulated to 0.557 ± 0.058 au after 24 h incubation in 140 mOsm 
DMEM (p≤ 0.001), and expression was increased following 72 h (0.642 ± 0.01 































































Figure 3.43. Densitometric quantification of MMP1, MMP3 and MMP13 expression 
in C20/A4 cells treated with 140 mOsm DMEM media.  
C20/A4 chondrocytes were stimulated with hypotonic media (140 mOsm) at time 0 and 
total RNA extracted 0-72 h post stimulation. PCR amplification with the respective 
primers for MMP1, MMP3 and MMP13 was used to detect and quantify gene expression 
on 2 % agarose gels in duplicates with β-actin used as internal control (Panel A). 
Comparison of densitometrically quantified MMP1, MMP3 and MMP13 expression 
induced by hypotonic saline (140 mOsm:H2O, Panel B) shown in arbitrary units, each 
value normalized to the respective β-actin expression. Data is presented as Mean± SEM 





3.3.7.2 Attenuation of extracellular hypo-osmolarity-induced matrix 
metalloproteinases production by melanocortin peptides α-MSH 
and D[TRP]8-γ-MSH.  
In order to investigate different aspects of the anti-inflammatory properties of the 
melanocortin peptides α-MSH and D[TRP]8-γ-MSH, their effect was evaluated on 
the up-regulated expression of catabolic proteinases caused by the hypo-osmotic 
challenge.  
C-20/A4 cells were incubated in 140 mOsm DMEM for 24 h + α-MSH (3.0 µg/ml) 
or D[TRP]8-γ-MSH (3.0 µg/ml).  Total RNA was extracted and MMP1, MMP3 and 
MMP13 gene expression was analysed by semi-quantitative PCR (Figure 3.44 A) 
with the specific primers for the amplification of the individual genes listed in 
Table 2.9. Following treatment for 24 h, α-MSH failed to cause any significant 
inhibition of the expression of MMP1, MMP3 and MMP13. Similarly, D[TRP]8-γ-
MSH at 3.0 µg/ml failed to cause any detectable change in the expression of 
MMP3, however, the MC3 agonist reduced the transcription of MMP1 (from 0.49 
± 0.12 au to 0.25 ± 0.05 au) and MMP13 (from 0.56 ± 0.06 au to 0.11 ± 0.01 au), 









































































Figure 3.44. Effect of melanocortins on MMP1, MMP3 and MMP13 expression in C-
20/A4 cells treated with 140 mOsm DMEM for 24 h measured by densitometry. 
C-20/A4 chondrocytes were pre-treated with α-MSH or D[TRP]8-γ-MSH prior to 
stimulated with hypotonic media (140 mOsm) at time 0 and total RNA extracted 24 h 
post stimulation. PCR amplification with the respective primers for MMP1, MMP3 and 
MMP13 was used to detect and quantify gene expression on 2 % agarose gels in 
duplicates with β-actin used as internal control (Panel A). Comparison of 
densitometrically quantified MMP1, MMP3 and MMP13 expression induced by hypotonic 
saline (140 mOsm; Panel B) shown in arbitrary units, each value normalized to the 
respective β-actin expression. Data are presented as Mean ± SEM of n=3 independent 





3.4 Effect of pro-inflammatory stimuli on primary bovine 
chondrocytes function.  
3.4.1 Detection of pro-inflammatory cytokines release following 
primary chondrocyte activation. 
C-20/A4 cell-line chondrocytes have been shown within this thesis to respond to 
TNF-α and LPS stimulation leading to the release of pro-inflammatory cytokines. 
Given these findings, primary bovine articular chondrocytes (freshly extracted, 
cultured in monolayers) were evaluated to determine whether primary cells 
responded in a similar fashion, as these have been shown to be a good model 
for human primary chondrocytes (Kerrigan and Hall, 2005). Isolated bovine 
articular chondrocytes were cultured and incubated in serum-free 380 mOsm 
DMEM medium for 24 h prior to stimulation with TNF-α (20.0 – 60.0 pg/ml) and 
LPS (1.0 – 10.0 µg/ml) for 6 h, cell-free supernatants were collected and 
analysed for IL-1β, IL-6 and IL-8 by ELISA. 
3.4.1.1 Effect of TNF-α and LPS on IL-6 and IL-8 release from bovine 
chondrocytes.  
TNF-α stimulation of primary bovine chondrocytes led to significant increases in 
IL-6 release (Figure 3.45 A). The pro-inflammatory cytokine (20.0 – 80.0pg/ml) 
caused a concentration-dependent increase in synthesis and release of IL-6 from 
the bovine articular chondrocytes with 20.0 pg/ml causing a significant release of 
38.54 ± 9.85 pg/ml of IL-6 (p≤ 0.05) compared to untreated controls (3.2 ± 1.38 
pg/ml). IL-6 levels doubled following stimulation with 40.0 pg/ml (78.59 ± 13.68 
pg/ml, p≤ 0.01). Increasing concentrations of TNF-α led to 174.38 ± 14.6 pg/ml 
(p≤ 0.001) and 347.07 ± 29.79 pg/ml (p≤ 0.001) of IL-6 production at 60.0 pg/ml 
and 80.0 pg/ml respectively. LPS (1.0 – 10.0 µg/ml) also caused significant 
increases in IL-6; however, all concentrations evaluated caused a similar 
response. A maximal response was achieved following stimulation with LPS (3.0 
µg/ml), where 163.23 ± 12.24 pg/ml of IL-6 was released. Both 1.0 and 10.0 
µg/ml of LPS had similar effect, causing 156.93 ± 15.35 pg/ml and 159.12 ± 





concentrations was significantly increased compared to the untreated controls 
(3.2 ± 1.38 pg/ml; p≤ 0.001; Figure 3.45 B). 
Following the determination of IL-6, IL-8 levels from stimulated bovine 
chondrocytes were evaluated. TNF-α (20.0 – 80.0 pg/ml) caused a bell-shaped 
concentration dependent effect, peaking at 40.0 pg/ml and 60.0 pg/ml with 46.67 
± 13.65 pg/ml (p<0.05) and 45.56 ± 2.94 pg/ml (p≤ 0.01) respectively, whilst 
higher concentrations of TNF-α (80.0 pg/ml) caused lower levels of IL-8 release 
(28.89 ± 3.9 pg/ml (p≤ 0.01; Figure 3.45 C). LPS (1.0 – 10.0 µg/ml) caused a 
similar response with 22.33 ± 3.1 pg/ml (p≤ 0.01) and 12.29 ± 1.98 pg/ml (p≤ 
0.05) IL-8 release for 3.0 µg/ml and 10.0 µg/ml respectively, however, 1.0 µg/ml 
of LPS failed to induce any significant increase in IL-8 compared to control 
values (p> 0.05; Figure 3.45 B).  
3.4.1.2 Effect of TNF-α and LPS on IL-1β and MCP-1 release from bovine 
chondrocytes.  
Treatment of bovine chondrocytes with TNF-α (20.0 – 80.0 pg/ml) caused a bell 
shaped concentration-dependent effect on IL-1β release following 6 h incubation, 
peaking at 60.0 pg/ml with 21.87 ± 0.2 pg/ml (p≤ 0.05) compared to untreated 
controls (0.82 ± 0.06 pg/ml; Figure 3.46 A). Lower concentrations of TNF-α 
caused 17.06 ± 0.65 pg/ml and 17.40 ± 0.23 pg/ml IL-1β release for 20.0 and 
40.0 pg/ml respectively (p≤ 0.05). Similar response was observed following 
stimulation with the highest tested concentration 80.0 pg/ml of TNF-α leading to 
17.92 ± 0.26 pg/ml IL-1β released (p≤ 0.05). LPS stimulation also activated the 
bovine chondrocytes to produce IL-1β at all concentrations tested (Figure 3.46 
B), with a maximal release following stimulation with 3.0 µg/ml, causing a release 
of 20.8 ± 3.8 pg/ml IL-1β (p≤ 0.05). LPS at 1.0 and 10.0 µg/ml led to significant 
17.9 ± 1.2 pg/ml and 19.8 ± 2.9 pg/ml IL-1β release from the chondrocytes 
compared to control (p≤ 0.05). 
Similarly to the effect on IL-1β, IL-6 and IL-8, TNF-α (20.0 – 80.0 pg/ml) and LPS 
1.0 – 10.0 µg/ml) caused significant production of MCP-1 (Figure 3.46 C). TNF-α 
caused a maximal response at 60.0 pg/ml with 159.44 ± 13.29 pg/ml (p≤ 0.001), 





but when the concentration was doubled to 40.0 pg/ml, there was a significant 
elevation in MCP-1 (79.86 ± 25.12 pg/ml; p≤ 0.001) compared to untreated 
controls. 
When primary bovine cells were treated for 6 h with LPS (1.0 – 10.0 µg/ml) there 
was a significant increase in MCP-1, with a maximal production of 108.05 ± 4.2 
pg/ml at 3.0 µg/ml LPS. All other concentrations caused very similar amount of 

















Figure 3.45   Effect of TNF-α  and LPS on IL-6 and IL-8 release from extracted 
bovine chondrocytes.  
Bovine chondrocytes were extracted from cartilage explants and cultured for plated for 
24 h in serum-free 380 mOsm DMEM prior to stimulation. Panel A and C: TNF-α (20.0-
80.0 pg/ml) and Panel B and D: LPS (1.0-3.0 µg/ml) for 6 h. Cell-free supernatants were 
collected and analysed for IL-6 IL-8 levels by ELISA. Data are presented as Mean ± 
SEM of n=4 independent experiments performed in triplicate. *p≤ 0.05, **p≤ 0.01 vs. 










Figure 3.46   Effect of TNF-α  and LPS on IL-1β  and MCP-1 release from extracted 
bovine chondrocytes.  
Bovine chondrocytes were extracted from cartilage explants and cultured for plated for 
24 h in serum-free 380 mOsm DMEM prior to stimulation. Panel A and C: TNF-α (20.0 – 
80.0 pg/ml) and Panel B and D: LPS (1.0 – 3.0 µg/ml) for 6 h. Cell-free supernatants 
were collected and analysed for IL-1β (Panels A, B) and MCP-1 (Panels C, D) levels by 
ELISA. Data are presented as Mean ± SEM of n=4 independent experiments performed 






3.4.2 Melanocortin receptors expression in bovine articular 
chondrocytes.  
 
Following the identification of cytokine release from primary bovine chondrocytes, 
expression of MC was determined. Gene and species specific primers were 
designed for both MC1 and MC5 in order to determine whether MC1 and MC5 
were expressed in the articular chondrocytes of Bos taurus. However, the full 
coding sequence of MC3 has not been revealed yet, therefore it was not possible 
to investigate its expression at that point. Total mRNA was extracted from non-
stimulated chondrocytes extracted from at least 5 individual bovine joints and 
conventional RT-PCR used to quantify the transcriptional levels of both genes.  
 
There was a marked expression of MC1 that was consistent between the 
individual animals and confirmed by the detection of size-specific bands on 2 % 
agarose gels, corresponding to the expected size of MC1 fragment of interest 
(Figure 3.47). The transcriptional studies of MC5 were non-conclusive, since the 
expression of the gene varied significantly between the tested animal tissues. All 










Figure 3.47 Endogenous expression of MC1 and MC5 in primary bovine 
chondrocytes.  
Freshly extracted bovine primary chondrocytes were cultured for 24 h in serum-free 380 
mOsm DMEM media and total RNA was subsequently extracted. PCR amplification with 
the respective primers for bovine MC1 and MC5 were used to detect and quantify gene 
expression on 2% agarose gels in triplicates with Gapdh used as internal control. 
Densitometrically quantified MC1 and MC5 shown in arbitrary units, each value 
normalized to the respective GAPDH expression. Data is presented as Mean ± SEM of 





3.4.3 Effect of melanocortin peptides on pro-inflammatory cytokine 
release from TNF-α stimulated primary bovine chondrocytes.  
Since the coding region of MC3 was not available to design the primers needed 
for the investigative study of MC3 expression, another approach was used that 
allowed research into whether MC3 was expressed by using the selective MC3 
agonist [DTRP8]-γ-MSH. The pan-agonist α-MSH, MC3 agonist D[TRP]8-γ-MSH 
and MC3/4 antagonist/MC1 agonist SHU9119 were used in separate experiments 
to reveal whether MC1 and MC3 were present and able to modulate the release 
of pro-inflammatory mediator release from primary bovine articular chondrocytes.  
In order to investigate the validity and efficacy of melanocortin peptides at 
inhibiting the release of pro-inflammatory cytokines following TNF-α stimulation, 
they were investigated in primary bovine chondrocytes (Figure 3.48). Primary 
bovine chondrocytes were extracted from bovine cartilage and monolayer 
cultures incubated in serum-free 380 mOsm DMEM medium for 24 h prior to pre-
treatment for 30 min with α-MSH, D[TRP]8-γ-MSH or SHU9119 (1.0 – 30.0 µg/ml) 
prior to stimulation with TNF-α (60.0 pg/ml) for 6 h.  Pre-treatment of primary 
bovine chondrocytes with α-MSH, D[TRP]8-γ-MSH and SHU9119 caused a 
significant decrease in IL-β levels. Concentrations between 1.0 and 10.0 µg/ml of 
α-MSH significantly reduced the levels of IL-1β produced by TNF-α from 21.87 ± 
0.23 pg/ml down to 12.85 ± 0.29 pg/ml (α-MSH 1.0 µg/ml), representing a 41% 
decrease (p≤ 0.05).  α-MSH (3.0 µg/ml) decreased IL-1β concentration to 13.30 ± 
0.71 pg/ml, a 39 % reduction (p≤ 0.05). Increasing the peptide concentration did 
not alter the inhibition of IL-1β compared to the lower 3.0 µg/ml concentration 
with a similar 39 % reduction. Higher concentrations of α-MSH (30.0 µg/ml) did 
not have a statistically significant effect (17.34 ± 1.4 pg/ml; p> 0.05; Figure 3.48) 
compared to TNF-α−treated controls.  
Treatment of primary chondrocytes with D[TRP]8-γ-MSH caused a bell shaped 
concentration dependent decrease in IL-1β levels with 1.0 µg/ml being essentially 
inactive (19.68 ± 1.58 pg/ml; p> 0.05). Levels of IL-1β were reduced by 61 % 
following stimulation with 3.0 µg/ml (p≤ 0.05) and a maximal effect of 76 % at 





concentration was increased to 30.0 µg/ml (39%). A modest inhibitory effect was 
observed with SHU9119 with 1.0 µg/ml (16.84±0.72 pg/ml; p≤ 0.05) and 3.0 
µg/ml (17.46 ± 0.9 pg/ml; p≤ 0.05) causing a reduction of 23 % and 20 % 
respectively. Higher concentrations had no significant effect on TNF-α induced 
IL-1β levels (Figure 3.48). 
 
 
Figure 3.48 Effect of melanocortin peptides on IL-1β  release from TNF-α  activated 
primary bovine chondrocytes.  
Bovine chondrocytes were extracted from bovine cartilage and cultured for 24 h in 
serum-free 380 mOsm DMEM medium. Chondrocytes pre-treated with α-MSH, D[TRP]8-
γ-MSH or SHU9119 (1.0-30.0 µg/ml) for 30 mins, prior to stimulation with TNF-α (60.0 
pg/ml) for 6 h. Cell-free supernatants were collected and analysed for IL-1β levels by 
ELISA. Data are presented as Mean± SEM of n=4 independent experiments repeated in 
triplicate, *p≤ 0.05 vs. culture treated with TNF-α alone. Dashed line represents TNF-α 






α-MSH caused a significant abrogation of TNF-α-induced IL-6 release from 
primary bovine chondrocytes (Figure 3.49 A). TNF-α-stimulation alone caused 
174.38 ± 14.6 pg/ml of IL-6 release. α-MSH was most effective at 1.0 µg/ml 
causing a 92.7 % inhibition in IL-6 release (12.74 ± 1.2 pg/ml; p≤ 0.001). Higher 
concentrations of peptide still exerted a significant inhibitory effect with 3.0 µg/ml 
causing an 87.3 % decrease (22.18 ± 0.9 pg/ml; p≤ 0.001), 10.0 µg/ml causing a 
76.4 % reduction (41.22 ± 0.57 pg/ml; p≤ 0.001) and 30.0 µg/ml a 48% decrease 
(90.8 ± 10.24 pg/ml; p≤ 0.01) compared to control.  
Following identification of the inhibitory effect of α-MSH, the MC3 agonist 
D[TRP]8-γ-MSH was evaluated.  D[TRP]8-γ-MSH (1.0 – 10.0 µg/ml) caused a bell 
shaped inhibitory effect of IL-6 release (Figure 3.49 A). The maximal effect was 
observed at 3.0 µg/ml with a 72 % decrease in IL-6 release, whilst 1.0 and 10.0 
µg/ml had a reduced inhibitory effect displaying 40.1 % (104.46 ± 3.11 pg/ml; p≤ 
0.01) and 48.2 % (90.34 ± 16.29 pg/ml; p≤ 0.01) reduction respectively. Higher 
concentrations (30.0 µg/ml) did not cause a statistically significant change in the 
release of IL-6 (p> 0.05) compared to TNF-α alone. The MC3/4 antagonist/MC1 
agonist SHU9119 failed to inhibit IL-6 release at all concentrations evaluated 
(Figure 3.49 A).  
D[TRP]8-γ-MSH attenuated IL-8 release elicited by TNF-α (60.0 pg/ml) in a bell 
shaped dependent fashion (Figure 3.49 B). The maximal effect was reached at 
3.0 µg/ml causing a 69.4 % decrease in IL-8 levels (13.93 ± 1.13 pg/ml; p≤ 0.01) 
compared to TNF-α treated controls (45.56 ± 2.94 pg/ml), a similar reduction was 
observed at 1.0 µg/ml with a 66.5 % decrease. At 10.0 µg/ml a 57 % inhibition 
was observed, however at 1.0 and 30.0 µg/ml of D[TRP]8-γ-MSH failed to inhibit 
IL-8 release (p> 0.05). In contrast all concentrations of α-MSH evaluated caused 
a significant inhibition of IL-8 with a maximal inhibition being observed at 3.0 
µg/ml of 66.02 % (15.49±1.28 pg/ml). As previously observed with IL-6, 
SHU9119 failed to inhibit significantly inhibit IL-8 release at all concentrations 








Figure 3.49 Effect of melanocortin peptides on IL-6 and IL-8 release from TNF-α-
activated primary bovine chondrocytes. 
Bovine chondrocytes were extracted from bovine cartilage and cultured for 24 h in 
serum-free 380 mOsm DMEM medium. Chondrocytes pre-treated with α-MSH, D[TRP]8-
γ-MSH or SHU9119 (1.0-30.0 µg/ml) for 30 mins, prior to stimulation with TNF-α  (60.0 
pg/ml) for 6 h. Cell-free supernatants were collected and analysed for IL-6 and IL-8 
levels by ELISA. Data is presented as Mean ± SEM of n=4 independent experiments 





3.4.4 Effect of MC3/4 antagonist SHU9119 on anti-inflammatory effect of 
α-MSH and D[TRP]8-γ-MSH in TNF-α activated bovine primary 
chondrocytes.  
To try and unravel whether MC1 and/or MC3 was mediating the effects of the 
melanocortin peptides α-MSH and D[TRP]8-γ-MSH, SHU9119 was added on 
TNF-α activated primary P0 bovine articular chondrocytes. Primary P0 bovine 
articular chondrocytes were extracted and cultured in a monolayer with serum-
free 380 mOsm DMEM medium for 24 h prior to stimulation. The cells were 
treated with the peptides (1.0 – 10.0 µg/ml) for 30 min ± SHU9119 (10.0 µg/ml) 
prior to stimulation with TNF-α (60.0 pg/ml) for 6 h and IL-1β, IL-6 and IL-8 levels 
were detected by ELISA (Figure 3.50). SHU9119 failed to significantly block the 
effect of α-MSH at 1.0 and 3.0 µg/ml (p>0.05), surprisingly however, at 10.0 
µg/ml α-MSH the inhibitory effect on IL-1β was blocked in the presence of 
SHU9119 (Figure 3.50 A). In contrast SHU9119 (10.0 µg/ml) abrogated the anti-
inflammatory effect of D[TRP]8-γ-MSH at all concentrations evaluated (Figure 
3.50 B).  
α-MSH inhibitory effect on IL-6 was not blocked in the presence of SHU9119 at 
1.0 and 3.0 µg/ml. (Figure 3.51 A) However when SHU9119 (10.0 µg/ml) was 
combined with higher doses of α-MSH (10.0 µg/ml), there was a synergistic 
effect that caused a marked decrease in IL-6 levels (13.33 ± 3.22 pg/ml) a 66.7 
% reduction compared to α-MSH alone (41.22 ± 0.56 pg/ml). In contrast D[TRP]8-
γ-MSH at all concentrations evaluated (1.0 – 10.0 µg/ml) was completely blocked 
when SHU9119 was given in combination (Figure. 3.51 B). IL-8 released 
following TNF-α stimulation of P0 chondrocytes showed that SHU9119 (10.0 
µg/ml) failed to inhibit the anti-cytokine effects of α-MSH (1.0 – 10.0 µg/ml, 
Figure 3.51 C). D[TRP]8-γ-MSH inhibition of IL-8 was abrogated in the presence 
of SHU9119 (Figure 3.51 D).  
Finally, given that SHU9119 blocked the action of D[TRP]8-γ-MSH but not of α-
MSH, we evaluated the effect of this combination on IL-10 synthesis. Treatment 
of the P0 bovine chondrocytes with α-MSH led to significant increase in IL-10 





with a combination of α-MSH and SHU9119 and the peptide’s actions were not 
significantly affected by the addition of the MC3/4 antagonist. There was a general 
reduction in the melanocortin effect, which could be attributed to its partial 
binding affinities to MC3 in contribution to MC1. However, SHU9119 prevented 
D[TRP]8-γ-MSH from binding to its receptor, therefore reduced significantly IL-10 
production (Figure 3.52 B). SHU9119 caused 89 % reduction of IL-10 in 1.0 
µg/ml and 10.0 µg/ml of D[TRP]8-γ-MSH treated cells, and 86 % when given 










Figure 3.50 Effect of the MC3/4 antagonist SHU9119 on IL-1β  release from TNF-α  
activated primary bovine articular chondrocytes following α-MSH and D[TRP]8-γ-
MSH treatment.  
Bovine chondrocytes were extracted from bovine cartilage and cultured for 24 h in 
serum-free 380 mOsm DMEM medium. Chondrocytes were then pre-treated with α-MSH 
(Panel A) or D[TRP]8-γ-MSH (1.0 – 10.0 µg/ml; Panel B) ± SHU9119 (10.0 µg/ml) for 30 
mins, prior to stimulation with TNF-α (60.0 pg/ml) for 6 h. Cell-free supernatants were 
collected and analysed for IL-1β levels by ELISA. Data are presented as Mean ± SEM of 








Figure 3.51. Effect of the MC3/4 antagonist SHU9119 on IL-6 release from TNF-α  
activated primary bovine articular chondrocytes following α-MSH and D[TRP]8-γ-
MSH treatment.  
Bovine chondrocytes were extracted from bovine cartilage and cultured for 24 h in 
serum-free 380 mOsm DMEM medium. Chondrocytes were then pre-treated with α-MSH 
(Panel A) or D[TRP]8-γ-MSH (Panel B; 1.0 – 10.0 µg/ml) ± SHU9119 (10.0 µg/ml) for 30 
mins, prior to stimulation with TNF-α (60.0 pg/ml) for 6 h. Cell-free supernatants were 
collected and analysed for IL-6 levels by ELISA. Data is presented as Mean ± SEM of 






Figure 3.52 Effect of the MC3/4 antagonist SHU9119 on IL-10 release from TNF-α  
activated primary bovine articular chondrocytes following α-MSH and D[TRP]8-γ-
MSH treatment.  
Bovine chondrocytes were extracted from bovine cartilage and cultured for 24 h in 
serum-free 380 mOsm DMEM medium. Chondrocytes were then pre-treated with α-MSH 
(Panel A) or D[TRP]8-γ-MSH (Panel B; 1.0 – 10.0 µg/ml) ± SHU9119 (10.0 µg/ml) for 30 
mins, prior to stimulation with TNF-α (60.0 pg/ml) for 6 h. Cell-free supernatants were 
collected and analysed for IL-10 levels by ELISA. Data is presented as Mean ± SEM of 





3.4.5 Cartilage impact and the effect of melanocortins and steroids on 
bovine chondrocytes in situ. 
Mechanical stress above the physiological range can profoundly influence 
articular cartilage causing matrix damage, changes to chondrocyte metabolism 
and cell injury/death (Bush and Hall, 2005) and therefore has been implicated as 
a risk factor for the development of osteoarthritis. The mechanism of cell damage 
is not understood, but chondrocyte volume could be a determinant of the 
sensitivity and subsequent response to load (Hall, 1998). In OA, it is possible that 
the chondrocyte swelling that occurs renders the cells more sensitive to the 
damaging effects of mechanical stress. Here, changes in viability of in situ 
chondrocytes following a single blunt impact have been investigated in the 
presence of α-MSH, D[TRP]8-γ-MSH, and the steroid dexamethasone evaluated 
at the time of impact and 6h post-impact. 
3.4.5.1 Cell viability of articular bovine chondrocytes in vivo following 
single impact.  
Explants of bovine articular cartilage were incubated with the fluorescent 
indicators 5.0 µM Calcein-AM and 1.0 µM Propidium Iodide, permitting the 
measurement of cell viability, respectively, using confocal laser scanning 
microscopy (CLSM). Cartilage was then subjected to a single impact with 1.14 N 
force delivered from a vertical drop tower, which caused areas of chondrocyte 
injury/death within the superficial zone (SZ) as shown on Figure 3.52.  
Cell death following single impact was quantified using Imaris 7.1.1 Spots 
analysis software and the results are shown in Figure 3.58. Impact caused a 
significant (*p<0.05) increase in cell death. Non-impacted cartilage showed 2.95 
± 0.26 % chondrocytes death, which following impact increased to 13.50 ± 1.72% 
(Figure 3.53).  Areas of chondrocyte injury inflicted from impact tower injury can 
be seen on Figure 3.58 and visually compared to non-impacted counterparts 










Figure. 3.52. A 3D-image of cartilage impacted chondrocytes.  
Cartilage explant was incubated for 30 min at 37ºC with 5.0 µM Calcein-AM and 1.0 µM 
Propidium Iodine for staining alive and dead cells respectively and visualized using 
CLSM at x630 magnification using x63 immersable lens. Iso-surface object were created 
for all cells, in order to create presentation image of an impacted piece of cartilage 
(image not used for volume analysis) Red cells represent chondrocytes undergoing cell 


















































Figure 3.53 Effect of single pact on cell death as quantified by Imaris 7.1.1 Spots 
Software. 
Bovine articulate cartilage explants were incubated with the fluorescent indicators 
Calcein-AM (5.0 µM) and Propidium Iodide (1.0 µM) prior to (Panel A, a) and at 6 h post-
mechanical trauma (Panel B, b) for 30 min, and visualized under CLSM. Imaris 7.1.1 
Spot Analysis software was used to quantify the number of viable (green) and non-viable 
(red) cells. Panels a, and b represent Spots analysis of the original CLSM images, taken 
at x100 magnification (Panels A and B). Percentage cell death was calculated based on 
the acquired results (Panel C). Data are representative images or Mean ± SEM of n=4 





3.4.5.1.1 The effect of melanocortins and dexamethasone on cell death. 
In order to investigate whether the melanocortin peptides have chondroprotective 
properties, cell viability was quantified as described earlier. Briefly, cells were 
treated for 6 h with 3.0 µg/ml α-MSH or D[TRP]8-γ-MSH, or 1.0 µM 
dexamethasone and then incubated with the fluorescent indicators Calcein-AM 
(5.0 µM) and Propidium Iodide (1.0 µM) for 30 min prior to CLSM, permitting the 
measurement of cell viability. 
Figure 3.54 demonstrates that α-MSH caused a reduction in chondrocyte death 
compared to basal levels (2.95 %). Cell death decreased to 0.97 %, when 
cartilage explants were incubated for 6 h with α-MSH (3.0 µg/ml) prior to CLSM 
imaging, representing 67 % reduction in cell death, compared to untreated 
controls (p≤ 0.05). However, neither D[TRP]8-γ-MSH (3.0 µg/ml) nor 








































Figure 3.54. Chondroprotective effect of melanocortin peptides as quantified by 
Imaris 7.1.1 Spots Analysis software.  
Bovine articular cartilage explants were treated with either DMEM (Panel A), α-MSH (3.0 
µg/ml; Panel B), D[TRP]8-γ-MSH (Panel C), or 1.0 µM dexamethasone (Panel D) for 6 h. 
Cartilage explants were then incubated for 30 min at 37ºC with the fluorescent indicators 
Calcein-AM (5.0 µM) and Propidium Iodine (1.0 µM) for staining alive and dead cells 
respectively, immediately following which the explants were visualized using CLSM at 
x100 magnification. Imaris 7.1.1 Spot Analysis software was used to quantify the number 
of viable (green) and non-viable (red) cells. Percentage cell death was calculated based 
on the acquired results (Panel E). Data are representative images or Mean ± SEM of 





3.4.5.1.2 The effect of melanocortins and dexamethasone on pro-
inflammatory cytokine release from non-impacted bovine 
chondrocytes in situ.  
In order to determine the basal levels of pro-inflammatory cytokines released 
from non-impacted bovine cartilage explants, the cartilage pieces were incubated 
in 380 mOsm DMEM for 24 h, following which the medium was replaced with 
fresh DMEM and IL-1β, IL-6 and IL-8 release was detected at 6 h by ELISA. 
Similarly, the effect of the melanocortins on pro-inflammatory cytokine release 
from non-injured cartilage pieces were evaluated in the supernatants at 6 h, post-
treatment of the bovine explants with α-MSH (3.0 µg/ml), D[TRP]8-γ-MSH (3.0 
µg/ml) or dexamethasone (1.0 µM) and compared to the basal levels of cytokine 
release (Figure 3.55).  
There was a significant basal production of cytokines detected in the 
supernatants of non-treated bovine articular cartilage explants, with 17.94 ± 4.61 
pg/ml/g (pg/ml per gram of cartilage tested) of IL-1β, 59.33 ± 8.75 pg/ml/g of IL-6 
and 97.11 ± 10.57 pg/ml of IL-8, values which were not significantly altered by 
the addition of any of the drugs as can be seen from Figure 3.55 Panels A, B and 






































































































Figure 3.55 Effect of α-MSH, D[TRP]8-γ-MSH and dexamethasone on basal 
production of IL-1β , IL-6 and IL-8.  
Bovine articular cartilage explants were treated with DMEM, α-MSH (3.0 µg/ml), 
[DTRP]8-γ-MSH (3.0 µg/ml), or dexamethasone (1.0 µM) for 6 h and cell-free 
supernatants were collected and analysed for IL-1β (Panel A), IL-6 (Panel B) and IL-8 
(Panel C) via commercially available ELISAs (R&D Systems). Results were corrected 
per gram of tissue tested. Data are presented as Mean ± SEM of n=4 experiments 





3.4.5.2 The effect of melanocortin peptides and dexamethasone on 
impacted cartilage explants.  
3.4.5.2.1 The effect of melanocortin peptides and dexamethasone on cell 
death as detected via CLSM.  
In order to investigate whether melanocortin peptides were able to exhibit a 
protective effect on impacted bovine chondrocytes in situ, cell viability was 
quantified as described previously. Briefly, cells were treated for 30 min with 
DMEM, α-MSH (3.0 µg/ml), D[TRP]8-γ-MSH (3.0 µg/ml), or dexamethasone (1.0 
µM) prior to impact and incubated for 6 h. 30 min prior to CLSM imaging, 
cartilage explants were incubated with the fluorescent indicators Calcein-AM (5.0 
µM) and Propidium iodide (1.0 µM).  
All drugs caused a significant decrease in cell death (p≤ 0.05) compared to 
DMEM-treated impacted sample (Figure 3.56). Upon single blunt impact using 
the vertical drop tower, 13.5 ± 1.72 % of the cells in the injured cartilage were 
found to be dead 6 h following the impact. Treatment of cartilage explants with 
melanocortin peptides or dexamethasone for 30 min prior to impact and left to 
incubate for 6 h resulting in significant protective effects on the chondrocytes. 
Cell death was reduced to 5.10 ± 1.42 %, when the articular cartilage explants 
were incubated with α-MSH (3.0 µg/ml), representing a 62% reduction (p≤ 0.05). 
Similar was the effect of the selective MC3 agonist D[TRP]8-γ-MSH with the 
peptide protecting 66 % of the cells during the first 6 h of impact, allowing for only 
4.63 ± 0.62 % of the chondrocytes to undergo cell death (p≤ 0.05). Similarly, 
dexamethasone exhibited chondroprotective properties and caused a 50 % 
reduction in cell death compared to DMEM-treated impacted cartilage explant 
with just 6.75 ± 2.38 % of the cells in the injured explant to undergo cell death (p≤ 
0.05).  
3.4.5.2.2 Melanocortin peptides and dexamethasone decrease pro-
inflammatory cytokines induced by mechanical trauma. 
In order to investigate the involvement of pro-inflammatory cytokines in the 
chondrocyte function following cartilage injury, bovine articular cartilage explants 





mechanical trauma, the cartilage were returned to their media for 6 h, when cell-
free supernatants were collected. Similarly, the cartilage explants were treated 
with the melanocortin peptides and dexamethasone for 30 min, following which 
period they were subjected to single impact and returned back in the same media 
containing the respective drug for additional 6 h. The supernatants were then 
collected and analysed for IL-1β, IL-6 and IL-8 production by ELISA.   
Upon impact, the chondrocytes in the DMEM-treated impacted explants 
produced 351.22 ± 24.12 pg/ml/g IL-1β (Figure 3.57), representing a 19-fold 
increase (p≤ 0.001) in the release of this pro-inflammatory cytokine compared to 
the basal amounts released by the chondrocytes from non-impacted cartilage 
explants. The injury led to 13-fold increase (p≤ 0.001) in IL-6 production 
compared to basal levels, with 448.41 ± 19.65 pg/ml/g at 6 h post-impact (Figure 
3.57 B). Similarly, there was a significant, 3-fold increase in the levels of IL-8 (p≤ 
0.001), with 293.46 ± 13.94 pg/ml/g (Figure 3.57 C). All of the drugs were found 
to be effectively reducing these amounts of pro-inflammatory cytokines, produced 
by the chondrocytes in response to the mechanical trauma. α-MSH (3.0 µg/ml) 
decreased the release of IL-1β by 41 % to 209.14 ± 2.22 pg/ml/g (p≤ 0.01) 
compared to the respective DMEM-treated samples (Figure 3.57 A). The 
selective MC3 agonist was significantly more potent in inhibiting the release of IL-
1β to 175.09 ± 19.13 pg/ml/g (50 %, p≤ 0.01). In similar fashion dexamethasone 
caused an even larger reduction of 58% of IL-1β release (149.80 ± 2.83 pg/ml/g; 
p≤ 0.001).  IL-6 release was significantly inhibited in the presence of α-MSH, 
D[TRP]8-γ-MSH and Dexamethasone down to 158.32 ± 12.87 pg/ml/g, 130.88 ± 
7.75 pg/ml/g and 73.57 ± 6.26 pg/ml/g for each of the peptides respectively, 
therefore representing 65%, 71% and 84% reduction in the secretion of this 
cytokine (p≤ 0.01).  A similar effect on IL-8 release was observed, with α-MSH 
causing a significant 53 % reduction, with detected levels of 137.26 ± 15.60 
pg/ml/g of IL-8 (p≤ 0.01, compared to DMEM-treated impacted controls). 
D[TRP]8-γ-MSH led to 54 % decrease down to 133.81 ± 22.05 (p≤ 0.01). 
Dexamethasone was slightly more effective in reducing IL-8 release with a 65 % 
decrease (104.10 ± 12.39 pg/ml/g) in the levels, detected in the supernatants of 








Figure 3.56 Effect of melanocortins and dexamethasone on chondrocyte death 
following impact as quantified by Imaris 7.1.1 Spots Analysis software.  
Bovine articular cartilage explants were treated with either DMEM (Panel A), α-MSH (3.0 
µg/ml; Panel B), [DTRP]8-γ-MSH (3.0 µg/ml Panel C), or 1.0 µM Dexamethasone (Panel D) 
for 30 min prior to blunt single impact delivered by a vertical drop tower and incubated for 6 
h. Cartilage explants were then incubated for 30 min at 37ºC with the fluorescent indicators 
Calcein-AM (5.0 µM) and Propidium Iodine (1.0 µM) for staining alive and dead cells 
respectively, immediately following which the explants were visualised using CLSM at x100 
magnification. Imaris 7.1.1 Spot Analysis software was used to quantify the number of viable 
(green) and non-viable (red) cells. Cell death was calculated based on the acquired results 
(Panel E). Data are representative images or Mean ± SEM of n=4 experiments, repeated in 






Figure 3.57. Effect of α-MSH, D[TRP]8-γ-MSH and dexamethasone on basal 
production of IL-1β , IL-6 and IL-8.  
Bovine articular cartilage explants were treated with DMEM, α-MSH (3.0 µg/ml), 
D[TRP]8-γ-MSH (3.0 µg/ml), or dexamethasone (1.0 µM) for 6 h and cell-free 
supernatants were collected and analysed for IL-1β (Panel A), IL-6 (Panel B) and IL-8 
(Panel C) via commercially available ELISAs (R&D Systems). Results were corrected 
per gram of tissue tested. Data are presented as Mean ± SEM of n=4 experiments 


















Osteoarthritis is a degenerative joint disorder, characterized by inflammation and 
cartilage degradation (Pelletier et al., 1991, Shinmei et al., 1991, Lotz et al., 
1992, Reboul et al., 1996, Melchiorri et al., 1998, Shlopov et al., 2000, 
Fernandes et al., 2002, Schuerwegh et al., 2003, Goldring et al., 2008, Rai et al., 
2008). It has long been known that the body produces endogenous compounds 
capable of repressing or resolving inflammation. These include annexin-1 (Flower 
and Blackwell, 1979, Hannon et al., 2003), galectins (La et al., 2003) and in the 
context of this thesis, the melanocortin peptides (Star et al., 1995, Ichiyama et 
al., 1999, Getting et al., 2001, 2002, Scholzen et al., 2003). They have been 
shown to possess a multitude of actions including inhibition of cytokines, 
chemokines and NO release from MØ (Star et al., 1995, Getting et al., 1999, 
2001 Kalden et al., 1999) and reduction of adhesion molecule expression on the 
endothelium (Kalden et al., 1999, Scholzen et al., 2003), all these actions help to 
modulate the host’s inflammatory response. Given the wealth of knowledge 
generated so far, few studies have looked at the potential anti-inflammatory 
effect of melanocortin peptides in osteoarthritis.  
This thesis investigates the ability of melanocortins to modulate pro-inflammatory 
cytokines production (such as IL-1β, IL-6, IL-8, MCP-1) and induce anti-
inflammatory protein release (HO-1 and IL-10), but also apoptotic pathways 
induction and cell death from cell line and primary bovine chondrocytes in vitro 
and in situ. This work has allowed for better understanding of their potential role 
of melanocortin peptides in modulating some of the inflammatory pathways and 
cell death aspects of degenerative pathologies such as osteoarthritis, but also to 
ascertain the role of chondrocytes in this disorder.  
Several main conclusions can be drawn from the results presented in this thesis. 
The first converges on the use of an in vitro cell culture-based model of 
chondrocyte inflammation that allows studying the effects of inflammatory 
mediators on chondrocyte metabolism and cytokine and chemokine production. It 
has been shown that monolayer cultures, yielding high cell density are one of the 
best tools for studying the cellular and molecular mechanisms of activated 





Furthermore, this thesis has evaluated whether the human C-20/A4 
chondrocytes are a suitable surrogate model for evaluating the effect of anti-
inflammatory drugs including melanocortin peptides on inflammatory mediator 
release from stimulated cells. The human C-20/A4 chondrocytic cell-line, and 
primary chondrocytes in vitro and in situ (cartilage explants) were investigated for 
expression of pro-inflammatory cytokines and cartilage degrading MMP 
production upon activation and the role that these cytokines play in cartilage 
metabolism (collagen type I and type II production) was also studied. These 
results suggested a possible role for chondrocytes in cartilage inflammation and 
damage.  
Secondly, functionally active MC receptors were detected in human C-20/A4 
chondrocytes and primary bovine articular chondrocytes, which upon activation 
led to a significant induction of cAMP formation, partial repression of pro-
inflammatory cytokine and matrix metalloproteinases production, and marked 
increase in production of the anti-inflammatory proteins HO-1 and IL-10.  
Thirdly, it was concluded that inhibition of MC3 activity by SHU9119 exacerbates 
the inflammatory response of the chondrocytes and abolishes the potent anti-
inflammatory effects displayed by D[TRP]8-γ-MSH, therefore suggesting a role for 
this receptor in modulating some of the inflammatory pathways elicited by 
activation of C-20/A4 chondrocytes.  
Finally, the protective effects of melanocortins were evaluated on TNF-α-induced 
chondrocyte death and inflammation, as well as identification of their 
cytoprotective and anti-inflammatory role in mechanically injured cartilage 
explants. During osteoarthritis ECM matrix degradation leads to tissue hydration 
that signifies a decrease in extracellular osmolarity and leads to chondrocyte 
sensitization to external stimuli. An in vitro model (using C-20/A4 chondrocytes) 
was established mimicking these conditions, which led to the production of pro-
inflammatory cytokines and MMPs and subsequently, the anti-inflammatory 
properties of the melanocortins in this model were confirmed. In all cases a 
strong correlation occurred with: melanocortin peptide dampening the pro-
inflammatory cytokine synthesis/release, inducing anti-inflammatory proteins and 





chondrocyte cell death resulting from both mechanical trauma (in the case of 
cartilage explants) and the cytotoxic effect of exogenous TNF-α.   
Chondrocytes play an important role in maintaining the integrity of cartillage, 
during osteoarthritis they become activated leading to the release of an array of 
pro-inflammatory mediators, apoptosis and alterations in the synthesis of ECM 
(Pelletier et al., 1991, Goldring et al., 1994b, Shlopov et al., 1997, 2000, Goldring 
et al., 2011). Immortalised chondrocytic cell lines have been developed to serve 
as easily accessible, reproducible models of chondrocyte function. Given the 
difficulty in obtaining human tissue, the use of human cell lines can be invaluable, 
in trying to dissect the inflammatory pathways involved in chondrocye function 
and identification of novel treatments for modulating these pathways.  Primary 
cultures of articular chondrocytes isolated from various animal and human 
sources have served as useful models for studying the mechanisms controlling 
the response of chondrocytes to various pro-inflammatory and catabolic factors 
and cytokines (Goldring, 2004). The use of human chondrocytes is problematic 
and the restricted access to human tissue posses great difficulties for using these 
cells as a surrogate model. The immortalized chondrocyte cell lines, instead of 
substituting for primary chondrocytes, may serve as models for increasing 
knowledge on chondrocyte function not achievable by the use of primary 
chondrocytes (Finger et al., 2004). Therefore a reproducible source of 
chondrocytes with human origin would be the most desirable model for studying 
cartilage function relative to human osteoarthritis (Goldring, 2004) and that is why 
the human cell line C-20/A4 chondrocytes were used to evaluate chondrocyte’s 










Effect of pro-inflammatory stimuli on nitric oxide release and on 
chondrocyte death. 
Inducible nitric oxide synthase (iNOS) gene expresses a calcium calmudolin-
independent enzyme which can catalyse NO production from L-arginine. The 
induction of iNOS activity has been demonstrated in a wide variety of cell types 
under stimulation with cytokines and LPS. Recent studies have indicated that 
human articular chondrocytes express iNOS (Schmidt et al., 2010).  C-20/A4 
chondrocytes monolayer cultures were stimulated with varying concentrations of 
H2O2, TNF-α, LPS and  MSU for 6 h and the ability of these stimuli to activate 
iNOS to produce NO was tested in conjunction with testing their effect on 
chondrocyte viability. Substantial amounts of NO, released from C-20/A4 cells 
following stimulation with H2O2 were detected at 6 h post stimulation via the 
Griess assay, demonstrating that the chondrocytes can react to oxidative stress 
by activating iNOS (Mendes et al., 2003a,b). In particular, the expression of iNOS 
has been associated with chondrocytes during the pathogenesis of OA 
(Grabowski et al., 1997) and the overproduction of nitric oxide was detected in 
synovial tissue and articular cartilage (Melhiorri et al., 1998). Mendes and 
collegaues., however demonstrated that H2O2 on its own cannot induce iNOS in 
human articular chondrocyte, but rather mediates IL-1β-induced iNOS expression 
and activation (Mendes et al., 2003 a,b). However, in preliminary studies, H2O2 
failed to cause significant induction in the release of IL-1β. Therefore the ability of 
C-20/A4 chondrocytes to release nitrate following H2O2 activation is not in 
agreement with previously published work by Mendes et al (Mendes et al., 2003 
a,b) and could thus be a characteristic of our cell-line. 
Inflammation is a characteristic feature of osteoarthrtis (Hegemann et al., 2005, 
Maccoux et al., 2007) and the role of TNF-α, as inflammation-propagator is well 
documented (Oppenheim et al., 1989; Pelletier et al., 1991; Westacott et al., 
1996; Martel-Pelletier et al., 1999). TNF-α receptors have been detected on the 
surface of human articular chondrocytes with expression levels significantly 
increased in osteoarthritic compared to healthy tissue (Westacott et al., 1994). 
This thesis demonstrates that TNF-α can activate C-20/A4 chondrocytic iNOS to 
produce NO in amounts significantly higher than those detected in non-





but was not significantly different from those observed following stimulation with 
lower concentrations of the cytokine. This ability of TNF-α to induce nitrite 
release agrees with findings obtained from TN-α-stimulated canine chondrocytes, 
where human recombinant TNF-α up-regulates iNOS expression (Rai et al., 
2008). It was concluded that TNF-α was able to induce nitric oxide synthesis in 
chondrocytes, suggesting a possible role of this cytokine in chondrocyte-induced 
inflammation and possibly matrix metalloprotienase induction.  
To further our understanding of the most appropriate stimulus for activation of C-
20/A4 chondrocytes the effect of LPS (the principle component of the outer 
membrane of Gram-negative bacteria) was determined, as cells have been 
shown to generally respond to LPS by up-regulating expression of variety of 
inflammatory cytokines and cytotoxic mediators, such as NO, observed in arthritis 
(Haglund et al., 2008, Campo et al., 2010). C-20/A4 chondrocyte stimulation by 
various concentrations of TNF-α and LPS, led to significantly elevated NO 
production, an event accompanied by a concentration-dependent increase in 
chondrocyte death. The effect of TNF-α and LPS on this parameter was modest 
but sufficient for the purposes of this study, thus making them suitable for further 
evaluation in this study.  
Given the role that MSU crystals play in gouty arthrirtis (McCarty et al., 1966, 
McGill and Dieppe, 1991, Chilappa et al., 2010) by depositing into the knee joint 
and driving leukocyte migration and the release of pro-inflammatory cytokines 
including IL-1β and KC in mouse (Getting et al., 2006), their effect on 
chondrocytes was investigated. However, MSU crystals were unable to activate 
these cells at any of the concentrations tested, since a non-significant amount of 
nitrite release and pro-inflammatory cytokines and chemokines were detected  To 
date no studies have shown that this cell line can be activated by MSU crystals, 
although a recent study has shown that MSU crystals can cause an upregulation 
in COX-2 in primary chondrocytes (Lee et al., 2009). The lack of effect could be 
due to differences often observed between primary and immortal cell-lines. 
However, although primarily thought to be the causative agent for gouty arthritis, 
there is conflicting evidence over the role they play in OA with a suggestion that 
urate crystals play an important role in contributing to the onset and/or 





Osteoarthritis is accompanied by extended apoptotic chondrocyte death, which 
has been thought to play a central role in the initiation and progression of the 
disorder (Blanco et al., 1998; Kim et al., 2000; Aigner et al., 2001). A diverse set 
of stimuli can trigger the apoptotic process in virtually all eukaryotic cells (Steller, 
1995, Thompson, 1995); therefore the cytotoxicity of various concentrations of 
H2O2, TNF-α, LPS and  MSU on C-20/A4 chondrocytes via the mitochondrial 
functionality assay, MTT, which is a convenient assay used to monitor cell death 
quantitatively rather than qualitatively was investigated. H2O2, caused an 80 to 95 
% reduction in cell-vialbility, even at the lowest concentration used.  The 
reduction in chondrocyte cell-viability due to the endogenous production of 
excessive amounts of ROS has been previously described (Del Carlo and 
Loeser, 2002). In addition, H2O2 stimulation in C-20/A4 chondrocyte model 
provides data relevant to chondrocyte death initiated by endogenous ROS 
production, which has been reported to occur after mechanical trauma (Kurz et 
al., 2004). The use of this stimulus validated that C-20/A4 chondrocytes were 
able to respond to oxidative stress; however its use was discontinued for the 
present study due to the amount of cell death determined. Given the high-level of 
cell-death attributed to using H2O2, the effect of TNF-α on this parameter was 
determined. TNF-α led to a marked concentration-dependent cell death, causing 
chondrocytes to possibly undergo cell death through recruitment of the 
mitochondrial pathway of apoptosis thought blc2 family (Thomas et al., 2000). Its 
cytotoxicity was highest at 80.0 pg/ml, leading to a near 30 % reduction in cell 
viability, whilst lower concentrations, such as 60.0 pg/ml led to a more moderate 
15 % decrease in cell viability and apoptosis. Moreover, the ability of TNF-α to 
trigger apoptosis in chondrocytes has been previously confirmed (Li et al., 2011). 
LPS stimulation caused ~20% decrease in chondrocyte viability, with lower 
concentrations (1.0 µg/ml) being more cytotoxic than higher concentrations (10.0 
µg/ml). Taken together, these results demonstrate that both TNF-α and LPS 








C-20/A4 chondrocytes respond to TNF-α and LPS by expressing and 
releasing pro-inflammatory cytokines. 
Following the identification that C-20/A4 human chondrocytes respond to TNF-α 
and LPS, the effects of these inflammogens on the release of pro-inflammatory 
cytokines/chemokines, degradive enzymes and catabolites were evaluated since 
they are released from chondrocytes upon stimulation (Goldring et al., 2011) 
Initially, RT-PCR showed that following stimulation with TNF-α and LPS there 
was an upregulation in mRNA levels of IL6 and IL8  with  TNF-α (60.0 pg/ml: a 
concentration chosen for sub-maximal release of nitrite and cell death) causing a 
marked increase in both IL6 and IL8 expression at all time points evaluated, with 
a peak at 2 h and decreasing thereafter. Upregulation of pro-inflammatory 
cytokines has been previously reported in this cell-line (Palmer et al., 2002) and 
that this observation is translated to primary chondrocytes (Rai et al., 2008). 
Given that these cells are in  monolayers, the fast upregulation of these genes 
could be explained as they are exposed to the inflammogen in the cell culture 
media directly, so they can act immediately after stimulation (Rai et al., 2008). 
After identifying the 6 h time-point as suitable for subsequent experiments, since 
it caused a sub-maximal up-regulation in IL-6 and IL-8 mRNA, different 
concentrations of TNF-α and LPS were evaluated.  TNF-α caused a bell-shaped 
response with 60.0 pg/ml causing a sub-maximal upregulation in the cytokines 
genes. These results are in accordance with published data, where TNF-α has 
been shown to stimulate the production of variety of pro-inflammatory cytokines 
(Shinmei et al., 1991; Shlopov et al., 2000; Rai et al., 2008) 
Even though LPS has been used to induce cartilage degradation for the last 30 
years (Jasin, 1983, Morales et al., 1984, Tian et al., 1989), the expression of its 
membrane receptor (TLR4) on chondrocytes and their response to LPS have 
only been recently investigated (Kim et al., 2006; Haglund et al., 2008). In order 
to gain a further insight into how chondrocytes respond to this pro-inflammatory 
stimulus, C-20/A4 chondrocytes were stimulated with increasing concentrations 
of LPS (0.1 – 1.0 µg/ml) and detected a concentration-dependent elevation in IL-
6 and IL-8 expression, peaking at 1.0 µg/ml, which was in accordance with other 





Following the identification of an upregulation in IL-6 and IL-8 mRNA, an ELISA 
assay was used to ascertain whether this message was genuinely translated into 
protein.  IL-6 and  IL-8  release was detected at 2, 6 and 24 h after stimulation 
with TNF-α and LPS and is in agreement with previous studies (Campo et al., 
2008, Henrotin et al., 1996, Lotz et al., 1992). For this part of the study, the 
concentration range of LPS was broadened by including 3.0 µg/ml and 10 µg/ml, 
in order to further investigate the effect of the concentration LPS on the 
production of these cytokines and to identify if a bell-shaped response could be 
observed. TNF-α and LPS caused a time and concentration-dependent effect 
with significant elevations in both IL-6 and IL-8 production. However, at 24 h post 
stimulation, all concentrations of LPS were equipotent, thus suggesting that a 
plateau might be reached at that time point. Previous studies have demonstrated 
that production of IL-1β, IL-6, IL-8, and TNF-α was responsive to a wide range of 
LPS concentrations (0.1 ng/ml – 10.0 µg/ml) and that these cytokines were first 
detected at 1 – 4 h and reached a plateau levels after 6 h (DeForge et al., 1992).  
The importance of these findings is related to the fact that the C-20/A4 cell-line 
responds to inflammatory stimuli in a similar fashion to primary cells/cartillage 
(Henrotin et al., 1996; Campo et al., 2008). Taken together, these findings 
demonstrated that the C-20/A4 chondrocytes are capable of expressing and 
producing IL-6, therefore suggesting that IL-6 may also play a physiological role 
in cartilage. An interesting finding of this study is the novel expression of IL-8  by 
the human chondrocytic cell line, showing significant up-regulation following TNF-
α-stimulation. Currently, the role of this chemokine has not been thoroughly 
investigated in human cartilage – a weak IL-8 mRNA signal had been detected in 
normal untreated chondrocytes (Lotz, 1992; David, 2007) and freshly isolated 
chondrocytes have been shown to spontaneously release detectable amount of 
IL-8 (Fan et al., 2005). Our data confirm these findings suggesting that IL-8 and 
other CXC chemokines, may trigger the release of matrix degradative enzymes 
and therefore the subsequent cartilage destruction (Lotz et al., 1992).  
In order to broaden our investigative spectrum of pro-inflammatory cytokines, we 
looked at IL-1β and MCP-1 mRNA and protein in response to TNF-α and LPS 
stimulation. These cytokines were chosen since IL-1β is active locally within 





progression (Fernandes, 1999 ; Kobayashi, 2005; Lopez-Armada, 2006; Kapoor, 
2011). Moreover, IL-1β has been immunolocalized in chondrocytes taken from 
human OA cartilage with histologically confirmed degenerative changes (Dayer, 
2002; Goldring et al., 2011) with its role as propagator of inflammation leading to 
cartilage degradation being well documented (Westacott, 1996; Martel-Pelletier, 
1999; Attur, 2000; Moldovan, 2000; Lopez-Armada, 2006; Kapoor, 2011).  
MCP-1 evels were then determined following activation of C-20/A4 chondrocytes 
with varying concentrations of TNF-α and LPS. Although its main role is 
monocyte chemotaxis and activation (Zachariae et al., 1990), it is involved in a 
vital pathologic relationship between chondrocytes and the synovium, where 
through the release of MCP-1, chondrocytes “invite” mononuclear phagocytes 
into the cartilage, resulting in rheumatoid pannus formation onto the articular 
surface (Villiger et al., 1992). Here, TNF-α and LPS caused MCP-1 to be release 
with low levels of detection at early time-points and detectable amounts at 6 h. 
The time-frame for MCP-1 release observed in chondrocytes is supported by 
previous studies, which demonstrated that maximal production of MCP-1 was 
detected 4 h  post induction of zymosan-peritonitis (Ajuebor et al., 1998). In 
addition, work by Lotz and colleagues, reveiled using in situ hybridization of 
cartilage organ cultures that chondrocytes in the superficial tangential zone 
responded within 2 h of stimulation with IL-1 by significantly increasing MCP-1 
transcripts and chondrocytes in deeper layers responded by 4 h and reached 
maximum MCP-1 expression by 8 – 12 h (Villiger et al.,1992). This release of 
MCP-1 from chondrocytes highlights the fact that monocytes can migrate into the 
joint, therefore promoting cartilage degradation in the later stages of OA. 
Therfore, targetting these cytokines may play an important role in stopping the 
development of this pathology.   
Following the identification of cytokine release from activated chondrocytes their 
effect on catilage degradation processes was determined (Brinckerhoff, 1992, 
Goldring et al., 2008,  2011, Grassel et al., 2009), consequential from the up-
regulation and activation of MMPs (Shlopov, 1997, 1999, 2000). The effect of 
TNF-α and LPS on matrix degradative enzymes was investigated as these 





(Gadher et al., 1990, Kevorkian et al., 2004). Generally, collagenase expression 
is believed to be  NF-κB dependent, a pathway that is also employed by the TLR 
receptors (Zhang et al., 2008). TNF-α and LPS caused a concentration-
dependent bell-shaped increase in MMP1 and MMP13 mRNA levels in C-20/A4 
chondrocytes. These results are in agreement with a previous study, in which a 
four-fold increase in MMP1 was was observed following stimulation with IL-1β 
(Grange et al., 2006) although it is reported for the first time here that MMP13 is 
also upregulated in these cells. This upregulation in MMP1 and MMP13 has 
previously been shown in primary chondrocytes (Shlopov et al., 2000; Rai et al., 
2008). This was substantiated by the observation, that the levels of these 
collagenases increased with extended incubation times observed here and 
previously (Rai et al., 2008). Interestingly, MMP1 expression was significantly up-
regulated in the stimulated samples, showing high similarity to the expression 
profile of MMP1 in normal and OA human knee cartilage, and demonstrating the 
opposite of what takes place in the human hip during end stages of OA, where 
MMP1 is down-regulated (Kevorkian et al., 2004). However, the current increase 
in the expression could suggest a possible role of MMP1 in this in vitro C-20/A4 
chondrocyte model, and suggest that it resembles more the processes that occur 
in knee OA, rather than than that of the hip OA.  
Statistically-significant changes were observed in the expression profile of MMP3 
with decreased expression, in a concentration-dependent manner, following a 
stimulation with both TNF-α and LPS for 6 h. This reduction in MMP3 has not 
been previously reported in this cell-line and correlates with data in knee OA 
cartilage (Bau et al., 2002). The down-regulation of MMP3 in this in vitro model is 
interesting especially when compared to the reported increase in the MMP3 
levels in the synovial fluid of RA patients (Matsuno et al., 2001). However, MMP3 
is reported to be the most highly expressed matrix metalloproteinase in normal 
knee cartilage, suggesting a maintenance function of this enzyme in normal 
cartilage metabolism, which was dysregulated in OA (Bau et al., 2002; Kevorkian 
et al., 2004).   
Further examination of the collagenases showed that the main catabolic enzyme 
for type II collagen found in cartilage, MMP13, was increased in TNF-α-





it is the principal collagenase in OA (Kevorkian et al., 2004). Previous studies 
have demonstrated that IL-6 promotes cartilage degradation (Shlopov et al., 
2000) by directly inducing MMP1 and MMP13. Here, its demonstrated that there 
is simultaneous up-regulation of IL-6 and MMP13, therefore confirming the 
hypothesis that IL-6 and MMP13 are involved in the progression of OA.  
Overexpression of these genes in the cartilage may further induce an increase of 
hypertrophic chondrocytes (Goldring et al., 2011, Tchetina et al., 2005) resulting 
in the destruction of the upper-layer cartilage matrix and progression of cartilage 
degeneration.  
In healthy articular cartilage, chondrocytes are actively maintaining the 
expression and ratio of collagens and proteoglycans (Hall, 1998). Chondrocytes 
are very sensitive to pro-inflammatory cytokines, an observation supported by 
this study. Studies have reported that pro-inflammatory cytokines either reduce or 
enhance the production of type II collagen, a marker of normal function of 
chodrocytes (Ho et al., 2006). Therefore to determine if the cell-line responded in 
a similar fashion to primary cells, the direct effect of TNF-α on the expression of 
the cartilage specific collagens was determined by RT-PCR. TNF-α stimulation 
caused COL1A1 and COL2A1 levels to decline significantly, therefore inhibiting 
the chondrocyte compensatory synthesis pathways, required to restore integrity 
of the degraded matrix (Goldring and Goldring, 2004). It is important to point out, 
that TNF-α did not influence the differentiation indicator ratio of COL2A1: 
COL1A1 detected in unstimulated C-20/A4 cells, which is an important 
observation as dedifferentiated cells would be undesirable for the purposes of 
this study. 
To ensure that our in vitro cell-line system responded in a similar fashion to 
primary cells the effect of the glucocorticoid dexamethasone and the NSAID 
Indomethacin was evaluated given the role they play in the treatment of 
inflammatory pathologies. Glucocorticoids are powerful anti-inflammatory 
molecules shown to be able to repress transcriptional activation of genes 
including IL1, IL-6, IL-8, TNF-α, γ-interferon, colony stimulating factor (CSF)-
1/macrophage, granulocyte macrophage (GM)-CSF (Taniguchi, 1988). Most of 
these genes are activated by the transcription factors NF-κB and AP-1, and their 





(Vayssiere et al., 1997). NSAIDs exert their effects by inhibiting COX enzyme 
(part of the arachidonic acid cascade) and reducing prostaglandins leading to a 
diminished inflammation and pain (Vane, 1971, 1976). At present only COX-1 
and COX-2 are clinically relevant, with COX-1 regarded as housekeeping 
enzyme responsible (via prostaglandins and thromboxane A2) for physiological 
functions including protection of gut mucosal integrity and vascular homeostasis 
(Chen et al., 2008), whilst COX-2 appears to be a more important mediator of 
inflammation and thus a key factor in arthritic pain (Chen et al., 2008).  
Dexamethasone and Indomethacin were administered 30 min prior to TNF-α 
stimulation of C-20/A4 chondrocytes. Dexamethasone and indomethacin have 
previously been shown to inhibit cytokine production in other cell systems 
(Mukaida et al., 1991). Glucocorticoids activate intracellular receptors that then 
bind to glucocorticoid-responsive elements in the promoters of various genes, or 
inhibit NF-κB transocation in the nucleus (Vayssiere et al., 1997). Furthermore, 
they inhibit AP-1 DNA binding ability and therefore block the respective gene 
expression (Vayssiere et al., 1997). In this study they were shown to inhibit TNF-
α (60.0 pg/ml) induced expression of IL-6 and IL-8 mRNA and protein, an effect 
accompanied by a abrogation of the expression of MMP1, MMP3 and MMP13 
over the time-course. This ability to modulate inflammatory pathways in this cell-
type was in agreement with previous studies utilizing primary chondrocytes 
(Richardson and Dodge, 2003).  Both the glucocorticoid dexamethasone and the 
NSAID indomethacin completely abrogated the production of IL-6 and IL-8 at all 
time points tested, and in doing so they negatively surpassed even the basal 
levels of production of these cytokines detected in unstimulated cells. However, 
although this effect may be desireable in management of acute inflammation, in 
chronic inflammatory diseases such as OA, this could lead to supression of the 
HPA axis and lead to impaired wound healing, Cushings syndrome and 
opportunistic infections (Gupta et al., 2000; Alekseev et al., 2001; Dorscheid et 
al., 2006). 
Data generated here looking at exempler cytokines, shows that TNF-α and LPS 
alone  trigger a cascade of cytokines in this in vitro model. The results obtained 
from the ELISA and the PCR revealed a minimum 2-fold increase in inflammatory 





observation that classical anti-inflammatory drugs (dexamethasone and 
indomethacin) were able to modulate these pathways. These data sugests that 
its possible to use this cell-line as a surrogate in vitro model for investigating 
inflammatory pathways within these cells and to evaluate the effects of the 
melanocortin peptides.  
Melanocortin receptor expression in C-20/A4 chondrocyte and the role of 
melanocortins in modulation of pro-inflammatory cytokine production  
Melanocortin peptides have potent antipyretic and anti-inflammatory effects 
(Grabbe, 1996; Getting et al., 1999, 2001, 2008, 2009; Getting 2002, 2006, 
Luger, 2000), which they deliver via activation of a family of 7TM-GPCRs 
(Catania et al., 2004). These are termed melanocortin receptors and to date five 
subtypes have been identified (Getting et al., 2009). Previous research within the 
field of inflammation has highlighted that these peptides can modulate the effect 
of several pro-inflammatory cytokines and chemokines such as TNF-α, IL-1β, IL-
6, and IL-8 (Catania et al., 1999; Grassel et al., 2009) and they are inducers of 
the anti-inflammatory cytokine IL-10 (Redondo et al., 1998; Lam et al.,  2005) . 
This study tested the hypothesis that targeting melanocortin receptors may 
provide a novel therapeutic approach to treatment of chondrocyte inflammation, 
such as that observed in OA.  
For this purpose, pharmacological and molecular techniques were used 
employing the melanocortin receptor pan-agonist α-MSH (Catania et al., 2006; 
Getting, 2002, 2006; Getting et al., 2009; Rajora et al., 1996, 1997) and the 
selective MC3 agonist D[TRP]8-γ-MSH (Grieco, 2000; Getting, 2006; Getting et 
al., 2008, 2009). To date, two receptors have been identified to mediate the anti-
inflammatory effects of melanocortin peptides, namely the MC1 and MC3 
(Getting, 2002, 2006, Getting et al., 2009). However, some evidence points 
towards a role played by MC5 in inflammation, since its expression has been 
detected on B-lymphocytes (Buggy, 1998) and T-lymphocytes (Taylor and 
Namba, 2001), suggesting a potential role in immuno-modulation.  
Initially, expression of MC1, MC3 and MC5 was determined in C-20/A4 
chondrocytes, reported here for the first time with a strong signal MC1 and MC3, 





was identified in the human chondrosarcoma cell line HTB-94 (Yoon et al., 2008), 
and MC1, MC3 and MC5 transcripts have been detected in primary articular 
chondrocytes (Grässel et al., 2009). Whilst the detection of MC1 is in agreement 
with previous studies, to our knowledge the detection of MC3 expression in 
human chondrocytes is novel. Given the apparent disparity in the results 
observed and those generated previously in primary cells, western blotting was 
used to determine if mRNA for MC1 and MC3 was translated into protein.  
Following the identification of mRNA and protein for MC1,3 and mRNA for MC5, 
the functionality of the receptors was determined by evaluating a panel of 
melanocortin peptides (displaying different receptor selectivity) on cAMP 
accumulation as detected by EIA. Melanocortin receptors are positively coupled 
to adenylate cyclase, which upon activation causes increase in intracellular 
cAMP formation (Catania et al., 2006 ; Gantz et al., 2003; Getting et al., 2009). In 
order to determine the functionality of the melanocortin receptors, at first we 
tested whether the MC1 receptor agonist α-MSH, the MC3 selective agonist 
D[TRP]8-γ-MSH, and the MC5 selective agonists SHU9119, PG901 and PG911 
could induce cAMP accumulation in the human C-20/A4 cells. Our functional 
studies showed that both α-MSH and D[TRP]8-γ-MSH were able to ellicit a 
significant and concentration-dependent increase in cAMP formation, this effect 
being observed in C-20/A4 chondrocytes for the first time. Whilst α-MSH has 
previously been shown to induce cAMP accumulation in chondrocytes (Grassel 
et al., 2009) the ability of the MC3 agonist D[TRP]8-γ-MSH to incude increases in 
cAMP has not been previously demostrated in chondrocytes. This increase in 
cAMP occurred in a bell-shaped manner and is in agreement with previous 
studies utilizing these peptides in other cell-types (Getting et al., 2006). 
Given that MC5 mRNA was observed in C-20/A4 chondrocytes and has 
previously been shown to be epxressed on primary articular chondrocytes 
(Grassel et al., 2009), the effect of selective MC5 agonists PG901, PG911 
(Grieco et al., 2002) and the mixed agonist/antagonist SHU9119 (Hruby et al., 
1995) was evaluated. Treatment of cells with these peptides at all the 
concentrations evaluated did not cause an increase in cAMP accumulation. This 





to the weak mRNA expression of this receptor, not translated to protein. Whilst 
we cannot completely rule out the expression of a functionally active MC5 in the 
C-20/A4 cell model, given the fact that more selective compounds maybe 
developed in the future, which would allow further investigation of this receptor. 
At present, it is highly unlikely that this receptor plays a role in modulating the 
effects of the melanocortin peptides given the low expression level and lack of 
functionality displayed here in this model.  
Given that α-MSH and D[TRP]8-γ-MSH significantly elevated cAMP levels, the 
peptides were evaluated in the presence of the MC3/4 anatagonist SHU9119 (Fan 
et al., 1997) used at a concentration previously shown to inhibit the cAMP 
accumulation elicited by these peptides (Getting et al., 2006), thus allowing 
identification of whether MC1 or MC3 was involved. Incubation of the C-20/A4 
chondrocytes with SHU9119 was able to inhibit D[TRP]8-γ-MSH confirming 
previous findings in other cell types (Getting et al., 2006) and in models of 
inflammation (Getting et al., 2008, Leoni et al., 2008, Patel et al., 2010), whereby 
D[TRP]8-γ-MSH mediates its effects via MC3. Not surprisingly, SHU9119 (10.0 
µg/ml) failed to block α-MSH at all concentrations, except 3.0 µg/ml, which 
caused an extremely modest reduction in cAMP levels. At MC3, the peptides 
ACTH1-39, α-MSH, β-MSH and γ-MSH are equipotent (Getting, 2006) and even 
though α-MSH preferentially activates MC1, it cannot be excluded that, at this 
concentration, some of the increase in cAMP observed with α-MSH may be 
inpart due to activation of the MC3. 
Numerous studies have highlighted the ability of melanocortin peptides to inhibit 
cytokine release in vitro (Lam et al., 2005, 2006) and also in vivo models of 
inflammation (Ceriani et al., 1994, Getting, 2002, Getting et al., 2003, 2006, 
2008). However, to date only one study has investigated the effect of 
melanocortin peptides on chondrocytes (Grässel et al., 2009) and none using the 
selective MC3 agonist D[TRP]8-γ-MSH. C-20/A4 chondrocytes were treated with 
α-MSH (3.0 µg/ml), D[TRP]8-γ-MSH (3.0 µg/ml), and SHU9119 (10.0 µg/ml) to 
ascertain their effect on basal release of cytokines from these cells. In order to 





1β, IL-6, IL-8 and MCP-1 levels were determind by ELISA and  showed that none 
of the peptides caused an elevation in basal cytokine release from these cells.  
The effect of melanocortin peptides on TNF-α induced inflammatory markers, 
was then evaluated since its has been shown to be involved in activation of 
chondrocytes leading to the degradation of cartillage within the knee joint. α-MSH 
has long been known to suppress inflammation by down-regulating the 
expression of pro-inflammatory cytokines, and to have anti-inflammatory and 
immuno-modulatory actions in rodent models of inflammation in a corticosterone-
independent manner (Getting et al., 1999). Here it inhibited TNF-α-induced 
release of IL-1β, IL-6, IL-8 and MCP-1 from C-20/A4 chondrocytes in a 
concentration-dependent manner. The peptide displayed potent anti-cytokine 
effects at both 2, and 6 h, a similar observation that was noted in primary murine 
peritoneal macrophages (Getting et al., 1999) and macrophage cell-lines (Lam et 
al., 2006). The peptide did not elicit any effect following 24 h incubation. The 
suppression of IL-1β, IL-6 and IL-8 by α-MSH in C-20/A4 chondrocytes is in 
accordance with the overall anti-inflammatory and protective capacity of the 
peptide (Catania et al., 2004). 
Given the elevation in cAMP observed with the MC3 agonist D[TRP8]-γ-MSH, it 
was evaluated in this model. Here the effect of D[TRP]8-γ-MSH (0.1 – 30.0 µg/ml) 
on modulation of pro-inflammatory cytokine release from human C-20/A4 
chondrocytes activated by TNF-α was determined. C-20/A4 chondrocytes were 
treated with the selective melanocortin peptide for 30 min prior to stimulation with 
TNF-α, and subsequently incubated for 2-24 h, when supernatants were 
collected and analysed for IL-1β, IL-6 and IL-8 release. D[TRP]8-γ-MSH showed a 
bell-shaped inhibition of IL-1β release with 3.0 µg/ml and 10.0 µg/ml being 
consistently the most potent concentrations, causing ~ 70-80 % inhibition. 
Similarly, a bell-shaped response in IL-6 was observed following 2 and 6 h of 
incubation, peaking at 3.0 µg/ml D[TRP]8-γ-MSH, however, when the treatment 
was continued for 24 h, the peptide showed a concentration dependent inhibition 
of IL-6. IL-8 production was inhibited by D[TRP]8-γ-MSH in a concentration-
dependent manner at all time points, with 10.0 and 30.0 µg/ml being the most 





These data highlight for the first time the ability of this peptide to inhibit cytokine 
release from chondrocytes. The peptide displayed efficacy at all time-points 
evaluated and was still active at 24 h post treatment, correlating with the findings 
of this peptide in urate crystal-induced inflammatory cytokine release from 
macrophages (Lam et al., 2005) The maximal anti-inflammatory effect at 2 and 6 
h post stimulation was reached by 3 and 10.0 µg/ml of D[TRP]8-γ-MSH 
concentrations previously shown to be effective (Getting et al., 2006, 2008) with 
a 70-80 % inhibition of IL-1β release. 
This ability of the peptide to supress cytokine release was recently confirmed in a 
model of LPS-induced lung inflammation (Getting et al., 2008). With respect to 
models of arthritis α-MSH has been shown to repress experimental adjuvant-
induced arthritis in rats (Ceriani et al., 1994), whilst a recent study by the Perretti 
group has highlighted the importance of the MC3 agonist D[TRP]8-γ-MSH in a 
model of serum transfer arthritis where the peptide was effective in wild type mice 
but not in MC3-/- null mice (Patel et al., 2010). However, neither of the selective 
MC5 agonists (MC3/4 antagonists) PG901 and PG911 was able to cause 
significant decrease of TNF-α-induced pro-inflammatory cytokines, which 
together with the inability of the peptides to elicit cAMP increases, suggesting 
that this receptor is not functionally active in C-20/A4 chondrocytes. 
The anti-inflammatory effects of α-MSH and D[TRP]8-γ-MSH were evaluated on 
IL-6 and IL-8 transcription levels in the presence or absence of the MC3/4 
antagonist SHU9119, at a dose previously shown to abrogate the inhibitory 
effects of γ2-MSH on chemokine release (10.0 µg/ml) (Getting and Perretti, 
2000). α-MSH has been shown previously shown to suppress an array of 
inflammatory cytokines including TNF-α (Rajora, 1997 ; Delgado Hernandez, 
1999) and IL-1β (Getting et al., 2003). α-MSH has tremendous effect on 
chemotaxis, further supported by the finding of Luger’s group that this 
melanocortin peptide inhibits the production and release of IL-8 (Brzoska et al., 
1999). Our study demonstrates and confirms the anti-inflammatory effect of not 
only α-MSH, but also D[TRP]8-γ-MSH in human C-20/A4 chondrocytes. The pre-
treatment of C-20/A4 chondrocytes with α-MSH (3.0 µg/ml) prior to TNF-α 





(25 %), therefore supporting the collected evidence that this peptide and its 
putative receptor have marked impact on IL-6 and IL-8 regulation. Additionally, α-
MSH not only inhibited the transcription of these genes, but also the protein 
release of IL-6, IL-8 and MCP-1 from the cells. Cytokine ELISAs showed that 
there was a 70 %, 60 % and 21 % reduction in IL-6, IL-8 and MCP-1 protein 
levels released from C-20/A4 chondrocytes. The ability of α-MSH to exert anti-
inflammatory actions has been well documented (Martin, 1991 ;Lipton, 1997, 
1999; Catania, 1999), whereas the use of the mixed MC3/4 antagonist SHU9119 
(Hruby et al., 1995; Fan et al., 1997; Getting et al., 2006) did not affect the 
observed anti-cytokine effects of α-MSH, suggesting that the latter must be 
preferentially activating MC1 in order to exert its effect.  
D[TRP]8-γ-MSH was also able to diminish pro-inflammatory cytokines expression 
causing 27% and 36% inhibition of TNF-α-stimulated IL-6 and IL-8 transcription, 
respectively. Furthermore, similarly to the action of α-MSH, D[TRP]8-γ-MSH led 
to 68 %, 45 % and 26 % reduction in IL-6, IL-8 and MCP-1 production, 
respectively, an observation in accordance with other studies exemplifying the 
anti-inflammatory and anti-migratory effects of D[TRP]8-γ-MSH on cultured Mø 
both in vitro and in vivo (Getting et al., 2006). An important finding was that 
SHU9119 completely obliterated the effect of D[TRP]8-γ-MSH not only on 
cytokine transcription levels, but also on the synthesis and release of IL-6, IL-8 
and MCP-1 from C-20/A4 cells compared to the effect of D[TRP]8-γ-MSH alone. 
These data, together with the functional studies of MC1 and MC3 receptor 
activation, highlight not only the anti-inflammatory properties of α-MSH and 
D[TRP]8-γ-MSH, but also confirms that both MC1 and MC3 might be the main 
targets for inflammation modulation in C-20/A4 chondrocytic system. Of interest 
is the fact that unlike dexamethasone and indomethacin, neither of the 
melanocortin peptides caused a complete abrogation of pro-inflammatory 
cytokine production. In contrast, they modulated the production of the tested 
cytokines, therefore allowing for some level of synthesis from the chondrocytes.  
A novel finding of this study is the expression of functionally active MC3 on C-
20/A4 chondrocytes and that agonism of this receptor modulates the 





However in this cell-line no one has ever investigated the effect of melanocortin 
peptides or their receptors on matrix metalloproteinases expression following 
TNF-α stimulation. We have shown that TNF-α potently up-regulates the 
expression of MMP1 and 13 and that there is an upregulation in pro-inflammatory 
cytokines confirming previous findings (Fernandes et al., 2002; Martel-Pelletier et 
al., 1999). α-MSH pre-treatment of TNF-α-activated C-20/A4 chondrocytes led to 
a marked 48 % reduction in transcription of MMP1, one of the interstitial 
collagenases, significantly up-regulated in human osteoarthritic cartilage 
compared to healthy tissue (Reboul et al., 1996; Kevorkian et al., 2004).  
Collagenase 3, or MMP13, is highly up-regulated in chondrocytes isolated from 
human osteoarthritic chondrocytes (Shlopov et al., 1997) and following TNF-α 
stimulation (Rai et al., 2008), and was significantly down regulated by α-MSH 
(3.0 µg/ml) in our model of TNF-α-activated C-20/A4 chondrocytes. The 
melanocortin peptide down-regulated the expression of MMP13 by 67 %, 
compared to TNF-α-stimulated levels. These findings are in agreement with a 
recent study showing that α-MSH can inhibit TNFα-induced MMP13 expression 
in the chondrosarcoma cell line HTB-94 (Yoon et al., 2008).  
In order to additionally confirm the involvement of MC1 and MC3 in the 
transmission of these effects, SHU9119 was added in conjunction with α-MSH, 
but no significant effect was observed on the expression of either MMP1 or 
MMP3. However, an interesting observation was made when analysing the effect 
of this combination on MMP13 expression. RT-PCR showed that SHU9119 and 
α-MSH synergistically inhibited the expression of this collagenase, leading to 87 
% reduction compared to TNF-α-stimulated levels, thereby suggesting other 
mechanism by which this combination might affect the expression of this 
particular collagenase.  
Similar results were obtained following pre-treatment of chondrocytes with the 
selective MC3 agonist. D[TRP]8-γ-MSH was more potent than α-MSH in reducing 
MMPs expression, with reductions of 89 %, 76 % and 92 % in MMP1, MMP3 and 
MMP13 expression, respectively, compared to levels detected following TNF-α 





the effect was completely attenuated in all cases, confirming the involvement of 
MC3 in the modulation of degradative matrix metalloproteinases. All these actions 
contribute to a local attenuation of the host’s inflammatory response. Given the 
wealth of knowledge generated so far, few studies have looked at the potential of 
the melanocortins in inducing anti-inflammatory mediators in chondrocytes 
(Iannone et al., 2001; Fernandes et al., 2002).  
In contrast to the suppressive effects of endogenous melanocortin peptides on 
pro-inflammatory cytokines production and release, they have been shown to 
elicit significant elevations in the production of the anti-inflammatory cytokine with 
potent immuno-suppressive properties, IL-10 (Bhardwaj et al., 1996; Redondo et 
al., 1998; Lam et al., 2006). The importance of IL-10 in melanocortin receptor 
biology was first demonstrated in a model of contact hypersensitivity, where an 
antibody against this cytokine abrogated the protective action attained by α-MSH 
application (Grabbe et al., 1996). The anti-inflammatory effect of α-MSH 
observed here and in other models, could be dependent on IL-10 induction, given 
that α-MSH was inactive in IL-10 knock out mice in a murine model of allergic 
airway inflammation (Raap et al., 2003). This study sought to reveal, whether α-
MSH and D[TRP]8-γ-MSH could stimulate the production of IL-10 in C-20/A4 
chondrocytes in the presence and absence of TNF-α. Additionally, the ability of 
SHU9119, PG901 and PG911 was tested in order to investigate whether these 
peptides could stimulate their cognate receptor (MC5) to induce IL-10 synthesis. 
Human chondrocytes from healthy and osteoarthritic cartilage have been shown 
to express the anti-inflammatory cytokine IL-10 and its putative receptor IL10R 
(Iannone et al., 2001), which upon interacting down-regulate TNF-α-induced 
MMP1 and MMP13 (Shlopov et al., 2000). Here, we have demonstrated, that 
treatment with α-MSH and D[TRP]8-γ-MSH (3.0 µg/ml), but not SHU9119 (10.0 
µg/ml), PG901 and PG911 (3.0 pg/ml) leads to significant increase in basal IL-10 
release from C-20/A4 chondrocytes. In addition, it was apparent that the 
response of the chondrocytes was time-dependent, with both α-MSH and 
D[TRP]8-γ-MSH causing maximal induction of IL-10 at 6 h post-stimulation. α-
MSH was significantly more potent than D[TRP]8-γ-MSH at inducingIL-10 
although both peptides elevated basal levels of IL-10 as early as 2 h post-





part melanocortin peptides can exert a homeostatic control over chondrocyte 
physiology with the ability to induce anti-inflammatory cytokines. This therefore 
suggests a possible role in modulating basal levels of pro-inflammatory synthesis 
in this cell type even when no apparent inflammation is occurring.  
Given the induction of basal IL-10 by the melanocortin peptides, their effect were 
investigated over a concentration range in the presence of TNF-α-induced 
chondrocyte inflammation over a time-course. α-MSH caused a concentration-
dependent bell shaped response with maximal release of IL-10 caused by 1.0 
µg/ml at early time-points and 10.0 µg/ml at later time points (24 h), whilst 
D[TRP]8-γ-MSH (30.0 µg/ml) caused a maximal release of IL-10 at 2 h post-
stimulation. The ability of α-MSH and D[TRP]8-γ-MSH to trigger the production of 
IL-10 clearly suggests that activated melanocortin receptors may have crucial 
anti-inflammatory properties, conducted through activation of this cytokine.  
The anti-inflammatory protein HO-1 has been implicated in the protection against 
tissue injury and is modulated by cytokines such as TNF-α (Fernandes et al., 
2003). It has been shown to be expressed and functionally active in human 
osteoarthritic chondrocytes from OA tissue with IL-10 shown to modulate its 
production (Lee and Chau, 2002; Fernandes et al., 2003). A potential link 
between melanocortin receptor-dependent cAMP formation and HO-1 induction 
has previously been identified (Lam et al., 2005). This idea stemmed from the 
fact that cAMP analogues have been shown to induce HO-1 in rat hepatocyte 
culture (Immenschuh et al., 1998). To address this, the human C-20/A4 
chondrocytes were employed to monitor alteration in HO-1 protein production, 
following incubation with α-MSH and D[TRP]8-γ-MSH at 3.0 µg/ml in the 
presence and absence of TNF-α. C-20/A4 chondrocytes produced detectable 
basal levels of HO-1, and melanocortin peptides were able to provoke a marked 
up-regulation of HO-1 evident at 6 h post-incubation with the melanocortin 
receptor pan-agonist α-MSH and the synthetic MC3/4 agonist D[TRP]8-γ-MSH. 
Interestingly, when chondrocytes were pre-treated with the melanocortin peptides 
prior to stimulation with TNF-α, there was notable elevation in HO-1 production. 
Together with the fact that TNF-α moderately, but significantly induced the 





(Wagener et al., 2003). The downstream sequence of events currently remains 
unclear, and further investigation would be needed to elucidate the action of 
melanocortin receptor signalling in chondrocytes.  
Chondrocyte apoptosis and the protective effect of melanocortin peptides  
Chondrocytes are the only cell type present within articular cartilage and thus 
chondrocyte apoptosis plays an important part during the processes of cartilage 
development, aging and in cartilage pathologies (Blanco et al., 1998). 
Chondrocytes have been shown to be susceptible to endogenous degradative 
stimuli, such as TNF-α and IL-1β by up-regulating the synthesis of pro-
inflammatory cytokines and matrix metalloproteinases, inhibiting collagen and 
proteoglycan synthesis, therefore causing loss of cartilage (Ismail et al., 1992; 
Martel-Pelletier et al., 1999; Fernandes et al., 2002; Kapoor et al., 2011). The 
importance of apoptosis has been identified with an increase in the number of 
apoptotic chondrocytes in osteoarthritic lesional than in non-lesional cartilage 
(Kim et al., 1999; Kim et al., 2000; Kouri et al., 2000; Hashimoto et al., 1998; 
Kirsch et al., 2000). In addition, chondrocyte apoptosis and the reduction of 
tissue cellularity represent an important step in 
the pathogenesis of cartilage degradation (Blanco et al., 1998; Maneiro et al., 
2003).  
Currently, it remains unclear which pathways induce apoptosis and are 
responsible for the loss of chondrocytes and subsequent cartilage degradation. 
DeWolf and colleagues observed that TNF-α (30.0 ng/ml) stimulated caspase-3 
driven apoptosis in human chondrocytic cell line (Nuttal et al., 2000) and that 
TNF-α induced apoptosis of bovine chondrocytes in vitro (Schuerwegh et al., 
2003). In our in vitro study, we demonstrate that TNF-α potently induces 
chondrocyte apoptosis, suggesting that this is part of the mechanism of cartilage 
destruction, thereby substantiating those existing data. TNF-α concentrations 
(60.0 – 80.0 pg/ml) caused approximately 28% of the C-20/A4 chondrocytes to 
die, whereas lower concentrations caused around 10-15 % rate. Clinical studies 
have demonstrated that pathophysiological concentrations of TNF-α detected in 
OA synovium of patients with severe disease progression are in the range of 1.0 





in this study. One reason for using lower concentrations is that chondrocytes in 
vivo die in the context of extracellular matrix, which may physically limit the levels 
of pro-inflammatory cytokines reaching the chondrocytes as opposed to in vitro 
experiments, where the chondrocytes are cultured in monolayer, allowing for fast 
and equal distribution of TNF-α to all chondrocytes, thereby increasing 
susceptibility of the chondrocyte to undergo apoptosis in response to TNF-α.   
Moreover, the expression of p55 TNF-α receptor has also been localized in areas 
of osteoarthritic lesions of human cartilage (Webb et al., 1997), and given that 
the pro-inflammatory cytokine TNF-α is particularly important in the 
pathophysiology of cartilage disease, I aimed to further investigate the precise 
role it plays in chondrocyte apoptosis. It was confirmed that TNF-α modulates the 
activation of apoptotic pathways in human C-20/A4 chondrocytes and may be 
partially dependent on the activation of caspase-3 and -7. Western blot analysis 
showed that there was a significant 24 % increase in the protein levels of the 
activated executioner caspase-3 (Asp-175; 17, 19 kDa) following treatment of the 
C-20/A4 chondrocytes with TNF-α for 6 h. In addition, TNF-α treatment (60.0 
pg/ml; 6 h) led to marked 5.7-fold increase in caspase-3/7 activities, which was 
confirmed by Caspase-Glo® 3/7 assay analysis. These results are an important 
finding and are not in accordance with the work by the Blanco group, who 
detected increased mRNA and protein levels of both caspase-3 and -7 in 
cultured human OA chondrocytes stimulated with TNF-α, but protein analysis 
detected only the intermediate, inactive forms of these enzymes (Lopez-Armada 
et al., 2006). Contrary to those reports, recent studies have demonstrated that 
TNF-α causes enhanced chondrocyte apoptosis by increasing capsase-3/7 
activities (Nuttal et al., 2000; John et al., 2007; Kayal et al., 2010).  
Role of melanocortins in prevention of pro-inflammatory cytokine-induced 
apoptosis.  
Following the identification of α-MSH’s and D[TRP]8-γ-MSH’s ability to markedly 
reduce the synthesis and production of pro-inflammatory cytokines, as well as 
down-regulating degradative matrix metalloproteinases expression, their effect 
on TNF-α induced cellular toxicity and cell-death inducing signals was evaluated.  





regulated the production and activity of caspase-3 and -7. Both peptides at all 
concentrations tested failed to cause any damage to the treated C-20/A4 
chondrocytes and additionally caused 40 - 50 % reduction in cleaved caspase-3 
protein expression as determined by western blot. These results were confirmed 
by testing the activity of the executioner caspases 3 and 7 and measuring 
mitochondrial functionality following pre-treatment with α-MSH and D[TRP]8-γ-
MSH on TNF-α-activated C-20/A4 chondrocytes. The peptides exhibited strong 
concentration-dependent protective effect against TNF-α-induced cell death, 
whereby 49 % and 55 % reduction in chondrocyte apoptosis was observed 
following treatment with α-MSH (3.0 µg/ml) and D[TRP]8-γ-MSH respectively.  
Other studies support the molecular mechanism by which melanocortin peptides 
prevent apoptosis in chondrocytes, with one particular study on neuronal cell-line 
GT1-I demonstrating the inhibitory effect of the melanocortin peptide NDP-MSH 
on caspase-3 activation as readout of apoptosis (Windebank et al., 1994) whilst 
α-MSH prevents LPS/INF-γ-induced astrocyte apoptosis via activation of MC4 
(Caruso et al., 2007).   
To our knowledge, this study is the first to show the inhibitory effect of α-MSH 
and D[TRP]8-γ-MSH in a model of TNF-α-induced chondrocyte apoptosis in vitro. 
Through antagonism of MC3/4, demonstrates that MC1 and MC3 are involved in 
the transmission of the anti-apoptotic effects of α-MSH and D[TRP]8-γ-MSH 
respectively in the human C-20/A4 chondrocytic cell line. SHU9119 (10.0 µg/ml) 
antagonized the effects of D[TRP]8-γ-MSH, but not α-MSH on down-regulating 
the production of cleaved caspase-3 as a marker of apoptosis and consistently 
reversed the protective effect of the selective MC3 agonist on mitochondrial 
function in the model of TNF-α-induced chondrocyte death. The combination led 
to 27 % up-regulation of cleaved caspase-3 production and cell death was 
observed at TNF-α-produced levels regardless of the concentration used.  
Combined, these results demonstrate, that MC3 is particularly important in 
transmitting the anti-inflammatory, cyto-protective, anti-apoptotic and immuno-
modulatory effects of melanocortin peptides. In addition, the role of MC1 has 
been also confirmed, given the fact that MC5 is non-functional in this C-20/A4 





Effect of hypotonic solution on chondrocyte function. 
To further understand the potential role that melanocortin peptides play in 
modulating chondrocyte activity, their effect was investigated on the function of 
osmotically challenged chondrocytes. Articular cartilage is highly hydrated tissue 
whereby approximately 30 % of the water in the cartilage is found within the 
collagen intrafibrillar space (Hall, 1998). The amount of water in the cartilage 
depends on the fixed charge density of the proteoglycans, which bear strong 
negative electrical charges (Maroudas et al., 1979), neutralised by positive ions 
in the surrounding fluid. The high concentration of ions in the extracellular matrix, 
compared to the outside the tissue, has been shown to increase osmotic 
pressure (Maroudas, 1979; Maroudas and Evans, 1972). In OA and upon matrix 
degradation, the water content of cartilage increases and leads to over-hydration 
of the negatively charged proteoglycans, which alters the chondrocyte 
extracellular physio-chemical environment by reducing the osmolality causing an 
increase in cell volume; an early event during osteoarthritis (Gardner, 1992; Bush 
& Hall, 2004).  
C-20/A4 chondrocytes were subjected to hypotonic conditions (280 to 140 
mOsm), and a significant time-dependent up-regulation of pro-inflammatory 
cytokines IL-6 and IL-8 from C-20/A4 chondrocytes was observed, with a 37-fold 
increase in IL-6 and 8-fold up-regulation of IL-8 expression at 24 h and 42-fold 
and 10 fold, respectively at 72 h. These results were further substantiated by 
ELISA detection of these cytokines, which confirmed that the intensification on 
cytokine transcription, in response to chronic hypo-osmotic challenge, was 
translated into protein released from the C-20/A4 chondrocytes.  
This study, to our knowledge, is the first to investigate the effect of lowered media 
osmolarity on C-20/A4 chondrocyte inflammatory profile. A novel finding, 
demonstrated by this work, is that upon reduction of extracellular osmolarity, C-
20/A4 chondrocytes respond by increasing not only pro-inflammatory cytokines, 
but also the expression of MMP1 and MMP13, which increased in a time-
dependent manner. MMP1 mRNA was up-regulated 2.3-fold following 24 h 
incubation in the 140 mOsm DMEM and this increased to 4-fold, compared to 





(which is not present in non-treated C-20/A4 or healthy human cartilage) was 
elevated following stimulation with 140 mOsm media, and the detected amounts 
were significantly higher compared to TNF-α-stimulated levels. Hypo-tonicity did 
not seem to affect MMP3 expression in the first 24 h of incubation, but caused 
increased transcription when the chondrocytes were incubated for 72 h. This 
finding is supported by work on other cell type showing that cellular stresses such 
as pro-inflammatory cytokines and osmotic stress activate MAPK pathways (JNK, 
ERK1/2 and p38) (Lewis, 1998; Garrington, 1999). It has been shown that JNK 
and ERKs phosphorylate AP-1 family member c-Jun (Karin, 1995, Leppa et al., 
1998), which then dimerizes with c-Fos and initiates the transcription of various 
MMP genes. Other groups have shown that the ERK1/2 pathway mediates the 
activation of the MMP1 promoter via an AP-1 element (Frost, 1994; Rutter, 1995; 
Korzus, 1997). 
However, whether the altered osmolality of the C-20/A4 chondrocytes media is 
directly triggering the expression of these MMPs cannot be concluded by this 
work, as 140 mOsm DMEM also affects the synthesis of various cytokines, such 
as IL-6, which in turn can directly alter both MMP1 and MMP13 gene expression 
in a concentration-dependent manner. This is an important finding, since 
osteoarthritic cartilage is also defined by increased expression and synthesis of 
pro-inflammatory cytokines, matrix metalloproteinases and increased tissue 
hydration. 
Since the events of OA, which we attempted to mimic here in the C-20/A4 
chondrocyte model  (increased production and release of pro-inflammatory 
cytokines and catabolic matrix metalloproteinases, increased degradation and 
reduced collagen type II production, chondrocyte apoptosis and cartilage 
hydration), it seems likely that a perpetuation of self-inducible and pathological 
events could lead to the chronic profile of this joint disorder, thus novel avenues 
for pharmacological intervention could look at targeting these processes. 
The effect of α-MSH and D[TRP]8-γ-MSH on hypo-tonicity induced over-
expression of matrix metalloproteinases was determined. D[TRP]8-γ-MSH down-
regulated both MMP1 and MMP13 expression even at 24 h post stimulation with 





decrease in the transcription of MMP1 and MMP13, its effect was not statistically 
different from the levels caused by the hypotonic media alone. None of the 
peptides altered the expression of MMP3 by C-20/A4 chondrocytes.  
These results suggest, that α-MSH probably due to its short half-life (6 h) is 
unable to down-regulate MMPs expression at 24 h, especially, since the hypo-
osmotic medium, surrounding the chondrocytes seems to be exerting strong pro-
inflammatory effects, which is unlike the effect of the pro-inflammatory stimuli 
used for various cell stimulation. The fact that IL-6 and IL-8 levels are increasing 
even at 72 h post incubation of C-20/A4 chondrocytes with 140 mOsm DMEM, 
suggested a possible role for these cytokines in the synergistic induction of 
MMPs expression at time-points as late as 24 and 72 h.  
Primary bovine chondrocyte (P0) activation by various pro-inflammatory 
stimuli. 
Following the identification of the protective role that melanocortin peptides could 
play on pro-inflammatory cytokines and MMP expression following TNF−α 
stimulation in C-20/A4 chondrocytes, it was decided to determine whether these 
effects translated to primary cells and cartillage. C-20/A4 chondrocytes have 
been shown throughout this thesis to respond to various stimuli by secreting 
significant amounts of pro-inflammatory cytokines, chemokines and other non-
cytokine pro-inflammatory mediators, such as NO and matrix metalloproteinases. 
Even though immortalized cell lines are a suitable method for studying the 
function and the response of chondrocytes to various stimuli, primary cultures of 
articular chondrocytes may respond differently to these stimuli. In order to 
elucidate whether the findings confirmed in the C-20/A4 cell-line chondrocytes 
are consistent with the responses detected within primary chondrocytes, we 
employed primary articular chondrocytes extracted from load bearing regions of 
bovine knee joint cartilage.  
High-density primary articular chondrocytes cultures (passage 0, P0) were 
established to study the effect of TNF-α and LPS on the release of pro-
inflammatory cytokines IL-1β, IL-6, IL-8 and MCP-1. Primary chondrocytes 





the production and release of all cytokines measured. TNF-α at all 
concentrations induced significant IL-6 release, which was highly comparable to 
the response observed in C-20/A4 cells, with the exception of the highest 
concentration of TNF-α  (which was less effective in C-20/A4 compared to P0 
primary chondrocytes). These results are in accordance with previous 
observations that IL-6 mRNA is up-regulated following TNF-α-stimulation of 
human articular chondrocytes (Shlopov et al., 2000), or in OA tissue (Hrycaj et 
al., 1995, Shinmei et al., 1991).  In addition, LPS was similarly potent in the 
induction of IL-6 secretion from both C-20/A4 cells and primary articular 
chondrocytes, despite somewhat higher levels in C-20/A4 cells.  
In addition, bovine articular chondrocytes, much like the C-20/A4 chondrocytes 
were readily inducible to release IL-8, which can promote neutrophil-mediated 
inflammation and cartilage degeneration. TNFα and LPS promoted abundant IL-8 
secretion from the primary bovine chondrocytes, a finding that is in agreement 
with the ability of these inflammogens to exert the same effect in human articular 
cartilage (Terkeltaub et al., 1991). The maximal IL-8 release from bovine 
chondrocytes was comparatively low, reaching just 50.0 pg/ml (TNF-α 40.0 – 
60.0 pg/ml), as opposed to 205 pg/ml of IL-8 detected in C-20/A4 chondrocytes 
following stimulation with the same concentrations of the cytokine. Regardless of 
these slight discrepancies, this study accentuates the fact that articular 
chondrocytes are readily inducible to express the IL-8 gene and secrete 
biologically active IL-8, which can promote neutrophil-mediated inflammation and 
cartilage destruction. 
TNF-α and LPS stimulated articular chondrocytes released significant amounts 
MCP-1, in concentrations concordant with the detected levels in C-20/A4 
chondrocytes (maximum 120 pg/ml) following 6 h stimulation, thus confirming our 
initial findings. In agreement with the results of this study is the work by Lotz and 
colleagues, who have demonstrated the ability of human articular cartilage to 
respond to IL-1β stimulation by significantly up-regulating the transcription of 
MCP1 within 2 – 4 h of stimulation (Villiger et al., 1992). The fact that 
chondrocytes release biologically active MCP-1 in response to factors that are 





mechanism by which chondrocytes implicate in the initiation and progression of 
cartilage degradation observed in osteoarthritis.  
Il-1β has a fundamental function in osteoarthritis pathophysiology as it controls 
the degeneration of articular cartilage matrix and severely affects chondrocyte 
apoptosis. Therefore targeting the activation mechanism of this catabolic 
cytokine seems to be essential as a therapeutic approach (Moldovan et al., 2000; 
Lopez-Armada et al., 2006; Kapoor et al., 2011). In this study, we have already 
demonstrated that both TNF-α and LPS are able to induce moderate secretion of 
this cytokine from human C-20/A4 chondrocytes. These findings were further 
substantiated by the detection of IL-1β secretion in response to TNF-α and LPS 
from primary articular chondrocytes as well. In both cell types, TNF-α generally 
initiated low (up to 40.0 pg/ml) levels of IL-1β secretion.  
As previously discussed, the expression and secretion of all these pro-
inflammatory cytokines has been previously detected in chondrocytes extracted 
from osteoarthritic cartilage (Martel-Pelletier et al., 1999; Maccoux et al., 2007; 
Villiger et al., 1992), which shows the relevance of the results acquired by the 
present study.  
Effect of melanocortin peptides on TNF-α-activated primary bovine 
articular chondrocytes.  
During this study, we have shown that human C-20/A4 chondrocyte express 
functionally active melanocortin receptors MC1 and MC3, and show very slight 
expression of MC5, which was found to be functionally inactive. Here we 
demonstrate the expression of MC1 in bovine primary chondrocytes and yet again 
we detected MC5 expression. The expression of MC3 unfortunately, was not 
investigated, because at the time the experiments were conducted the full 
sequence of the bovine MC3 gene was not yet discovered, preventing the 
construction of primers.  
Here, bovine articular chondrocytes consistently express MC1, which is in 
agreement with other studies reporting the expression of this receptor in 
chondrocyte cell lines as well as primary cells (Yoon et al., 2008; Grässel et al., 





tested animals, with some samples showing slight expression, and others none 
at all. Additional work is required to fully unravel the expression of this 
melanocortin receptor in bovine primary chondrocytes.  
To support our RT-PCR detection of the melanocortin receptors, we evaluated 
the pan agonist α-MSH, to test MC1 functional activity, whilst the synthetic 
selective MC3 agonist D[TRP]8-γ-MSH was used to evaluate whether bovine 
chondrocytes possess a functionally active MC3. The MC3/4 antagonist and potent 
MC1 agonist SHU9119 was also evaluated to determine 1) to determine whether 
D[TRP]8-γ-MSH specifically activates its putative receptor (MC3) by blocking its 
binding sites; and 2) to conclude the role of α-MSH and MC1 in modulation pro-
inflammatory cytokines levels in the primary articular chondrocytes (P0).  
Pre-treatment of primary chondrocytes with α-MSH and D[TRP]8-γ-MSH prior to 
stimulation with TNF-α caused a concentration-dependent decrease in IL-1β a 
similar observation to that noted in the cell-line. However, a note should be taken 
that the inhibitory effect of α-MSH (1.0 and 3.0 µg/ml) on IL-1β concentrations (~ 
40 % reduction) was lower in bovine chondrocytes compared to the cell-line, 
where similar concentrations caused > 80 % reduction.  
Interestingly, lower concentrations of SHU9119 (1.0 and 3.0 µg/ml) led to a low 
20 % inhibition in IL-1β release from bovine chondrocytes, suggesting a potential 
role for MC1. However, SHU9119 was not capable of reducing either IL-6 or IL-8 
production at any of the concentrations tested, which is in agreement with our 
findings from the human C-20/A4 chondrocytic cell-line. Conversely, both α-MSH 
and D[TRP]8-γ-MSH led to marked concentration-dependent bell shaped 
decreases in both IL-6 and IL-8 production. Unlike the effect of α-MSH on IL-1β, 
1.0 and 3.0 µg/ml of α-MSH abrogated IL-6 production from the cultured primary 
bovine chondrocytes, by 93 % and 87 % reduction respectively. Similarly, 
D[TRP]8-γ-MSH (3.0 µg/ml) caused a similar degree of inhibition of IL-6, whilst 
both peptides inhibited IL-8 release, a similar observation as noted in the cell-
line. This observation of bell-shaped inhibition of cytokine production by 
melanocortin peptides from primary cells was initially observed in macrophages 





The MC3/4 antagonist SHU9119, did not significantly alter the anti-inflammatory 
effect elicited by α-MSH on TNF-α-induced IL-1β, IL-6 and IL-8 production. 
Interestingly, SHU9119 and α-MSH (30.0 µg/ml) appeared to be synergistically 
acting to reduce the production of IL-6. From the results, it seemed that, with 
increasing concentrations of α-MSH, it started to slowly lose its effectiveness, 
and thus a combination with SHU9119 allowed it to “help” the α-MSH (30.0 
µg/ml) to maintain the same level of cytokine inhibition. These findings are 
controversial, and may suggest that: 1) α-MSH does not act through activation of 
MC3 in chondrocytes; 2) SHU9119, being relatively selective MC5 agonist might 
be causing very mild reduction in IL-6 levels, only if high concentrations of α-
MSH are used. This might be a resulting from desensitization of the receptors on 
chondrocytes and possible internalisation of MC1, allowing for or inducing a 
switch in the mechanisms by which the peptides works. It has been long known 
that GPCRs, such as melanocortin receptors, are regulated via multiple 
mechanisms(Clark, 1986, Perkins, 1991). This has been well illustrated by 
studies of β2-adrenergic receptor, reviewed in detail (Carman and Benovic, 1998, 
Ferguson et al., 1998, Lefkowitz et al., 1998), where agonist-induced activation of 
the receptor activates adenylate cyclase within seconds of binding (von Zastrow 
and Kobilka, 1992). However, following prolonged activation of the receptors, 
their ability to induce cAMP formation declined significantly. In addition, many 
GPCRs can be regulated by ligand-induced endocytosis or internalization (von 
Zastrow and Kobilka, 1992). SHU9119 (10.0 µg/ml) potently blocked and 
reversed the anti-inflammatory effect of D[TRP]8-γ-MSH at all concentrations 
tested, thereby suggesting that MC3 receptor is expressed and functionally active 
in bovine primary chondrocytes.  
Given the ability of these peptides to modulate pro-inflammatory cytokines, the 
peptides were evaluated on production of pro-resolving anti-inflammatory 
cytokines. IL-10 production was observed from stimulated bovine primary 
chondrocytes and is in agreement with that observed in human chondrocytes 
from healthy and osteoarthritic cartilage, which express both IL-10 and its 
putative receptor IL10R (Iannone et al., 2001). Consistent with previous findings 
α-MSH caused the release of IL-10 (Bhardwaj et al., 1996), the melanocortin 





Primary bovine chondrocytes did not produce detectable basal IL-10 release; 
however, following 30 min pre-treatment of TNF-α-activated primary 
chondrocytes, there was a bell-shaped elevation of this cytokine following 
stimulation. Once again, SHU9119 failed to block the effect of α-MSH but 
completely abolished the anti-inflammatory effect of D[TRP]8-γ-MSH, therefore 
indicating a dual role for both MC1 and MC3 in modulating the inflammatory 
response in these cells. 
Cartilage impact and the anti-inflammatory and protective effect of 
melanocortins in models of mechanical trauma on cartilage tissue. 
Cartilage metabolism is contingent in part with mechanical forces, including shear 
stress and hydrostatic pressure that occur during normal joint loading. Previous 
in vitro work confirms that chondrocytes in culture continue to respond to a 
variety of loading conditions (Mankin and Lippiello, 1970). The distinctive 
properties of cartilage are believed to affect the chondrocyte reaction to pressure. 
It is largely documented that within physiological limits mechanical loading of 
healthy joints contributes significantly to the maintenance of the articular cartilage 
ECM by chondrocytes, but the precise relationship between mechanical loading 
and chondrocyte metabolism is still vague (Saamanen et al., 1987). Mechanical 
loading above physiological ranges and/or frequency gives rise to substantial 
cartilage injury (Burton-Wurster et al., 1993; Guilak et al., 1994) including 
increase in synthesis and release of pro-inflammatory mediators and degradative 
enzymes (Pickvance et al., 1993, Guilak et al., 1994, Wang et al., 2010b). 
Alteration in joint loading is additionally considered an important factor in the 
initiation of osteoarthritis (Anderson and Felson, 1988).  
The effect of mechanical trauma on the functionality and metabolism of 
chondrocytes is receiving increasing attention (D'Lima, 2001a,b; Borrelli, 2004; 
Kurz, 2004), particularly because within mature articular cartilage, chondrocytes 
do not undergo cell division (Sailor, 1996; Buckwalter, 1998). Additionally, 
osteoarthritis is featured by reduced cellularity (Stockwell, 1991), a fact that is 
thought to contribute to the inability of the remaining chondrocytes to maintain 
normal matrix synthesis, thereby contributing to cartilage degradation (Bush et 





Given the importance of this in the development of OA, the effect of a single 
impact blunt mechanical impact, delivered via drop tower (Bush et al., 2005) on 
chondrocyte viability and rates of pro-inflammatory mediator synthesis were 
determined. Following impact in situ chondrocytes within the superficial zone 
were shown to be particularly sensitive to mechanical injury confirming previous 
observations using bovine articular cartilage explants (Bush et al., 2005). 
Chondrocyte cell death was apparent 6 h post impact and was visibly localized to 
the distinct areas of impact. Confocal laser scanning microscopy and imaging 
allowed us to study the cell viability of individual chondrocytes within bovine 
articular cartilage explants subjected to a single blunt impact.  
The data showed that ~3 % of the chondrocytes in non-impacted cartilage were 
non-viable following excision of the explant from the joint and increased 
significantly to 13 % following application of mechanical injury to the cartilage 
explant. The experiments conducted in this study were performed on cartilage 
explants excised from the underlying bone. However, judging from the results 
and the confinement of chondrocyte damage to the superficial zone, it is unlikely 
that the subchondral bone is a major factor of cartilage surface properties within 
these experiments (Bush et al., 2005).  
It is important to note that this study has not been designed to clarify in vivo 
response to single blunt impact. The drop tower is a useful technique for 
simulating true impact (Bush et al., 2005), but it is not possible to mimic the 
impact waveform or displacement applied to the cartilage explant during 
compression. Nevertheless, the observed changes in matrix structure, surface 
damage to cartilage explant and the loss of chondrocytes in the superficial zone 
(Quinn et al., 1998, Quinn et al., 1999) are similar to the changes observed in 
osteoarthritic cartilage (Thompson et al., 1991; Wilder et al., 2002). Within this 
study, we have demonstrated the protective properties of melanocortin peptides 
in a model of TNF-α-induced chondrocyte apoptosis/cell-death. Here, we have 
shown that α-MSH (3.0 µg/ml), but not D[TRP]8-γ-MSH or dexamethasone (1.0 
µM) are able to inhibit basal chondrocyte apoptosis in non-impacted cartilage. 
The melanocortin receptor pan-agonist decreased chondrocyte cell-death from 3 





In order to expand our study on the effect melanocortins on primary 
chondrocytes in situ, we detected basal levels of pro-inflammatory mediator 
release of IL-1β, IL-6 and IL-8 in non-impacted cartilage and compared them to 
the effect of melanocortin peptides and dexamethasone. Our data demonstrates 
that chondrocytes from non-impacted cartilage produce significant basal levels of 
IL-1β, IL-6 and IL-8 cytokines, consistent with the effect of TNF-α on the 
chondrocytic cell-line. Previously, freshly isolated chondrocytes have been 
shown to spontaneously release detectable amounts of IL-8, but these are 
rapidly increased following stimulation, suggesting that functionally expressed 
chemokines by chondrocytes may trigger the release of matrix degradative 
enzymes and subsequent cartilage destruction (Lotz et al., 1992). IL-1β was also 
detected in cartilage explants prior to impact, similarly to that observed in normal 
human articular cartilage (Middleton et al., 1996). Bovine articular chondrocytes 
in situ also produced IL-6, a potent pleuotropic cytokine and important mediator 
of the cell interactions in osteoarthritis. This was consistent with the finding of 
Shinmei and collegues, who detected the expression of this cytokine in human 
articular chondrocytes (Shinmei et al., 1989). These basal release of cytokines 
were not modified by α-MSH, D[TRP]8-γ-MSH or dexamethasone.  
However, the peptides led to significant reduction of cell death when 
administered 30 min prior to single blunt impact inflicted by the drop tower. At 6 h 
post-impact, α-MSH and D[TRP]8-γ-MSH caused significant protection of the 
chondrocytes from cell death, compared to levels detected following mechanical 
trauma in the absence of the peptide.  Dexamethasone also caused a protective 
effect following impact although with a lower level of protection being observed 
compared to the peptides. Consistent with our previous observations that 
melanocortins can protect against TNF-α-induced chondrocyte apoptosis, these 
data confirms that melanocortins exert cyto-protective properties not only in cell-
line chondrocytes in vitro, but also in primary articular chondrocytes in situ.   
Mechanical injury was associated with a significant upregulation of IL-1β, IL-6 
and IL-8 release compared to levels produced by chondrocytes in non-impacted 
cartilage, and the melanocortin peptides α-MSH, D[TRP]8-γ-MSH and 





MSH was the least effective of the three treatments on cytokine release, whilst 
D[TRP]8-γ-MSH was more effective than α-MSH in reducing these cytokines 
levels. Dexamethasone showed the greatest effect in reducing pro-inflammatory 
synthesis caused by mechanical trauma to the cartilage explants. Here, in 
accordance with our previous results, melanocortins exhibited modulatory effects 
on the production of pro-inflammatory cytokines from impacted cartilage, rather 
than complete abrogation of the cytokine response as previously seen in models 
of acute inflammation (Getting et al., 1999, 2002, 2006, 2008). However, the data 
for dexamethasone was contradictory to the previous findings, showing that 
dexamethasone abrogated completely the release of these cytokines from cell-
line chondrocytes. One explanation for these findings might be the relatively low 
permeability of the cartilage matrix, compared to culture media, which poses no 
physical barrier for the drugs to reach and affect chondrocytes and their function. 
Furthermore, pro-inflammatory mediator release from C-20/A4 cell line was 
caused by exogenous TNF-α-stimulation, whereas in situ articular chondrocytes 
were activated by mecanical trauma. Nevertheless, it is important to note that 
joint trauma leads to excessive synthesis of pro-inflammatory cytokines, one of 
the major ones being TNF-α (Ertel et al., 1995), which could potentiate the 


























5.1 Conclusion.  
The results generated in this thesis indicate that C-20/A4 chondrocytes and 
primary articular chondrocytes in vitro and in situ respond to exogenous stress 
(pro-inflammatory mediators, changes in extracellular osmolarity, mechanical 
trauma) by producing significant amounts of pro-inflammatory cytokines (such as 
IL-1β, IL-6, IL-8 and MCP-1), and collagen derisive matrix metalloproteinases 
(MMP1 and MMP13), therefore corroborating the possible role of the 
chondrocyte in initiation and progression of cartilage degradation, as observed in 
OA. In addition, the work presented here indicates that there is significant down 
regulation of cartilage ECM components such as collagen type I and type II upon 
TNF-α-activation of C-20/A4 chondrocytes, which if translated to in vivo work 
could additionally lead to a reduction in the quality of the cartilage matrix, thereby 
leaving the cartilage prone to injury.  
Melanocortins have been previously shown to possess a vast range of 
physiological and pharmacological actions. However, little research has occurred 
with respect to their role in chondrocyte inflammation. This thesis highlights the 
anti-inflammatory and anti-apoptotic effects of melanocortin peptides α-MSH and 
D[TRP]8-γ-MSH in an in vitro chondrocyte-based model of TNF-α-induced 
stimulation. The melanocortin peptides were able significantly down regulate pro-
inflammatory cytokines and cartilage degradative MMPs, but also to lower 
cytokine-induced apoptosis and to induce the anti-inflammatory proteins (IL-10 
and HO-1) in this cell-line. These effects were transmitted through the activation 
of MC1 and MC3, both of which were found to be expressed and functionally 
active in C-20/A4 chondrocytes. The influence of the peptides was not limited to 
the human cell-line chondrocytes; instead, the results highlight the ability of the 
peptides to reduce TNF-α-induced pro-inflammatory cytokine and MMP 
expression in primary bovine articular chondrocytes. 
Moreover, the data presented here confirm that mechanical impact is an effective 
modulator of chondrocyte metabolism in vitro. This information adds to our basic 
understanding of how mechanical loading influences articular cartilage 
metabolism. Understanding the precise mechanisms by which impact trauma 





approaches for the treatment of arthritic pathologies. The melanocortin peptides 
not only showed chondroprotective effect in C-20/A4 chondrocytes, but also in 
articular chondrocytes in situ. This is a novel finding, suggesting potential clinical 
implications whereby people with joint injury/trauma or people suffering from OA 
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Figure 5.1 Melanocortins modulate pro-inflammatory cytokine production and 
exhert anti-infammatory and cytoprotective properties in chondrocytes.  
The binding of melanocortins to either MC1 or MC3, functionally active on the membrane of 
chondrocytes, increases cAMP, which activates protein kinase A (PKA), therefore leading to four 
main effects. First, PKA activation induces the phosphorylation of the cAMP-responsive-element-
binding protein (CREB) prevents the association of CBP with p65. b) The activated PKA hinders 
IκB kinase (IKK), which stabilizes the IκB inhibitor and stops nuclear translocation of NF-κB. c) 
PKA activation prevents MAPK/ERK kinase kinase 1 (MEKK1) phosphorylation and activation, 
and activation of p38 and TATA-binding protein (TBP). Non-phosphorylated TBP is unable to bind 
to the TATA box and to form dynamic trans-activating complex with CBP and NF-κB. A reduction 
in the amounts of nuclear p65, CBP and phosphorylated TBP inhibits the formation of the 
conformationally active trans-activating complex that is required for the transcription of most 
cytokine and chemokine genes, therefore a great reduction in the synthesis of IL-1β, IL-6, IL-8 
and MCP-1 by the chondrocyte is observed. d) Fourth, inhibition of MEKK1 deactivates JUN 
kinase (JNK) and cJUN phosphorylation. The composition of the activator protein 1 (AP1) 
complex changes from the transcriptionally active cJun–cJun, to the transcriptionally inactive 
cJun–cFos or CREB. In addition, melanocortin peptides inhibit chondrocyte apoptosis by 
significantly inhibiting TNF-α-induced caspase-3 production and deactivating both executioner 
caspases - caspase-3 and caspase-7. Furthermore, activation of MC1 and MC3 led to significant 
up-regulation of production of IL-10 and HO-1, which support and assist the resolution of 
inflammation.  
The final consequence is that the transcriptional machinery of chondrocytes is significantly 
disrupted by the melanocortin treatment, thereby driving pro-resolution of inflammation and 
emphasizing the anti-inflammatory and cytoprotective properties of the melanocortin peptides. 
This study exploits the melanocortin pathways as a first step towards possible development of 











5.2 Future work 
•   To investigate the effect of melanocortin peptides on collagen production 
by activated/osteoarthritic chondrocytes.  
•   To localize IL-6, IL-8, MMP1 and MMP13 gene loci to either euchromatin 
or heterochromatin in healthy and osteoarthritic chondrocytes and to 
investigate the effect of selective melanocortin peptides on the localization 
of these gene loci. 
•   To scrutinize the mechanism of hyper- and hypomethylation of MMP1, 
MMP3 and MMP13 following stimulated/osteoarthritic chondrocytes; to 
evaluate how epigenetic changes may relate to the pathogenesis of 
osteoarthritis.  
•   To investigate the effect of melanocortin treatment on cytokine and MMP 
genes methylation status in normal and osteoarthritic chondrocytes.  
•  To evaluate the peptides in pre-clinical models of OA and to look at the 
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